

CURRICULUM VITAE

Erik Magnus Ohman, MB, FRCPI, FESC, FACC

ADDRESS

Duke University Medical Center
8676A HAFS Building
Box 3126 DUMC
Durham, NC 27710
Tel: 919-681-2069
Fax: 919-681-6443

CURRENT POSITION

Professor of Medicine
The Kent and Siri Rawson Director, Duke Program for Advanced
Coronary Disease
Associate Director, Duke Heart Center
Senior Investigator, Duke Clinical Research Institute
Duke University Medical Center

MEDICAL EDUCATION

(b) (6)

Royal College of Surgeons of Ireland, Dublin 2, Ireland

St. Laurence's (Richmond) Hospital, Dublin 7, Ireland

PROFESSIONAL EXPERIENCE

1981 - 1982	Intern in Surgery and General Medicine, St. Laurence's Hospital, Dublin 7, Ireland
1982 - 1983	Resident in Medicine, St. Laurence's Hospital, Dublin 7, Ireland
1983 - 1984	Resident in Medicine, St. Vincent's Hospital, Dublin 4 and Nenagh County Hospital, Ireland
1984 - 1987	Research Fellow, Department of Cardiology and Department of Clinical Pharmacology, St. Laurence's Hospital, Dublin 7, Ireland
1987 - 1991	Fellow, Division of Cardiology, Duke University Medical Center, Durham, North Carolina
1991 - 1992	Cardiologist, Veterans Administration Hospital, Durham, North Carolina
1991 - 1993	Associate in Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina
1993 - 1997	Assistant Professor of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina
1994 - 2001	Assistant Director, Duke Critical Care Transport Program, Duke University Medical Center, Durham, North Carolina
1997 - 1999	Associate Professor of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina
1999 - 2001	Associate Professor of Medicine, with Tenure, Division of Cardiology, Duke University Medical Center, Durham, North Carolina
2001 - 2005	Professor of Medicine and Chief of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
2001 - 2005	Director of the UNC Heart Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

2005 – Present	Professor of Medicine Duke University Medical Center
2005-2012	Director, Program for Advanced Coronary Disease
2005 - 2012	Director, Cardiology Outpatient Clinics
2008 – Present	Associate Director, Duke Heart Center
2013 – Present	The Kent and Siri Rawson Director, Duke Program for Advanced Coronary Disease

ACADEMIC APPOINTMENTS

1985 - 1987	Assistant Lecturer in Clinical Pharmacology, Royal College of Surgeons of Ireland, Dublin, Ireland
1986 - 1987	Secretary, Collegiate Members Committee of the Royal College of Physicians of Ireland, Dublin, Ireland
1988 - 1990	Andrew W. Mellon Foundation Scholar and Research Fellow, Duke University Medical Center, Durham, North Carolina
1990 – 1998	Coordinator of Clinical Trials in Interventional Cardiology, Duke University Medical Center, Durham, North Carolina
2001 – 2005	Adjunct Professor of Clinical Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

CERTIFICATION AND DEGREES

1981	Licentiate of the Royal College of Physicians and Surgeons in Ireland (LRCP & SI)
1981	MB, BCh, BAO, National University of Ireland
1981	Medical Diploma, Royal College of Surgeons in Ireland
1981	Licentiate of the Royal College of Physicians in England (LRCP)
1981	Member of the Royal College of Surgeons in England (MRCS)
1981	ECFMG Examination
1983	U.S. Visa Qualifying Examination
1984	Member of the Royal College of Physicians in Ireland (MRCPI)

1991	Fellow of the Royal College of Physicians in Ireland (FRCPI)
1992	Fellow, European Society of Cardiology
1993	Fellow, American College of Cardiology

AWARDS AND DISTINCTIONS

1981	Sheppard Prize - for best research paper by Junior Staff, St. Laurence's Hospital, Dublin, Ireland
1985	Sheppard Prize - for best research presentation by Junior Staff, St. Laurence's Hospital, Dublin, Ireland
1996	Visiting Professor - Cleveland Clinic Foundation, Cleveland, Ohio
1998	Visiting Professor, University Hospital, Uppsala, Sweden
1999	Visiting Professor, University of Florida, Gainesville, Florida
1999	Visiting Professor, University of Texas at Galveston, Galveston, Texas
2000	Visiting Professor, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
2001	Visiting Professor, University of Michigan, Ann Arbor, Michigan
2001	Visiting Professor, Don Chapman Lecturer, Baylor College of Medicine, Houston, Texas
2003	Visiting Professor, Emory University School of Medicine, Atlanta, Georgia
2003	Visiting Professor, University of California-San Diego, San Diego, California
2003	Visiting Professor, University of Chicago, Chicago, Illinois
2005	John S. Graettinger, MD, Memorial Lecture, Rush University Medical Center, Chicago, Illinois
2008	Visiting Professor, Mt. Sinai Medical Center, New York, New York
2010	Visiting Professor, Case Western University, Cleveland, Ohio
2012	Eugene Braunwald Visiting Scholar, Brigham and Women's Hospital, Boston, Massachusetts

INTERNATIONAL AWARDS

1985	Young Investigator's Travel Award - International Symposium on Sports Cardiology, Belgium
1985	Edith Walsh Award - British Medical Association, England
2014	The CADECI 2014 Career Achievement Award, International Annual Congress of Cardiology, Guadalajara, Mexico

PROFESSIONAL SOCIETIES

1981 - 1987	Member, Irish Medical Association
1981 - 1987	Member, British Medical Association
1982 - Present	Fellow, Royal Society of Medicine
1984 - Present	Associate Member, Irish Cardiac Society
1984 - 1988	Collegiate Member, Royal College of Physicians of Ireland
1984 - 1992	Member, European Society of Cardiology
1991 - 1994	Affiliate Member, American College of Chest Physicians
1991 - 1993	Affiliate Member, American College of Cardiology
1994 - 1999	Fellow, American College of Chest Physicians (FCCP)
1996 - Present	Fellow, Society for Cardiac Angiography and Interventions (FSCAI)
2002 - Present	Member, Association of University Cardiologists

COMMITTEES

Institutional Committees

1992 - 1999	Department of Medicine representative on the Institutional Review Board, Duke University Medical Center
1993 - 2001	Member, Clinical Chemistry Advisory Board, Duke University Medical Center
1996 - 2001	Member, Point of Care Testing Committee, Duke University

	Medical Center
1997	Member, Ph.D. Dissertation Committee, Department of Biomedical Engineering, Duke University
1998 - Present	Member, Cardiovascular Faculty Advisory Board, Duke Clinical Research Institute
2001 - 2004	Member, Ph.D. Dissertation Committee, University of North Carolina at Chapel Hill School of Nursing

International or National Committees

American Heart Association

1998 - 2001	Member, Scientific Sessions Program Committee
2001 - 2002	Member, Acute Care Committee
2003 - 2005	Vice-Chair, Acute Care Committee
2003 - 2007	Member, Council of Clinical Cardiology
2005 - 2007	Chair, Acute Care Committee
2009 - 2011	Member, Executive Database Steering Committee
2011-2013	Member– CLCD/CVN Cardiovascular Disease in Older Populations Committee

American College of Cardiology

2003 - 2004	Member, American College of Cardiology Emergency Care Committee
2004 - 2008	ACC Representative on the AHA Acute Care Committee
2006- 2010	Steering Committee, National Cardiovascular Data Registry - CathPCI Registry
2007 - 2010	Member, Steering Committee, Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry Steering Committee
2010 - Present	ACCF/AHA Task Force on Practice Guidelines

American College of Chest Physicians

1995	Member, 4 th Consensus Group on Anti-Thrombotic Therapy, American College of Chest Physicians
------	--

2001	Member, 6 ^h Consensus Group on Anti-Thrombotic Therapy, American College of Chest Physicians
2004	Member, 7 ^h Consensus Group on Anti-Thrombotic Therapy, American College of Chest Physicians

European Society of Cardiology

1995 - 1998	Member, Scientific Committee
2003 - 2013	ESC Guidelines Writing Committee

Society of Cardiac Angiography and Interventions

1998 - 2001	Member, Ad Hoc Writing Committee for the Society for Cardiac Angiography and Interventions
2001 - 2003	Member, Board of Trustees

Executive / Steering Committees

1990 - 1993	Steering Committee Member and Regional Coordinator in the Southeast Region for the Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries (GUSTO) Study
1993 - 1996	Steering Committee Member for the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-2) Study
1994 - 1996	Steering Committee Member for Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON) Trial
1995 - 1997	Steering Committee Member for Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial
1995 - 1997	Steering Committee Member for the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-III) Study
1996 - 1997	Principal Investigator for the Thrombolysis And Counterpulsation To Improve Cardiogenic shock Survival (TACTICS) Trial

1997 - 1999	Steering Committee Member for the Sibrafiban vs Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) Trial
1997 - 2000	Operations and Steering Committee Member for the GUSTO-IV (Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes) Trial
2000 - 2001	Co-Principal Investigator for the Fibrinolytics and Aggrastat (tirofiban) in ST Elevation Resolution (FASTER) Trial
2001- 2006	Executive Co-Chairman of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) National Quality Improvement Initiative
2002 - 2007	Co-Chairman and Principal Investigator for the Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry
2003 - Present	Member, Scientific Council of the Reduction of Atherothrombosis for Continued Health (REACH) Registry
2006 - Present	Chairman, TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) Trial
2007 - Present	Member, PROTECT II Steering Committee, a prospective, multi-center randomized controlled trial of the IMPELLA RECOVER LP 2.5 system vs. Intra-aortic Balloon Pump in Patients Undergoing Non-emergent High Risk PCI.
2008 - 2010	Member, Steering Committee, Best Expert Agreement for Care of Occult MI Nationally (BEACON)
2008 - Present	Member, Antiplatelet Therapies Steering Committee
2008 - 2012	Principal Investigator, Counterpulsation to Reduce Infarct Size Pre-PCI for Acute Myocardial Infarction (CRISP AMI) Trial

Data And Safety Monitoring Boards

1990 - 1991	Member, for the Duke University Clinical Cardiology
-------------	---

	Studies (DUCCS-1; APSAC with or without Heparin)
1992 - 1993	Member, for the tPA-Heparin Duration Trial, St. Louis University, St. Louis
1993	Member, for the APSAC no Heparin tPA Heparin Reperfusion (ANOTHER) Trial, Duke University Medical Center
1993 - 1996	Chairman, for the Magnesium in Cardiac Arrest (MAGIC) Trial, Duke University Medical Center
1996	Member, for the Study of Microstents Ability to Limit Restenosis (SMART) Trial, Cardiovascular Data Analysis Center, Beth Israel Hospital, Boston, Massachusetts
1997 - 1998	Member, for the Vein Graft AngioJet™ Study Randomized (VeGAS 2) Trial, Cardiovascular Data Analysis Center, Beth Israel Hospital, Boston, Massachusetts
1998 - 1999	Chairman, for the Vasoflux International Trial for AMI Lysis (VITAL) Study
1998 - 2000	Chairman, for the Acolysis During Treatment of Lesions Affecting Saphenous Vein Bypass Grafts (ATLAS) Trial
2002- 2003	Member, for the TAXUS™ IV Trial
2003 - 2005	Chairman, for the TAXUS™ V Trial
2001 - 2004	Chairman, for the EP Technologies/Boston Scientific Cardiac Ablation for Sustained or Recurrent Type I Atrial Flutter using the EPT-1000 XP™ Cardiac Ablation System
2002 - 2004	Chairman, for the Acute Myocardial Infarction With Hyperoxemic Therapy (AMIHOT) Trial
2002 - 2004	Chairman, for the Xa Neutralization in Atherosclerotic Disease Understanding in Acute Coronary Syndromes (XaNADU ACS) Trial
2002 - 2004	Chairman, for the Symbiot Covered Stent System for the treatment of saphenous vein graft disease (SYMBIOT III) Trial
2001- 2004	Chairman, for the Cryoplasty Hyperplasia Inhibition Prevents Late Loss Feasibility (Pre-CHILL) Trial
2004 - 2006	Chairman, for the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) Trial

2006 - 2009	Member, Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) PCI Trial
2007 - Present	Chairman, for the Prehospital Administration of Thrombolytic Therapy with Urgent Culprit Artery Revascularization (PATCAR) Trial
2008 - 2010	Member, for the GRAVITAS: Gauging Responsiveness with a VerifyNow Assay – Impact on Thrombosis and Safety
2008 - Present	Member, for the Maintenance of Platelet Inhibition with Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery (BRIDGE) Trial
2010 – Present	Member, NIH Testosterone Trial
2011 - Present	Chair, A Placebo-Controlled, Multicenter, Randomized, Double Blind Trial To Evaluate The Safety And Effectiveness Of Ix-5001 For The Prevention Of Remodeling Of The Ventricle And Congestive Heart Failure After Acute Myocardial Infarction (PRESERVATION I) Trial
2013 - Present	Chair, The Cardiovascular and Metabolic Effects of Lorcaserin In Overweight And Obese Patients (CAMELLIA-TIMI 61 Study)
2013 - Present	Member, A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER)
2013 - Present	Member, RE-DUAL PCI study, comparing a dual antithrombotic regimen to a triple antithrombotic regimen in patients with atrial fibrillation who have undergone PCI

Other Committees

1986 - 1987	National Coordinator for the International Study of Infarct Survival (ISIS) Group of Ireland (jointly with Dr. John Horgan)
1989 - 1996	Investigator in the Bypass Angioplasty Revascularization Investigation (BARI) Study at Duke University Medical Center
1992 - 1993	Member, Fibrinolytic Therapy Trialist Collaborative Group, Oxford University, Oxford, England

1995	Member, Colloquium for Tailored Thrombolytic Therapy: Therapy for Individual Patients with Evolving Myocardial Infarction, Erasmus University, Rotterdam, The Netherlands
2002 - Present	Member, Association of University Cardiologists
2002 - 2003	Member, Association of Professors of Cardiology
2003 - 2005	Trustee, Association of Professors of Cardiology
2012	Member, TCT (2012) Organizing Committee

U.S. GOVERNMENT ACTIVITIES:

National Institute of Health - Study Sections

1990	Consultant to the National Institute of Neurological Disorders and Stroke Study (NINDS)
2008 - Present	Member, Small Business Innovation Research, NIH Cardiovascular Sciences ZRG1 CVA-K 10 Study Section
2010 - Present	Member, DSMB, NIH Testosterone Trial

Food and Drug Administration

2009 - Present	Member, Circulatory System Devices Panel
----------------	--

EDITORIAL EXPERIENCE:

Associate Editor:

1996 - Present	American Heart Journal
1997 - 2001	Cardiovascular Clinical Trials Forum
2000	Current Controlled Trials in Cardiovascular Medicine

Editorial Board Member:

1997 - Present	American Journal of Cardiology
1999 - 2004	The Canadian Journal of Cardiology
1999 - 2006	Expert Opinion on Pharmacotherapy
1999 - 2003	Current Interventional Cardiology Reports
1999 - 2005	HeartDrug
2003 - 2009	European Heart Journal
2003 - 2006	Journal of Interventional Cardiology
2005 – Present	Journal of the American College of Cardiology

Manuscript Reviewer:

Annals of Internal Medicine
American Journal of Cardiology
American Journal of Managed Care
American Heart Journal
British Medical Journal
Canadian Journal of Cardiology
Catheterization and Cardiovascular Diagnosis
Circulation
Coronary Artery Disease
Heart (formerly British Medical Journal)
Journal of the American College of Cardiology
Journal of the American Medical Association
Journal of Interventional Cardiology
Journal of Epidemiology
New England Journal of Medicine
Thrombosis and Haemostasis

LICENSURE:

Ireland - Full License 1982 - 1987
United Kingdom - Full License 1982, Overseas License 1987
U.S.A., North Carolina - July 20, 1991 (b) (6)

INVENTORSHIP:

U.S. Patent No. 5,246,001 (September 21, 1993) Method of assessing reperfusion after thrombolytic therapy

U.S. Patent No. 6,033,364 (March 7, 2000) Method of assessing reperfusion after thrombolytic therapy

U.S. Patent No. 6,662,114 (December 9, 2003) Methods for evaluating therapies and predicting clinical outcome related to coronary conditions

UNDERGRADUATE AND POST-GRADUATE RESEARCH PRECEPTORSHIP

1. (b) (6) M.D. Cardiology Fellow (Duke) 1996-1998
Current Position: Assistant Professor of Medicine, Mayo Clinic, Rochester, Minnesota
2. (b) (6), M.D. Cardiology Fellow (Duke) 1996-1998
Current Position: Cardiologist, Sarasota Heart Specialists, Sarasota, Florida
3. (b) (6) M.D. Cardiology Fellow (Duke) 1997-1999
Current Position: Assistant Professor of Medicine, Johns Hopkins Hospital, Baltimore, Maryland
4. (b) (6) M.D. Research Fellow (Duke) 1998-2000
Awarded Royal College of Physicians and Surgeons of Canada-MRC/PMAC-Novartis Clinical Research Fellowship
Current Position: Assistant Professor of Medicine, University of Toronto, St. Michael's Hospital, Toronto, Ontario, Canada
5. (b) (6) Medical Student (Duke) 1998-1999
Awarded 1998-1999 Stead Scholarship - Duke University
Current Position: Dermatologist, Philadelphia Institute of Dermatology Skin Cancer and Surgery Center, Philadelphia, Pennsylvania
6. (b) (6) M.D. Cardiology Fellow (Duke) 1998-2000
Current Position: Assistant Professor of Medicine, Director, Coronary Care Unit, Co-Director, Henry Ford Clinical Trial Coordinating Center, Henry Ford Hospital, Detroit, Michigan
7. (b) (6) Medical Student (Duke) 2000-2001
Awarded Five School Program and American Diabetic Association Young Investigator's Award
Awarded 2001 Senior Merit Scholarship from Duke University
Current Position: Resident, Emergency Medicine, Oregon Health & Science University, Portland, Oregon
8. (b) (6) Research / Cardiology Fellow (Duke) 1997-1999
Junior Faculty (UNC-Chapel Hill) 2003-2008
Current Position: Associate Professor of Clinical Medicine & Director, Cardiac Cath Lab-University of Miami Hospital, Miami, Florida

9. (b) (6) Cardiology Fellow (UNC-Chapel Hill) 2003-2005
Junior Faculty (UNC-Chapel Hill) 2005-2007
Awarded 2004 Society of Angiography and Interventions BRACCO Award
Current Position: Cardiologist, Dublin, Ireland
10. (b) (6) Resident (Duke) 2006-2009
Current Position: Cardiology Fellow, Cleveland Clinic Foundation, Cleveland, Ohio

ABSTRACTS

1. **Ohman EM**, Butler J, Fitzgerald D, Kelly J, Horgan J, O'Malley K. Beta-adrenoceptor changes following physical training. **Danish Medical Bulletin** 1983;30 (Suppl. 1):17.
2. **Ohman EM**, Butler J, Fitzgerald D, Kelly J, Horgan J, O'Malley K. Beta-adrenoceptor changes following physical training. **Irish Journal of Medical Science** 1984;153:288.f
3. **Ohman EM**, Teo KK, Johnson A, Collins P, Dowsett D, Ennis J, Horgan J. Cardiospecific creatine kinase after strenuous exercise in female athletes. **European Heart Journal** 1984;5 (Suppl. 1):170.
4. **Ohman EM**, Walsh T, Kelly J, O'Malley K. The effect of platelet contamination on beta-adrenoceptor binding assays in lymphocytes. **Irish Journal of Medical Science** 1985;154:478-479.
5. **Ohman EM**, Mulcahy D, Johnson A, Collins P, Horgan J. The value of acute-phase proteins in the detection of significant coronary-artery disease. **Acta Medica Scandinavica** 1986; (Suppl. 712):122.
6. **Ohman EM**, Teo KK, Johnson A, Collins P, Horgan J. A comparison of cardiospecific creatine kinase responses in female and male athletes after strenuous exercise. **Journal of The Irish Colleges of Physicians and Surgeons** 1986;15:94.
7. **Ohman EM**, Butler J, Kelly J, O'Malley K. Platelet alpha-2-adrenoceptor changes during acute exercise in man. **Acta Pharmacologica et Toxicologica** 1986;59 (Suppl. 5):53.
8. **Ohman EM**, Casey C, Tormey W, Horgan J. Analysis of early markers of myocardial infarction. **British Heart Journal** 1987;57:563-564.
9. Brady H, Kinirons M, Lynch T, **Ohman EM**, Horgan J. Comparison between maximal exercise treadmill testing and tournament squash in men over 45 years. **British Heart Journal** 1987;57:574.
10. Conlon P, Crowe B, **Ohman EM**, Horgan J. Cardiac rehabilitation: exercise response and major cardiac events. **European Heart Journal** 1987;8 (Suppl. 2):58.
11. Buggy D, Graham T, O'Callaghan D, **Ohman EM**, Horgan J. Attitude to illness after cardiac rehabilitation. **European Heart Journal** 1987;8 (Suppl. 2):162.
12. **Ohman EM**, Helmy S, Stern H, Adams D, Kisslo J. In-vitro relationship of jet flow with area by Doppler color flow: are there correlations? **Journal of American College of Cardiology** 1988;11 (Suppl. A):19A.
13. Lynch T, Kinirons M, O'Callaghan D, Ismail Suad, **Ohman EM**, Horgan J. Effect of serial tournament squash games on some cardiovascular and metabolic measurements. **British Heart Journal** 1988;59:99.

14. Muller DW, Ellis SG, Kline EM, **Ohman EM**, Sigmon KN, Califf RM, Topol EJ. Silent vs clinically overt reocclusion following successful thrombolysis for evolving myocardial infarction. **European Heart Journal** 1989;10(Abstr Suppl.):276.
15. **Ohman EM**, Sigmon K, Wall TC, Lee KL, Candela RJ. Why do people die after thrombolytic therapy? **Circulation** 1989;80 (Suppl. II):II-349.
16. **Ohman EM**, Nelson C, Kong YH, Peter RH, Bauman RP, Herndon JE. Characteristics and clinical consequences of reinfarction: benefits of aggressive reperfusion. **Circulation** 1989;80 (Suppl. II):II-479.
17. Christenson R, **Ohman EM**, Clemmensen P, Wagner GS. Creatine kinase MM3/MM1 and MB1/MB2 isoform ratios after reperfusion in patients with acute myocardial infarction. **Circulation** 1989;80 (Suppl. II):II-513.
18. Munster M, Bengtson J, Aronson L, **Ohman EM**. Long term ICU stay: benefit or burden. **Heart & Lung** 1990;19:310.
19. Chapman GD, O'Connor CM, Kereiakes DJ, George BS, Candela RJ, Abbottsmith CW, Harrelson L, **Ohman EM**. Consequences of misdiagnosis of acute myocardial infarction leading to thrombolytic therapy: a multicenter experience. **Journal of the American College of Cardiology** 1990;15 (Suppl. A):227A.
20. **Ohman EM**, Califf RM, Lee KL, Fortin DF, Frid DJ, Bengtson JR. Restenosis after angioplasty: overview of clinical trials using aspirin and omega-3 fatty acids. **Journal of the American College of Cardiology** 1990;15 (Suppl. A):88A.
21. Stack RS, Phillips HR, Quigley PJ, Tcheng JE, Bauman RP, **Ohman EM**, O'Neill WW, Galichia JT, Walker C. Multicenter registry of coronary atherectomy using the transluminal extraction-endarterectomy catheter. **Journal of the American College of Cardiology** 1990;15 (Suppl. A):196A.
22. Christenson RH, **Ohman EM**, Clemmensen P, Wagner G. Release of the tissue isoforms of creatine kinase, MM3 and MB2, is simultaneous after myocardial reperfusion. **Clinical Chemistry** 1990;36:1128.
23. Christenson RH, **Ohman EM**, Clemmensen P, Grande P, Wagner GS. Assay dependency for assessing creatine kinase-MB release after myocardial reperfusion. **Clinical Chemistry** 1990;36:1129.
24. Clemmensen P, **Ohman EM**, Sevilla D, Peck S, Wagner N, Lee KL, Grande P, Wagner G. Changes in standard electrocardiographic ST segment elevation predictive of successful reperfusion in evolving acute myocardial infarction. **European Heart Journal** 1990;11(Abstr Suppl.):411.
25. Nelson CL, Tcheng JE, Frid DJ, Fortin DF, **Ohman EM**, Califf RM, Stack RS. Incomplete angiographic follow-up results in significant underestimation of true restenosis rates after PTCA. **Circulation** 1990;82 (Suppl. III):III-312.

26. Gurbel PA, **Ohman EM**, Sawchak SR, Phillips HR, Peter RH, Kong Y, Stack RS. An alternative to rescue PTCA: intracoronary urokinase infusion by a new technique. **Circulation** 1990;82 (Suppl. III):III-190.
27. **Ohman EM**, Christenson RH, Sigmon KN, Flanagan CH, Frid DJ, Califf RM, for the TAMI Study Group. Non-invasive detection of reperfusion after thrombolysis using rapid CK-MB analysis. **Circulation** 1990;82 (Suppl. III):III-281.
28. Christenson RH, **Ohman EM**, Sigmon KN, Flanagan CH, and the TAMI Study Group. Release of the tissue specific MM-3 and MB-2 isoforms of creatine kinase is simultaneous during reperfusion after myocardial infarction. **Circulation** 1990;82 (Suppl. III):III-297.
29. Clemmensen P, **Ohman EM**, Sevilla D, Peck S, Wagner NB, Grande P, Wagner GS. Changes in standard electrocardiographic ST segment elevation predictive of successful reperfusion in evolving acute myocardial infarction. **Circulation** 1990;82 (Suppl. III):III-356.
30. **Ohman EM**, George BS, Kereiakes DJ, Samaha JK, Topol EJ, Berrios ED, Sigmon KN, Califf RM, for the TAMI Study Group. Event-free hospitalization after early and sustained patency using combination thrombolytic therapy in acute myocardial infarction. **Journal of the American College of Cardiology** 1991;17 (Suppl. A):187A.
31. **Ohman EM**, Sigmon KN, Samaha JK, Stack RS, George BS, Pickel A, Kereiakes DJ, Lee KL, Califf RM, for the TAMI Study Group. Prediction of reocclusion after successful reperfusion during acute myocardial infarction. **Journal of the American College of Cardiology** 1991;17 (Suppl. A):187A.
32. Christenson RH, **Ohman EM**, Sigmon KN and the TAMI Study Group. Use of creatine kinase-MB and the MB isoforms for non-invasively assessing reperfusion after thrombolytic therapy in acute myocardial infarction (AMI) patients. **Clinical Chemistry** 1991;37(6):913.
33. Clemmensen P, **Ohman EM**, Sevilla D, Wagner NB, Grande P, Wagner GS. Electrocardiographic estimation of global and regional function of acutely jeopardized myocardium. **European Heart Journal** 1991;12 (Abstr Suppl.):137.
34. Clemmensen P, Jurlander B, Grande P, **Ohman EM**, Wagner GS. Monitoring peak serum-myoglobin for non-invasive prediction of coronary reperfusion in patients. **Circulation** 1991;84 (Suppl. II):II-116.
35. Kleiman NS, **Ohman EM**, Kereiakes DJ, Ellis SG, Weisman HF, Topol EJ, for the TAMI 8 Investigators. Profound platelet inactivation with 7E3 shortly after thrombolytic therapy for acute myocardial infarction. **Circulation** 1991;84 (Suppl. II):II-522.

36. **Ohman EM**, Marquis JF, Ricci DR, Brown RIG, Knudtson ML, Kereiakes DJ, Samaha JK, Margolis JR, Niederman AL, Dean LJ, Gurbel PA, Sketch MH, Wildermann NM, Lee KL, Califf RC, for the PBC Study Group. Effect of gradual prolonged inflation during angioplasty on in-hospital and long-term outcome: results of a multicenter randomized trial. **Journal of the American College of Cardiology** 1992;19 (Suppl. A):33A.
37. Califf RM, Topol EJ, **Ohman EM**, Kereiakes DJ, George BS, Leimberger JD, Mark DB, Klinker KA, and the TAMI Study Group. Isolated recurrent ischemia after thrombolytic therapy is a frequent, important and expensive adverse clinical outcome. **Journal of the American College of Cardiology** 1992;19 (Suppl. A):301A.
38. Christenson RH, **Ohman EM**, Wall TC, Sigmon KN, Martin LH, Chapekis AT, Topol EJ, Califf RM, for the TAMI Study Group. Relationship between infarct related coronary artery flow after thrombolytic therapy and release of tissue specific isoforms of creatine kinase. **Journal of the American College of Cardiology** 1992;19 (Suppl. A):303A.
39. **Ohman EM**, Califf RM, Topol EJ, Leimberger JD, George B, Berrios ED, Anderson LC, Kereiakes DJ, Stack RS, and the TAMI Study Group. Aortic counterpulsation with thrombolysis for myocardial infarction: salutary effect on reocclusion of the infarct related artery. **Journal of the American College of Cardiology** 1992;19 (Suppl. A):381A.
40. Clemmensen P, **Ohman EM**, Sevilla D, Wagner NB, Grande P, Wagner GS. Should coronary reperfusion with TIMI 2 flow following thrombolysis be termed a therapeutic success or failure? **European Heart Journal** 1992;13 (Abstr Suppl.):187.
41. Hillegass WB, Mark DB, Jollis JG, **Ohman EM**, Pryor DB. Streptokinase therapy for acute myocardial infarction is cost-effective in the elderly. **Circulation** 1992;86 (Suppl.):I-40.
42. Granger CB, O'Connor CM, Bleich SD, Col JJ, Keeler GP, **Ohman EM**. An overview of the effect of intravenous heparin on clinical endpoints following thrombolytic therapy for acute myocardial infarction. **Circulation**. 1992;86 (Suppl.):I-259.
43. Kleiman NS, **Ohman EM**, Ellis SG, Aguirre FV, Weisman H, Schaible T. Infarct vessel patency is enhanced by profound platelet inhibition with fibrinogen receptor blockade with 7E3 in patients receiving thrombolysis for acute myocardial infarction. **Circulation** 1992;86 (Suppl.):I-260.
44. **Ohman EM**, Christenson RH, Granger CB, Berrios E, Worley S, O'Connor CM, Sigmon K, Lee K, Phillips HR. Non-invasive detection of reperfusion after thrombolysis based on clinical assessment and rapid CK-MB analysis. **Circulation** 1992;86 (Suppl.):I-268.

45. Granger CB, **Ohman EM**, Bates E. Pooled analysis of angiographic patency rates from thrombolytic therapy trials. **Circulation** 1992;86 (Suppl.):I- 269.
46. **Ohman EM**, Christenson RH, Califf RM, Krucoff MW, Sigmon K, Quintero K, George BS, Ellis SG, Topol, EJ. Clinical outcome based on a probability index for non-invasive detection of reperfusion. **Journal of the American College of Cardiology** 1993;21:197A.
47. Kereiakes DJ, Knudtson ML, **Ohman EM**, Broderick TM, Marquis J-F, Gurbel PA, Tchong JE, Owens P, Sketch MH. Prolonged dilation improves initial results during PTCA of complex coronary stenoses: Results from a randomized trial. **Journal of the American College of Cardiology** 1993;21:290A.
48. **Ohman EM**, Kelsey SF, Wisniewski SR, Lee KL, Alderman EL, Califf RM. Consistency of assessment of eligibility for multivessel revascularization by physician enrolling in the bypass angioplasty revascularization investigation. **Journal of the American College of Cardiology** 1993;21:339A.
49. **Ohman EM**, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ, Lundergan C, Hartmann JR, Talley JD, Frey MJ, Taylor G, Leimberger JD, Owens PM. The use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: Results of a randomized trial. **Journal of the American College of Cardiology** 1993;21:397A.
50. Christenson RH, **Ohman EM**, Duh SH, Sigmon KN, Klinker KA, Vollmer RT, Wall TC. How well does time-to-peak enzyme concentration predict coronary patency after thrombolytic therapy? **Journal of the American College of Cardiology** 1993;21:398A.
51. **Ohman EM**, George B, White C, Kern M, Gurbel P, Freedman R, Lundergan C, Hartmann J, Talley D, Taylor G, Leimberger J, Owens P, Stack R, Califf R. The use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: results of a randomized trial. **European Heart Journal** 1993;14 (Abstr Suppl.):119.
52. Kleiman NS, White HD, **Ohman EM**, Topol EJ, for the GUSTO Investigators. Mortality 24 hours after thrombolysis in the GUSTO trial: Corroborating evidence for the importance of early reperfusion. **Circulation** 1993;88 (Suppl.):I-17.
53. **Ohman EM**, George BS, White CJ, Gurbel PA, Freedman RJ, Lundergan CF, Hartmann JR, Prince CR, Frey M, Taylor G, Leimberger JD, Stack RS, for the Randomized IABP Study Group. Reocclusion of the infarct-related artery after primary or rescue angioplasty: Effect of aortic counterpulsation. **Circulation** 1993;88 (Suppl.):I-107.
54. Miller J, Granger C, Bovill E, Krucoff M, Berrios E, Harrington R, **Ohman EM**, Califf RM. Rebound increase in thrombin activity after cessation of intravenous heparin. **Circulation** 1993;88 (Suppl.):I-202.

55. Christenson RH, **Ohman EM**, Sigmon KN, Berrios E, Alonsozana GL, Smith DD, Duh SH, Krucoff MW, for the TAMI Study Group. Use of myoglobin for noninvasively assessing coronary reperfusion. **Circulation** 1993;88 (Suppl.):I-258.
56. **Ohman EM**, Armstrong PW, Guerri AD, Vahanian A, for the GUSTO Trial Investigators. Reinfarction after thrombolytic therapy: experience from the GUSTO trial. **Circulation** 1993;88 (Suppl.):I-490.
57. Barbash GI, **Ohman EM**, White HD, Granger C, Califf RM, for the GUSTO Trial Investigators, Rescue thrombolysis for suspected reinfarction following thrombolytic therapy: experience from the GUSTO trial. **Journal of the American College of Cardiology** 1994;23 (Suppl.):29A.
58. Wilson JS, **Ohman EM**, Perez JA, Gardner LH, Nelson CL, Phillips HR, Sketch MH. Use of prolonged perfusion balloon inflation of 60 minutes as a "temporary stent" to salvage initially unsuccessful coronary interventions: acute and long-term outcome. **Journal of the American College of Cardiology** 1994;23 (Suppl.):58A.
59. Ellis SG, Lincoff AM, George BS, Kereiakes DJ, Krucoff MW, **Ohman EM**, for the TAMI Investigators. Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for acute myocardial infarction. **Journal of the American College of Cardiology** 1994;23 (Suppl.):244A.
60. Labinaz M, Tanguay J-F, Puma JA, **Ohman EM**, Phillips H, Sketch MH. The role of perfusion balloon angioplasty in the management of saphenous vein bypass grafts. **Journal of the American College of Cardiology** 1994;23 (Suppl.):352A.
61. Labinaz M, **Ohman EM**, Sketch M, Marquis J-F, Fortin D, Labinaz D, Owens P, Dowell H, Green C, Wildermann N, Califf R. Directional coronary atherectomy versus perfusion balloon angioplasty in the proximal left anterior descending artery. **Journal of the American College of Cardiology** 1994;23 (Suppl.):386A.
62. Hillegass WB, Brott BC, **Ohman EM**. Outcomes after percutaneous transluminal coronary angioplasty: a physician derived composite index. **Catheterization and Cardiovascular Diagnosis** 1994;32:93.
63. **Ohman EM**, George BS, White CJ, Kern MJ, Freedman RJ, Hartmann JR, Leimberger JD, Berdan LG, Stack RS, for the Randomized IABP Study Group. Long-term follow-up after aortic counterpulsation insertion in acute myocardial infarction: results from a randomized clinical trial. **Circulation** 1994;90 (Suppl.):I-169.

64. **Ohman EM**, Kleiman NS, Talley JD, Gacioch G, Navetta FI, Carney RJ, Worley S, Anderson HV, Cohen M, Kereiakes D, Joseph D, Sigmon KN, Topol EJ, for the IMPACT-AMI Study Group. Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. **Circulation** 1994;90 (Suppl.):I-564.
65. Talley JD, **Ohman EM**, George BS, Kern MJ, White CJ, Lundergan C, Hartmann JR, Gurbel PA, Phillips HR, Berdan LG, Lam LC, Califf RM, Mark DB. Cost implications of aortic counterpulsation in acute myocardial infarction: results from a randomized clinical trial. **Journal of the American College of Cardiology** 1995;25 (Suppl.):87A.
66. Hillegass WB, **Ohman EM**, O'Hanesian MA, Harrington RA, Faxon DP, Fortin DF, Ellis SG, Stack RS, Holmes DR, Califf RM. The effect of preprocedural intracoronary thrombus on patient outcome after percutaneous coronary intervention. **Journal of the American College of Cardiology** 1995;25 (Suppl.):94A.
67. **Ohman EM**, Armstrong P, Califf, RM, O'Hanesian MA, Hamm CW, Katus H, Granger CB, Christenson RH, Cianciolo C, Topol EJ for the GUSTO-IIa Investigators. Risk stratification in acute ischemic syndromes using serum troponin T. **Journal of the American College of Cardiology** 1995;25 (Suppl.):148A.
68. Christenson RH, **Ohman EM**, Sigmon KN, O'Hanesian MA, Alonsozana GL, Newby KN, Duh SH, Krucoff MW, Califf RM for the TAMI Study Group. Combining myoglobin and clinical variables for assessing coronary reperfusion after thrombolytic therapy. **Journal of the American College of Cardiology** 1995;25 (Suppl.):148A.
69. Talley JD, Krucoff MW, Ferguson J, Whitlow P, Ellis S, Tcheng JE, **Ohman EM**, Califf RM, Rawert M, Ziegler C. Survival of patients with severe ischemic left ventricular dysfunction: results from the high risk myocardial ischemia trial-II registry. **Catheterization and Cardiovascular Diagnosis** 1995;35:88.
70. Alonsozana, G, Duh SH, **Ohman EM**, Cianciolo C, O'Hanesian MA, Christenson RH. Estimation of the analytical cutoff in EDTA plasma for a rapid assay device for cardiac troponin-T. **Clinical Chemistry**, 1995;41:S154.
71. **Ohman EM**, Talley JD, George BS, Kern MJ, White CJ, Lundergan C, Hartmann JR, Gurbel PA, Phillips HR, Berdan LG, Lam LC, Califf RM, Mark DB. Cost implications of aortic counterpulsation in acute myocardial infarction: results from a randomized clinical trial. **European Heart Journal**. 1995;16 (Suppl.):102.
72. Christenson, RH, O'Hanesian M, Newby LK, Duh SH, O'Connor C, Worley S, George B, Vollmer RT, Sigmon KN, **Ohman EM**, and TAMI Group. Relation of area under the CK-MB release curve and ventriculographic and clinical outcomes in myocardial infarction patients treated with thrombolytic therapy. **European Heart Journal**. 1995;16 (Suppl.):122.

73. **Ohman EM**, Armstrong P, Califf RM, O'Hanesian MA, Hamm CW, Katus H, Granger CB, Christenson RH, Cianciolo C, Topol EJ, for the GUSTO-IIa Investigators. Risk stratification in acute ischaemic syndromes using serum troponin T. **European Heart Journal**. 1995;16 (Suppl.):179.
74. Gurbel P, Navetta F, Muhlstein B, Tenaglia A, Muller D, Davidson C, Berdan L, McKenzie D, Bovill E, **Ohman EM**. Prospective study of lesion-directed tissue plasminogen activator combined with intracoronary heparin prior to percutaneous transluminal coronary angioplasty in unstable angina with thrombus: acute and long-term results. **European Heart Journal**. 1995;16 (Suppl.):426.
75. Anderson RD, Stebbins AL, Bates E, Stomel R, Granger CB, **Ohman EM**. Underutilization of aortic counterpulsation in patients with cardiogenic shock: observations from the GUSTO-I study. **Circulation**. 1995;92 (Suppl. I):I-139.
76. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, **Ohman EM**, Faxon DP. Impact of estrogen replacement therapy on restenosis following percutaneous coronary interventions. **Circulation**. 1995;92 (Suppl. I):I-345.
77. Berger PB, **Ohman EM**, O'Hanesian MA, Murphy J, Bell MR, Faxon DP, MARCATOR Investigators. Is the high six month reocclusion rate following successful PTCA of chronic coronary occlusions associated with adverse cardiovascular events? Results from the MARCATOR trial. **Circulation**. 1995;92 (Suppl. I):I-345.
78. Krucoff MW, **Ohman EM**, Trollinger KM, Green CL, Sawchak ST, Kleiman NS, Gacioch G, Worley S, Carney RJ, Nevetta FI, Pope JE, for the IMPACT-AMI Investigators. Beneficial impact of a platelet inhibitor, integrelin, on parameters of continuous 12-lead ST-segment recovery during myocardial infarction. **Circulation**. 1995;92 (Suppl. I):I-416.
79. Harrington RA, **Ohman EM**, Sigmon KN, Kleiman NS, Schulman SP, Kottke-Marchant K, Lincoff AM, Joseph D, Parker J, Kitt MM, Tcheng JE. Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states. **Circulation**. 1995;92 (Suppl. I):I-488.
80. Christenson RH, Armstrong PW, O'Hanesian MA, Hamm CW, Katus H, Cianciolo C, **Ohman EM**, for the GUSTO-IIa Investigators. The value of serial troponin T measurements for risk stratification in patients with acute ischemic syndromes. **Circulation**. 1995;92 (Suppl. I):I-663.
81. **Ohman EM**, Kleiman NS, Gacioch G, Worley S, Talley JD, Navetta FI, Anderson HV, Spriggs D, Miller M, Cohen M, Kereiakes D, George BS, Sigmon KN, Krucoff M, Califf RM, Topol EJ, for the IMPACT-AMI Group. Simultaneous platelet glycoprotein IIb/IIIa Integrin blockade and front-loaded tissue plasminogen activator in acute myocardial infarction: results from a randomized trial. **Journal of the American College of Cardiology**. 1996;27 (Suppl. A):167A

82. Anderson RD, Wildermann NM, Holmes DR, Jr., O'Conner CM, Harrington RA, Phillips HR, Califf RM, **Ohman EM**. Prognostic value of a history of congestive heart failure in patients undergoing percutaneous coronary interventions. **Journal of the American College of Cardiology**. 1996;27(Suppl. A):180A
83. Sketch MH, Jr., DeFranco AC, Puma JA, Stinnett SS, **Ohman EM**, Topol EJ, Califf RM, for the GUSTO-I Investigators. Impact of percutaneous revascularization on clinical outcome following acute myocardial infarction - an analysis of 40,745 patients. **Journal of the American College of Cardiology**. 1996;27 (Suppl. A):220A
84. Pilote L, **Ohman EM**, Miller DP, Califf RM, Topol EJ, GUSTO-I Investigators. Ischemia after thrombolysis is frequent, somewhat predictable, and pre-empted by early angiography. **Journal of the American College of Cardiology**. 1996;27 (Suppl. A):249A
85. Chaitman BR, Jacobs AK, **Ohman EM**, Krone RJ, Mullany CJ, Sopko G, Gussak I, Sutton-Tyrrell K, Rosen AD, and the BARI Investigators. Periprocedure myocardial infarction rates in the bypass angioplasty revascularization investigation (BARI). **Journal of the American College of Cardiology**. 1996;27 (Suppl. A):361A
86. Barbeau GR, Marquis JF, Almond D, Kells C, Adelman A, **Ohman EM**, on behalf of the PRIME Investigators. PRIME: A multicenter study comparing efegatran sulfate to heparin in conjunction with tPA and aspirin in acute myocardial infarction. **Canadian Journal of Cardiology**. 1996;12 (Suppl. E):169E.
87. Kern MJ, Lasorda D, **Ohman EM**, Schnitzler RN, King DL, Ohley WJ, Grayzel J. Effects of new intraaortic balloon counterpulsation timing methods on optimizing hemodynamics in patients. **Circulation**. 1996;94 (Suppl. I):I-111.
88. **Ohman EM**, Christenson RH, Peck S, Pieper K, Katus H, Newby K, Armstrong P. Comparison of troponin I and T for risk stratification in patients with acute coronary syndromes. **Circulation**. 1996;94 (Suppl. I):I-323.
89. **Ohman EM**, Slovak JP, Anderson RL, Grossman WJ, Barbeau GR, Butler JF, Frey MJ, Talley DJ, Leimberger JD, Scherer JC, Kleiman S, The PRIME Group. Potent inhibition of thrombin with efegatran in combination with tPA in acute myocardial infarction: results of a multicenter randomized dose ranging trial. **Circulation**. 1996;94 (Suppl. I):I-430.
90. Barsness GW, Peterson ED, **Ohman EM**, Nelson CL, Califf RM. The role of diabetes in long-term survival after coronary bypass and angioplasty. **Circulation**. 1996;94(8):I-436.
91. Anderson RD, Wildermann NW, Harrington RA, Barsness GW, Faxon DP, **Ohman EM**. The association between a history of diabetes and outcome in patients undergoing percutaneous interventions. **Circulation**. 1996;94 (Suppl. I):I-436.

92. Kleiman NS, **Ohman EM**, Tracy RP, Sigmon KN, Joseph D, Kitt M, Harrington RA, Worley S, Talley JD, The IMPACT AMI Investigators. Thrombin generation and activity persist despite more effective thrombolysis with glycoprotein IIb/IIIa inhibition and t-PA: a role for thrombin antagonists? **Circulation**. 1996;94 (Suppl. I):I-511.
93. Barsness GW, **Ohman EM**, Thompson TD, Sketch MH Jr., Holmes DR Jr., Califf RM. Early hazard of “rescue” angioplasty after thrombolysis is reduced by improved long-term outcome. **Journal of the American College of Cardiology**. 1997;29 (Suppl. A):71A.
94. Krucoff MW, Green CL, Trollinger KM, Pope JE, Harrington RA, Granger CB, **Ohman EM**, Neuhaus K, Topol EJ, Califf RM. Temporal distribution of important ECG information in patients with MI: when should you take the next ECG after lytics? **Journal of the American College of Cardiology**. 1997;29 (Suppl. A):131A.
95. Newby LK, **Ohman EM**, Granger BB, Sawyer T, Sedor F, Holleman CM, Califf RM. Use of diagnostic tools in a chest pain evaluation unit: value of troponin T testing. **Journal of the American College of Cardiology**. 1997;29 (Suppl. A):211A.
96. Tardiff BE, Mabe B, Wildermann N, Sketch MH, Jr., Holmes DR, Jr., **Ohman EM**, Califf RM. Predictors of myocardial infarction (MI) with percutaneous revascularization in a large multicenter population. **Journal of the American College of Cardiology**. 1997;29 (Suppl. A):277A-278A.
97. Overlie PA, Shawl FA, George BS, **Ohman EM**, Mooney MR, Freedman RJ, Jr., Teirstein PS, Smith SC, Jr., Stertzer S, Vogel RA for the National Registry of Emergency Cardiopulmonary Bypass Investigators. Cardiogenic shock: survival rates from the National Registry for Emergency Cardiopulmonary Bypass Investigators. **Journal of the American College of Cardiology**. 1997;29 (Suppl. A):398A.
98. Krucoff MW, Green CL, Trollinger KM, Pope JE, Granger CB, **Ohman EM**, Califf RM. ST-segment recovery parameters predictive of outcome in AMI: variability with infarct artery location and implications for therapeutic targets. **Journal of the American College of Cardiology**. 1997;29 (Suppl. A):412A-413A.
99. Barsness GW, **Ohman EM**, Leimberger JD, Berrios ED, George BS, Kereiakes DJ, Topol EJ, Califf RM, for the TAMI Study Group. Beneficial effect of early aortic counterpulsation with rescue angioplasty for failed thrombolysis in myocardial infarction. **Catheterization and Cardiovascular Diagnosis**. 1997;41(1):109.
100. Barsness GW, **Ohman EM**, Trollinger KM, Green CL, Krucoff MW for the PRIME Investigators. Antithrombotic therapy with efegatran improves 12-lead ST-segment recovery during myocardial infarction. **European Heart Journal**. 1997;18: 636 (Suppl.).

101. Miller JM, Phillips HR, Sketch MH, Jr., Wildermann N, Barsness GW, Wightman MB, Anderson D, Smith P, **Ohman EM**. Discordance of clinical and angiographic characteristics in predicting early PTCA failures and mortality. **Circulation**. 1997;96 (Suppl. I):I-22.
102. Newby K, Christenson RH, Peck S, Katus HA, Hamm CW, Armstrong PW, **Ohman EM**. Risk stratification by troponin T occurs within the first 30 days of acute coronary syndromes: one year results from the GUSTO-IIa Troponin T Substudy. **Circulation**. 1997;96 (Suppl. I): I-215.
103. **Ohman EM**, Armstrong PW, Weaver WD, Gibler WB, Bates ER, Stebbins AL, Hochman JS. Prognostic value of whole-blood qualitative troponin T testing in patients with acute myocardial infarction in the GUSTO-III trial. **Circulation**. 1997;96 (Suppl. I): I-216.
104. Janning C, Newark N, Moffie I, Gibler B, Schildcrout JS, **Ohman EM**. Can bolus reteplase therapy enhance time to thrombolysis? observations from the GUSTO-3 Nursing Substudy. **Circulation**. 1997;96 (Suppl. I): I-259.
105. Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, **Ohman EM**. Platelet aggregation and major surface receptor expression during the first 24 hours of reteplase or alteplase treatment in patients with acute myocardial infarction: the GUSTO-III Platelet Study. **Circulation**. 1997;96 (Suppl. I): I-261.
106. Miller JM, Barsness GW, Leimberger JD, Gard J, **Ohman EM**, Glassman J, Brown DL, Bengtson JR, Marsh D, Carr K, Moliterno DJ. Direct thrombin inhibition with efegatran does not suppress heightened thrombin generation during thrombolysis for acute myocardial infarction. **Circulation**. 1997;96 (Suppl. I): I-534.
107. Menon V, Hochman J, Holmes D, Bates E, Anderson R, Califf R, Topol E, **Ohman EM** for the GUSTO III Investigators. Lack of progress in cardiogenic shock: lessons from the GUSTO Trials. **Journal of the American College of Cardiology**. 1998;31 (Suppl. A):136A.
108. Miller J, **Ohman EM**, Schildcrout J, Smalling R, Betriu A, Califf R, Topol E. Survival Benefit of Abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III trial. **Journal of the American College of Cardiology**. 1998;31 (Suppl. A):191A.
109. Krucoff M, Green C, Trollinger K, Granger C, **Ohman EM**, O'Conner C, Harrington R, Armstrong P, Simoons M, Topol E, Califf R. A comparison of static serial vs continuous ST-segment recovery to predict outcome after lytics for MI. **Journal of the American College of Cardiology**. 1998;31 (Suppl.A):228A-229A.

110. Anderson R, White H, **Ohman EM**, Wagner G, Krucoff, Armstrong P, Iparraguirre H, Weaver W, Gibler W, Califf R. Resolution of ST-segment elevation 90 minutes after thrombolysis for acute myocardial infarction predicts outcome: a GUSTO-III substudy. **Journal of the American College of Cardiology**. 1998;31 (Suppl. A):371A.
111. Kong DF, Hasselblad V, Tcheng JE, **Ohman EM**, Topol EJ, Califf RM. Clinical outcome improvements from coronary stenting: a systematic overview. **European Heart Journal**. 1998;19 (Suppl.):571.
112. Miller JM, **Ohman EM**, Schildcrout JS, Moliterno DJ, Hochman JS, Karnash SL, Califf RM. Hormone replacement therapy among postmenopausal women with acute myocardial infarction: Insights from GUSTO-III. **Circulation**. 1998;98 (Suppl.): I-8.
113. Cohen MG, Stebbins AL, Grinfeld LR, Cagide AM, Betriu A, **Ohman EM**. Outcome and resource use among Hispanics with myocardial infarction: the GUSTO-I and III experience. **Circulation**. 1998;98 (Suppl.) I-274.
114. Barsness GW, Buller CE, **Ohman EM**, Hasdai D, Schechter E, Pucillo AL, Taylor M, Miller MJ, Reiner JS, Churchill D, Wildermann N, Holmes DR. Reduced thrombus burden in saphenous vein grafts with abciximab given through a local delivery catheter. **Circulation**. 1998; 98 (Suppl.): I-354.
115. Fu Y, Armstrong PW, Chang W, **Ohman EM**, Gupta M, Morris A, Roth SN, Granger CB, Califf RM, Mark DB. Impact of temporal trends in management on outcomes of acute myocardial infarction in Canada versus US. **Circulation**. 1998; 98 (Suppl.): I-479.
116. Hudson MP, White HD, Anderson RD, Stebbins AL, Greenbaum AB, Wagner GS, Armstrong PW, **Ohman EM**. Bedside risk stratification using both troponin T and ST-segment resolution in acute myocardial infarction: a GUSTO-III substudy. **Circulation**. 1998; 98 (Suppl.): I-493.
117. **Ohman EM**, Lincoff AM, Bode C, Bachinsky WB, Ardissino D, Betriu A, Schildcrout JS, Oliverio R, Barnathan E, Scherer J, Sketch MS, Topol EJ. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: preliminary results from the GUSTO-IV Pilot (SPEED) dose-ranging trial. **Circulation**. 1998;98 (Suppl.): I-504.
118. Greenbaum AB, Harrington RA, Hudson MP, Miller GP, MacAulay CM, Berdan LG, Guerci A, Kitt MM, Califf RM, **Ohman EM**. Enhanced benefit of eptifibatide in patients with acute coronary syndromes using a seamless transition from community hospitals to tertiary care centers. **Circulation**. 1998; 98 (Suppl.): I-561.

119. Miller JM, **Ohman EM**, Hasselblad V, Granger CB, Sketch MH, Kong DF, Califf RM. Can TIMI grade 3 flow at 60 minutes after thrombolysis substitute as a new angiographic standard? a meta-analytic approach. **Circulation**. 1998; 98 (Suppl.): I-784.
120. Cantor WJ, Wildermann NM, Sketch MH, Peterson ED, Zidar JP, Tcheng JE, Califf RM, **Ohman EM**. Favourable clinical outcomes with standard balloon angioplasty when stent-like results are achieved. **Journal of the American College of Cardiology**; 1999 (Suppl. A) 33:81A.
121. **Ohman EM**, The GUSTO Investigators. Durability of treatment effect of thrombolysis for acute myocardial infarction: The GUSTO trials. **Journal of the American College of Cardiology**. 1999; 33 (Suppl. A):380A.
122. Kip KE, Detre KM, Jacobs AK, Bourassa MG, Keller NM, **Ohman EM**, Schwartz L, Sopko G, Weiss M, Klee GG. Relationship between C-reactive protein and 5-year clinical outcome in a subset of patients from the bypass angioplasty revascularization investigation (BARI). **Journal of the American College of Cardiology**. 1999; 33 (Suppl. A):288A.
123. Hudson MP, Granger CB, Pieper KS, Armstrong PW, Guerci AD, Vahanian A, Califf RM, **Ohman EM**. Reinfarction after thrombolytic therapy: experience from the GUSTO-I and -III trials. **Journal of the American College of Cardiology**. 1999; 33 (Suppl. A):325A.
124. Verheugt FWA, **Ohman EM**, Antman EM. Emergency room infusion of abciximab speeds up reperfusion in acute myocardial infarction eligible for primary PTCA. **Journal of the American College of Cardiology**. 1999; 33 (Suppl. A):354A.
125. Lederman RJ, Hagan PG, Knight BP, Eitzman DT, **Ohman EM**, Bates ER. Cardiogenic shock complicating right ventricular myocardial infarction: outcome after percutaneous revascularization. **Journal of the American College of Cardiology**. 1999; 33 (Suppl. A):367A.
126. Cohen MG, Granger CB, Gore JM, Ferreira JS, Criger DA, **Ohman EM**, Topol EJ, Califf RM. Mortality is not increased with pulmonary artery catheterization in acute coronary syndromes: The GUSTO trials. **Journal of the American College of Cardiology**. 1999; 33 (Suppl. A):395A.
127. Bode C, Cantor WJ, **Ohman EM**, Betriu A, Forycki F, Morocutti G, Ardissino D, Aylward PE, Califf RM, Topol EJ. Importance of antithrombin therapy in combination with abciximab and low-dose fibrinolytic therapy: preliminary results of the GUSTO IV Pilot study. **European Heart Journal**. 1999;20 (Suppl.):286.
128. Verheugt FWA, **Ohman EM**, Antman EM. Emergency room infusion of abciximab speeds up reperfusion in acute myocardial infarction eligible for primary PTCA. **European Heart Journal**. 1999; 20 (Suppl.):616.

129. Herrmann HC, Moliterno DJ, Bode C, Betriu A, Lincoff AM, **Ohman EM**. Combination abciximab and reduced-dose reteplase facilitates early PCI in acute MI: results from the SPEED trial. **Circulation**. 1999; 100 (Suppl.):I-188.
130. Kaplan AL, Newby K, Granger BB, Sedor FA, **Ohman EM**. Long-term prognostic value of troponin T testing in a Chest Pain Unit. **Circulation**. 1999; 100 (Suppl.):I-290.
131. Hudson MP, Granger CB, Stebbins AL, White HD, Bates ER, Greenbaum AB, **Ohman EM**. Cardiogenic shock survival and use of intraaortic balloon counterpulsation: results from the GUSTO I and III trials. **Circulation**. 1999; 100 (Suppl.):I-370.
132. Singh M, **Ohman EM**, Gallup D, Reeder GS, Holmes DR, Hodgson P. Is angiographic thrombus still a marker of adverse outcome? **Circulation**. 1999; 100 (Suppl.):I-435.
133. Armstrong PW, Fu Y, Chang WC, Kaul P, Newby K, Granger CB, **Ohman EM**. Increased early discharge does not compromise mortality: insights from GUSTO I and GUSTO III. **Circulation**. 1999; 100 (Suppl.):I-499.
134. Cantor WJ, Kramer JM, Miller JM, Hellkamp AS, Peterson ED, Hasselblad V, Zidar JP, **Ohman EM**. Higher mortality in women following angioplasty explained by difference in **body** size, not **vessel** size. **Circulation**. 1999; 100 (Suppl.):I-780.
135. Cantor WJ, Peterson ED, Cowper PA, Hellkamp AS, Sketch MH, **Ohman EM**, Califf RM. Cost-effectiveness of two strategies for provisional stenting based on “stent-like” results. **Circulation**. 1999; 100 (Suppl.):I-790.
136. Stone GW, Castner CM, Cuffey RR, Miller MF, Ferguson JJ, Cohen M, Freedman R, **Ohman EM**, Graeber GM. Contemporary patterns of utilization and outcomes of intraaortic balloon counterpulsation in acute myocardial infarction. **Circulation**. 1999; 100 (Suppl.):I-809.
137. Goldmann BU, **Ohman EM**, Hamm CW, Bastos E, Newby K, Granger CB, Christenson RH, Califf RM. Is the adverse outcome with positive troponin T neutralized by revascularization? Results from GUSTO IIa. **Circulation**. 1999; 100 (Suppl.):I-810.
138. Roe MT, Granger CB, **Ohman EM**, Califf RM, Hellkamp A, Topol EJ, White HD, Hochman J, Van de Werf F. Hirudin significantly reduces ischemic events following coronary intervention for acute coronary syndromes. **Journal of the American College of Cardiology** 2000; 35(Suppl. A):39A.
139. Ferguson JJ, Cohen M, Miller MF, Joseph DL, Cuffey RR Jr., Freedman R, Jr., **Ohman EM**. Intra-aortic balloon counterpulsation in patients with cardiogenic shock: The BENCHMARK Registry experience. **Journal of the American College of Cardiology** 2000; 35(Suppl. A):197A.

140. Roe MT, Harrington RA, **Ohman EM**, Califf RM, Lincoff AM, Bhatt DL, Prosper DM, Topol EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. **Journal of the American College of Cardiology** 2000; 35(Suppl. A):347A.
141. Maas AC, Green CL, Shah SA, Trolling KM, French JK, **Ohman EM**, Harrington R, White HD, Topol EJ, Califf RM, Krucoff MW. Incremental effects of anti-platelet, anti-thrombin and fibrinolytic therapy on the speed and stability of ST-segment recovery after acute MI. **Journal of the American College of Cardiology** 2000; 35(Suppl. A):372A.
142. Hudson MP, Barbash GI, Granger CB, Birnbaum Y, Houbracken K, Pieper KS, **Ohman EM**, Topol EJ, Califf RM, Van de Werf F. Temporal and regional differences in therapy for reinfarction following thrombolysis: results from GUSTO I and ASSENT II. **Journal of the American College of Cardiology** 2000; 35(Suppl. A):386A.
143. Wong B, Gnarpe J, Teo KK, **Ohman M**, Prosser C, Gibler B, Langer A, Chang WC, Armstrong PW. Serologic evidence of current Chlamydia pneumoniae infection in acute coronary syndromes. **Canadian Journal of Cardiology** 2000;16(Suppl. F):161F.
144. O'Shea JC, Wilcox RG, Granger CB, Skene AM, Stebbins AL, Aylward PE, Sadowski, Z, Bode C, Califf RM, **Ohman EM**. Neither education level nor social isolation is an independent predictor of short-term mortality after acute myocardial infarction: results from the GUSTO III trial. **Circulation** 2000;102:18(Suppl.):II-511.
145. Wong CK, White HD, Wilcox RG, Criger DA, **Ohman EM**. New atrial fibrillation after acute myocardial infarction independently predicts mortality: the GUSTO-III experience. **Circulation** 2000;102:18(Suppl.):II-573.
146. Wong CK, White HD, Wilcox RG, Criger DA, **Ohman EM**. Does antiarrhythmic treatment alter outcome in atrial fibrillation complicating acute myocardial infarction? the GUSTO-III experience. **Circulation** 2000;102:18(Suppl.):II-573.
147. Newby LK, Storrow AB, Garvey JL, Tucker JF, Kaplan AL, Schreiber DH, Ross CR, Gibler WB, **Ohman EM**. Earlier and more effective risk stratification in chest pain units using near-patient, multimarker testing: results of the CHECKMATE study. **Circulation** 2000;102:18(Suppl.):II-588.
148. Newby LK, Christenson RH, **Ohman EM**, Armstrong PW, Harrington RA, White HD, Irl C, Califf RM, Topol EJ. Conversion of high-risk acute coronary syndromes to low(ER) risk via the use of troponin and platelet glycoprotein IIb/IIIa blockade. **Circulation** 2000;102:18(Suppl.):II-589.
149. Moliterno DJ, Antman EM, **Ohman EM**, Miller J, Marble SJ, Murphy SA, Ivanc TB, Schuhwerk K, Gibson CM. Concordance between core labs in trial results using TIMI flow grades & frame counts. **Circulation** 2000;102:18(Suppl.):II-590.

150. **Ohman EM**, Nanas J, Stomel RJ, Leeser MA, Nielsen D, Hudson MP, Fraulo B, Shaw LK, Lee KL, O'Dea D, Rogers FJ, Harber D. Thrombolysis and counterpulsation to improve cardiogenic shock survival (TACTICS): results of a prospective randomized trial. **Circulation** 2000;102:18(Suppl.):II-600.
151. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Armstrong PW, Califf RM, **Ohman EM**. Elevated troponin-I after percutaneous coronary intervention is a powerful prognostic indicator. **Circulation** 2000;102:18(Suppl.):II-753.
152. Mahaffey KW, Bastos EM, Christenson RH, Every NR, Weaver WD, **Ohman EM**. Peak creatine kinase and creatine kinase MB after acute myocardial infarction strongly correlate with ejection fraction and infarct size by nuclear imaging. **Circulation** 2000;102:18(Suppl.):II-796.
153. Bahit MC, Criger DA, Granger CB, **Ohman EM**, Wagner GS. Elevation of CK-MB greater than 2-fold and troponin greater than 3-fold are the best thresholds for identifying MI associated with ECG evolution. **Journal of the American College of Cardiology** 2001;37:115A-116A.
154. Al-Khatib SM, Ohman EM, Whiter HD, Granger CB, Califf RM, Kilaru R, Topol EJ. Atrioventricular nodal block in acute myocardial infarction treated with thrombolytic therapy is common and portends poor prognosis: results from large trials of thrombolytic therapy. **Journal of the American College of Cardiology** 2001;37:341A
155. Dyke CK, Mahaffey KW, Berdan LG, **Ohman M**, Newby K, Sparapani RA, Berger PB, Kleiman NS, White HD, Hochman JS, Van de Werf F, Armstrong PW, Califf RM, Harrington RA, Topol EJ. Optimal dosing of a glycoprotein IIb/IIIa antagonist with a simplified renal-based algorithm: pharmacodynamic and clinical findings from PARAGON B. **Journal of the American College of Cardiology** 2001;37:343A.
156. Goodman SG, Barr A, Granger C, **Ohman M**, Langer A, Armstrong P, Gibler B, Topol E. Medication errors and outcomes with fixed double-bolus r-PA versus bolus plus weight-adjusted infusion t-PA fibrinolysis: The GUSTO-III experience. **Journal of the American College of Cardiology** 2001;37:351A.
157. Yamada DM, Al-Khatib SM, **Ohman EM**, Topol. Effect of anti-arrhythmic treatment for sustained ventricular tachycardia in the setting of acute myocardial infarction. **Journal of the American College of Cardiology** 2001;37:357A.
158. Mahaffey KW, Roe MT, Sparapani R, Dyke CB, Alexander JH, Berdan LG, Granger CB, **Ohman M**, Califf RM, Topol EJ, Harrington RA. Cardiac enzyme elevations after coronary artery bypass grafting associated with increased risk of death: results from PARAGON-B. **Journal of the American College of Cardiology** 2001;37:359A.

159. McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, **Ohman EM**, Dougherty FC, Harrington RA, White HD, Van de Werf F, Califf RM, Topol EJ, the SYMPHONY Investigators. Diabetes doubles the risk of death among patients presenting with acute coronary syndromes: Insights from SYMPHONY, a large international trial. **Journal of the American College of Cardiology** 2001;37:372A-373A.
160. Roe M, **Ohman EM**, Bahr R, Fesmire FM, Yang H, Christenson R, Gibler WB. A randomized, placebo-controlled trial of early use of eptifibatide for patients with non-ST-segment elevation acute coronary syndromes in the emergency department-the EARLY pilot trial. **European Heart Journal** 2001; 22:(Suppl).
161. Giugliano RP, Roe MT, Antman EM, **Ohman EM**, Ronner E, Thompson SL, McCabe CH, Harrington RA, Braunwald E. Percutaneous coronary intervention with concomitant glycoprotein IIb/IIIa blockade following administration of full-dose fibrinolytic therapy. **Circulation** 2001;104:17(Suppl.):II-87.
162. Hudson MP, O'Connor CM, Gattis WA, Tasissa G, Holleman CM, Lu M, Sandberg KR, Gaulden LH, Sedor F, Hasselblad V, **Ohman EM**. Implications of elevated C-reactive protein in patients with heart failure. **Circulation** 2001;104:17(Suppl.):II-366.
163. Sanchez, CD, Newby LK, Hasselblad V, McNulty SE, Storrow AB, Gibler B, Garvey JL, Schreiber DH, Tucker JF, **Ohman EM**. Should diabetic patients with chest pain be assigned to chest pain units? **Circulation** 2001;104:17(Suppl.):II-378.
164. Ferguson JJ, Cohen M, Freedman R, **Ohman EM**, Stone GW, Christenson J, Reddy R, Urban P, Miller M, Dewhurst G. Evolving indications, complications and outcomes of IABC: results of the Benchmark Registry. **Circulation** 2001;104:17(Suppl.):II-439.
165. Hasdai D, Topol EJ, Kilaru R, Battler A, Simoons ML, Harrington RA, Vahanian A, **Ohman EM**, Granger CB, Van de Werf F, O'Connor CM, Holmes DR. Frequency, patient characteristics, and outcomes of mild to moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from four international fibrinolytic therapy trials. **Circulation** 2001;104:17(Suppl.):II-483.
166. Rao SV, Newby LK, **Ohman EM**, Granger CB, Hasselblad V, Gibler B, Christenson R. Elevated cardiac markers across a spectrum of patients with ACS: defining the role of isolated troponin or CK-MB elevation. **Circulation** 2001;104:17(Suppl.):II-708.
167. Greenbaum AB, **Ohman EM**, Gibson MS, Borzak SL, LeMay M, Lu M, Stebbins AL, Emanuelsson H, Weaver WD. Intravenous adenosine diphosphate P2T platelet receptor antagonism as an adjunct to fibrinolysis for acute myocardial infarction. **Journal of the American College of Cardiology** 2002;39(Suppl. A):281A.

168. Menon V, She L, Arshad R, Hellkamp AS, Rao SV, Hochman JS, **Ohman EM**. Outcomes for Asian Indians following acute ST elevation myocardial infarction: results from the GUSTI trials. **Journal of the American College of Cardiology** 2002;39(Suppl. A):290A.
169. Midodzi WK, Chang W, Fu Y, Boersma E, Cooper J, Barnathan E, Simoons ML, Wallentin L, **Ohman EM**, Armstrong PW. Assessment of international differences in 30-day event of death and reinfarction amongst patients with acute coronary syndromes: insights from GUSTO IV ACS. **Journal of the American College of Cardiology** 2002;39(Suppl. A):293A.
170. Aviles RJ, Askari AT, **Ohman EM**, Mahaffey KW, Newby LK, Berger P, Jia G, Califf RM, Lindahl B, Wallentin L, Topol EJ, Lauer MS. The inter-relationship between creatinine clearance, cardiac troponin T and outcomes in patients with acute coronary syndromes. **Journal of the American College of Cardiology** 2002;39(Suppl. A):305A.
171. **Ohman EM**, Califf RM, Lincoff M, Armstrong P, Kleiman N, Hochman J, White H, Savonitto S, Piedmonte M, Booth J, Topol EJ,. Prevention of reinfarction using half-dose reteplase and abciximab: observation from the GUSTO-5 trial. **Journal of the American College of Cardiology** 2002;39(Suppl. A):305A.
172. Kaul P, Fu Y, Newby LK, Mahaffey KW, Harrington RA, **Ohman EM**, Van de Werf F, Armstrong PW. Does troponin positivity add prognostic value to quantitative ST segment depression in predicting death and myocardial infarction in non-ST elevation acute coronary syndrome patients? **Journal of the American College of Cardiology** 2002;39(Suppl. A):311A.
173. Roe MT, Christenson RC, Yang H, Bahr R, Fesmire FM, Mollod M, **Ohman EM**, Gibler WB. Heterogeneity of infarct sizing in non-ST segment elevation acute coronary syndromes: results from the EARLY Pilot Trial. **Journal of the American College of Cardiology** 2002;39(Suppl. A):326A.
174. Gurbel PA, **Ohman EM**, Roe MT, Bahr RD, Gibler WB, Serebruany VL for the EARLY Trial Investigators. Is age related to platelet activity in patients presenting with acute coronary syndromes? **Journal of the American College of Cardiology** 2002;39(Suppl. A):334A.
175. Sanchez CD, McGuire DK, Newby LK, Hasselblad V, Feinglos MN, Ohman EM. Diabetes-related knowledge is not associated with measures of risk factor control in patients with diabetes and acute coronary syndromes. **Journal of the American College of Cardiology** 2002;39(Suppl. A):343A.

176. Roe MT, Peterson E, Pollack CV, Smith S, Brindis R, Christenson R, Gibler WB, **Ohman EM**, on behalf of the CRUSADE Investigators. 4Roe MT, Peterson E, Pollack CV, Smith S, Brindis R, Christenson R, Gibler WB, Ohman EM, on behalf of the CRUSADE Investigators. Roe MT, Peterson E, Pollack CV, Smith S, Brindis R, Christenson R, Gibler WB, Ohman EM, on behalf of the CRUSADE Investigators. Targeting improved adherence to the ACC/AHA guidelines for the management of non-ST-segment elevation acute coronary syndromes. **European Heart Journal** 2002;23:626.
177. Gurbel PA, Roe M, Bahr RD, Gibler W, Malinin A, **Ohman EM**, Serebruany VL. The EARLY platelet substudy. **European Heart Journal** 2002;23:722.
178. Bhatt DL, Greenbaum A, Roe MT, Harrington RA, Li Y, Peterson E, Berger PB, Cannon CP, Gibson CM, Cohen D, Saucedo J, Kleiman N, Smith S, Gibler WB, Pollack C, **Ohman EM**, on behalf of the CRUSADE Steering Committee. An early invasive strategy is underused in the treatment of acute coronary syndromes: results from the CRUSADE Registry. **American Journal of Cardiology** 2002;90(Suppl 6A):163H-164H.
179. Bhatt DL, Greenbaum A, Roe R, Harrington RA, Li Y, Smith S, Gibler BW, Pollack C, Peterson E, **Ohman EM** on behalf of the CRUSADE Steering Committee. An early invasive approach to acute coronary syndromes in CRUSADE: a dissociation between clinical guidelines and current practice. **Circulation** 2002;106(Suppl.):II-494.
180. Adams JE, Kleinfeld A, Roe M, Yang H, Christenson RH, **Ohman EM**, Gibler WB for the EARLY Investigators and Emergency Medicine Cardiac Research and Education Group (EMCREG). Measurement of levels of unbound free fatty acid allows the early identification of patients with acute coronary syndrome. **Circulation** 2002;106(Suppl.):II-532.
181. Bahr RD, Gurbel PA, Malinin AI, Christenson RH, Roe MT, Gibler B, Kitt M, **Ohman M**, Serebruany VL. Correlation of platelet activation and myocardial ischemia biomarkers dependent on a chest pain onset: does prodroma matter? **Circulation** 2002;106(Suppl.):II-537-8.
182. Chen EW, Canto JG, Parsons LS, Littrell KA, Every NR, Hochman JS, Cheeks M, Barron HV. High hospital intra-aortic balloon counterpulsation volume is associated with lower mortality in acute myocardial infarction complicated by cardiogenic shock. **Circulation** 2002;106(Suppl.):II-762.
183. Westerhout CM, Ottervanger J, Armstrong PW, Hochman JS, James S, Wallentin L, Barnathan ES, **Ohman EM**, Simoons ML, Boersma E. Predictors of one-year death in men and women: GUSTO-IV acute coronary syndrome. **Journal of the American College of Cardiology** 2003;41(Suppl. A):325A.

184. Roe MT, Giugliano RP, Tuttle R, Hasselblad V, Murphy S, Antman EM, **Ohman EM**, Harrington RA, Granger CB, Mahaffey KW, Cannon CP, Lincoff AM, Gibson CM, Armstrong PW, Van de Werf FJ, Califf RM, Topol EJ, Braunwald E. Safety of adjunctive glycoprotein IIb/IIIa blockade during rescue/early percutaneous coronary intervention following full-dose fibrinolytic therapy for acute myocardial infarction. **Journal of the American College of Cardiology** 2003;41(Suppl. A):332A.
185. Meine TJ, Al-Khatib SM, Alexander JH, Granger CC, Kilaru R, Williams K, **Ohman EM**, Topol EJ, Califf RM. Predictors and long-term mortality of atrioventricular block after acute myocardial infarction treated with thrombolysis. **Journal of the American College of Cardiology** 2003;41(Suppl. A):346A.
186. Khot UN, Khot MB, Bajzer CT, Sapp S, **Ohman EM**, Brener SJ, Ellis SG, Topol EJ. The eminently preventable pattern of coronary heart disease: focus on the four conventional risk factors. **Journal of the American College of Cardiology** 2003;41(Suppl. A):353A.
187. Gurbel PA, Bahr RD, Roe MT, Serebruany VL, Malinin AI, Gibler WB, **Ohman EM**. EARLY platelet substudy. **Journal of the American College of Cardiology** 2003;41(Suppl. A):365A.
188. Roe MT, Peterson ED, Li Y, Harrington RA, Pollack CV, Brindis RG, Christenson RH, Smith Jr. SC, Gibler WB, **Ohman EM**. Suboptimal adherence to the ACC/AHA non-ST elevation acute coronary syndrome practice guidelines for patients with positive troponin levels. **Journal of the American College of Cardiology** 2003;41(Suppl. A):390A.
189. Saucedo JF, Bhatt DL, Li Y, Roe MT, Harrington RA, Berger PB, Cannon CP, Gibson M, Kleiman N, Brindis R, Peterson ED, Gibler WB, **Ohman EM**. Use and predictors of early cardiac catheterization in high-risk patients with acute coronary syndrome. Analysis from the CRUSADE National Registry. **American Journal of Cardiology** 2003;92(Suppl 6A): 71L-72L.
190. Greenbaum AB, Kleiman NS, Berger PB, Cohen DJ, Cannon CP, Brindis R, Li Y, Roe MT, Harrington RA, Peterson E, Gibler WB, **Ohman EM**. Improved outcomes with “upstream” use of glycoprotein IIb/IIIa Inhibition prior to early percutaneous coronary intervention after admission for non-ST-segment elevation acute myocardial infarction. **American Journal of Cardiology** 2003;92(Suppl 6A): 72L.
191. James S, Lindahl B, **Ohman M**, Venge P, Stridsberg M, Wallentin L. A combination of NT-proBNP and creatinine clearance is a strong predictor of long-term mortality in females as well as in males with non-ST elevation acute coronary syndrome. **Circulation** 2003;108:IV-314.

192. Singh KP, Roe MT, Chen AY, Harrington RA, Brindis RG, Smith SC Jr., Pollack CV Jr., **Ohman EM**, Gibler WB, Peterson ED. Improved outcomes with low-molecular-weight heparin versus unfractionated heparin for patients receiving glycoprotein IIb/IIIa antagonists for acute coronary syndromes: results from the CRUSADE Initiative. with non-ST elevation acute coronary syndrome. with non-ST elevation acute coronary syndrome. **Circulation** 2003;108:IV-579-IV-580.
193. Hoekstra JW, Menon V, Li Y, Roe MT, Peterson ED, Pollack CV, Palabrica T, Brindis R, Gibler B, **Ohman M**. Early GP IIb/IIIa inhibitor use for non-ST-elevation acute coronary syndromes is associated with lower mortality. **Circulation** 2003;108:IV-580.
194. Roe MT, Boden WE, Chen A, Calvin JE Jr, Smith SC Jr, **Ohman EM**, Gibler WB, Pollack CV Jr, Brindis RG, Califf RM, Peterson ED. Is the “hub-and-spoke” model working? Patterns of transfer for high-risk acute coronary syndromes patients from community hospitals without revascularization capacity. **Journal of the American College of Cardiology** 2004; 43(Suppl A):1A.
195. Kelly RV, Tan W, **Ohman EM**, Struthers AD. Diastolic heart failure in patients hospitalized with symptomatic cerebral and peripheral vascular disease. **Journal of the American College of Cardiology** 2004; 43(Suppl A):242A.
196. Hudson MP, Greenbaum AB, Brenton L, Sala MF, McKendall GR, Bluguermann J, **Ohman EM**, Weaver WD. Effect of therapeutic transcutaneous ultrasound following thrombolysis: results of the perfusion by thrombolytic and ultrasound (PLUS) trial. **Journal of the American College of Cardiology** 2004; 43(Suppl A):265A.
197. Zia M, Goodman SG, Roe MT, Mulgand J, Langer A, Tan M, **Ohman EM**, Gibler WB, Pollack CV Jr, Peterson ED. Paradoxical utilization of invasive cardiac procedures for patients with non-ST-segment elevation myocardial infarction: an American-Canadian comparison from the CRUSADE Initiative and Canadian registries. **Journal of the American College of Cardiology** 2004; 43(Suppl A):276A.
198. Ryan JW, Peterson ED, Chen A, roe MT, **Ohman EM**, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Pollack CV Jr, Cohen DJ. Early versus delayed intervention in non-ST-elevation acute coronary syndromes: a natural experiment from the CRUSADE Initiative. **Journal of the American College of Cardiology** 2004; 43(Suppl A):276A.
199. Roe MT, Newby LK, Peterson ED, Li Y, Christenson RH, Bahr RD, Pollack CV Jr, Diercks DB, Fesmire FM, Peacock WF, **Ohman EM**, Gibler WB. Suboptimal treatment of patients with n on-ST-elevation acute coronary syndromes presenting with positive baseline troponin values. **Journal of the American College of Cardiology** 2004; 43(Suppl A):300A.

200. Blomkalns AL, Newby LK, Chen A, Peterson ED, Trynosky K, Diercks D, Boden WE, Roe MT, **Ohman EM**, Gibler WB, Hochman JS. Sex disparities in the treatment of non-ST-segment elevation acute coronary syndromes. **Journal of the American College of Cardiology** 2004; 43(Suppl A):304A.
201. Newby LK, Peterson ED, Chen A, Harrington RA, Pollack CV Jr, Hoekstra JW, Christenson RH, Jesse RL, Gibler WB, **Ohman EM**, Roe MT. Clinical implications of discordant creatine kinase-MB and troponin results in pts with acute coronary syndromes. **Journal of the American College of Cardiology** 2004; 43(Suppl A):306A.
202. Peterson ED, Roe MT, Lytle BL, Newby LK, Fraulo ES, Gibler WB, **Ohman EM**. The association between care and outcomes in patients with acute coronary syndrome: national results from CRUSADE. **Journal of the American College of Cardiology** 2004; 43(Suppl A):406A.
203. Varanasi JS, Costello F, Tudor GE, Hinderliter AL, Tan WA, Cohen MG, **Ohman EM**, Menon V. Screening for asymptomatic coronary artery disease in the potential renal transplant recipient. **Journal of the American College of Cardiology** 2004; 43(Suppl A):411A.
204. Calvin JE, Roe MT, Chen A, Brogan GX Jr, DeLong ER, Gibler WB, **Ohman EM**, Fintel D, Smith SC Jr, Peterson ED. Higher mortality and less evidence-based therapies among Medicaid-insured patients with high-risk acute coronary syndromes: results from CRUSADE. **Journal of the American College of Cardiology** 2004; 43(Suppl A):413A.
205. Sonel AF, Good CB, Mulgand J, Roe MT, Gibler WB, Smith SC Jr, Cohen MG, Zalenski R, Pollack CV Jr, **Ohman EM**, Peterson ED. Racial variations in treatment and outcomes of African American and white patients with non-ST-elevation acute coronary syndromes: insights from CRUSADE. **Journal of the American College of Cardiology** 2004; 43(Suppl A):414A.
206. Crespo EM, Becker RC, Berger PB, Granger CB, Kleinman NS, Moliterno DJ, Moll S, Rice L, Abrams CS, Rodgers J, Steinhubl SS, Tanson VF, Anstrom KJ, **Ohman EM**. Incidence and evaluation of heparin-induced thrombocytopenia (HIT) among patients treated with prolonged heparin and among thrombocytopenic patients in the Cardiac Care Unit: preliminary results of the CATCH Registry. **Journal of the American College of Cardiology** 2004; 43(Suppl A):501A.
207. Oliveira G, Anstrom K, Moliterno D, Abrams C, Becker R, Steinhubl S, Granger C, **Ohman EM**, on behalf of the CATCH Registry Investigators. Heparin-induced thrombocytopenia is common and associated with poor outcomes, yet uncommonly evaluated and detected: preliminary results of the multicentre CATCH registry. **European Heart Journal** 2004;25(Suppl):93.

208. Crespo EM, Becker RC, Berger PB, Moll S, Moliterno DJ, Rice L, Abrams CS, Rodgers JE, Steinhubl SR, Tapson VF, Honeycutt EF, Anstrom KJ, **Ohman EM**. Evaluation and outcomes of thrombocytopenia developing while on heparin among cardiac care unit patients: insights from the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. **Circulation** 2004; 110:III-307.
209. Rodgers JE, Anstrom KJ, Honeycutt EF, Abrams CS, Becker RC, Berger PB, Crespo EM, Moliterno DJ, Moll S, Rice L, Steinhubl SR, Tapson VF, **Ohman EM**. Withholding direct thrombin inhibitor therapy while awaiting laboratory confirmation of heparin-induced thrombocytopenia is associated with an increased rate of thromboembolic complications: results of the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. **Circulation** 2004; 110:III-371.
210. **Ohman EM**, Kandzari DE, Menon V, Chen AY, Gibler WB, Cohen MG, Roe MT, Smith SC. Underutilization of revascularization in early cardiogenic shock among NSTEMI patients: observations from the CRUSADE Initiative. **Circulation** 2004; 110:III-410.
211. Dyke CK, Roe MT, Cohen DJ, **Ohman EM**, Bhatt DL, Lytle BL, Saucedo JF, Smith SC Jr. Patients with non-ST-segment elevation acute coronary syndromes receive less aggressive discharge care after bypass surgery versus percutaneous coronary intervention. **Circulation** 2004; 110:III-420.
212. Oliveira GB, Anstrom KJ, Honeycutt EF, Abrams CS, Becker RC, Berger PB, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, **Ohman EM**, Granger CB. Days on intravenous heparin predicts thrombocytopenia and drop in platelet count on heparin predicts mortality: findings from the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. **Circulation** 2004; 110:III-559.
213. Varanasi JS, Hinderliter AL, Duch PM, Menon V, Oppenheimer SM, **Ohman EM**, Sen S. Elevated homocysteine level is independently associated with progression of aortic arch atheroma. **Circulation** 2004; 110:III-641.
214. Peterson ED, Chen AY, Kontos MC, Smith SC, Miller C, Pollack CV Jr., **Ohman EM**, Roe MT. Associating changes in hospital non-ST-segment elevation acute coronary syndromes guidelines adherence with changes in patient outcomes: results from CRUSADE. **Circulation** 2004;110:III-785.
215. Gibler WB, Peterson ED, Roe MT, Hoekstra JW, Milford-Beland S, Diercks DB, Pollack CV Jr., Peacock WF, Fermann GJ, Summers R, **Ohman EM**. Early treatment for non-ST-segment elevation acute coronary syndromes is associated with appropriate discharge care: The CRUSADE experience. **Journal of the American College of Cardiology** 2005;45(Suppl. A):5A.

216. Shah MR, Hasselblad V, Tasissa G, Binanay C, O'Connor CM, **Ohman EM**, Stevenson LW, Califf RM. Rapid assay B-type natriuretic peptide (BNP) predicts outcomes and hemodynamics in patients hospitalized with decompensated heart failure. **Journal of the American College of Cardiology** 2005;45(Suppl. A):165A.
217. Halabi AR, Chen AY, Harrington RA, Smith SC Jr., **Ohman EM**, Gibler WB, Peterson ED, Roe MT. Increased in-hospital mortality in patients without traditional risk factors presenting with non-ST-segment elevation myocardial infarction: insights from the CRUSADE Initiative. **Journal of the American College of Cardiology** 2005;45(Suppl. A):215A.
218. Diercks DB, Roe MT, Chen AY, Peterson ED, Newby LK, Kirk JD, Pollack CV Jr, Gibler WB, Hoekstra JW, Smith SC, **Ohman EM**, Hochman JS. Disparities by sex in timing of initial electrocardiogram for patients presenting with acute coronary syndromes. **Journal of the American College of Cardiology** 2005;45(Suppl. A):221A.
219. Peterson ED, Chen AY, Yang X, Roe MT, Rao SV, Brindis RG, Gibler WB, **Ohman EM**. Blood transfusions in patients admitted with non-ST-segment elevation acute coronary syndromes: results from CRUSADE. **Journal of the American College of Cardiology** 2005;45(Suppl. A):232A.
220. Singh KP, Roe MT, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, **Ohman EM**, Gibler WB, Pollack CV. The safety of antithrombin therapy in non-ST-segment elevation acute coronary syndromes patients: results from the CRUSADE Initiative. **Journal of the American College of Cardiology** 2005;45(Suppl. A):233A.
221. Steg PG, Bhatt DL, **Ohman EM**, Rother J, Wilson PWF, on behalf of the REACH Registry Investigators. Undertreatment of atherothrombotic patients worldwide: baseline data from the REACH Registry. **Journal of the American College of Cardiology** 2005;45(Suppl. A):390A.
222. **Ohman EM**, Abrams CS, Honeycutt EF, Becker RC, Crespo EM, Anstrom KJ, Moliterno DJ, Rice L, Rodgers JE, Steinhubl SR, Granger CB. High mortality after discharge among patients with high risk for developing heparin-induced thrombocytopenia or thrombosis: 6-month follow-up results of the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. **Journal of the American College of Cardiology** 2005;45(Suppl. A):411A.
223. Bhatt DL, Steg G, **Ohman EM**, Rother J, Wilson PWF, on behalf of the REACH Registry Investigators. Risk profile and undertreatment of peripheral arterial disease – 7,013 patients from the international REACH Registry. **Journal of the American College of Cardiology** 2005;45(Suppl. A):417A.

224. Steg PG, Bhatt DL, Abola MTB, Baumgartner I, **Ohman EM**, Rother J, Uchiyama S, Wilson PWF, on behalf of the REACH Registry Investigators. Undertreatment of women with atherothrombosis: results from the worldwide REACH registry. **European Heart Journal** 2005;26(Suppl. 1):245.
225. Bhatt DL, Steg PG, Hirsch A, Liao CS, **Ohman EM**, Rother J, Wilson PWF, on behalf of the REACH Registry Investigators. The prevalence of obesity in the international REACH Registry – a truly global epidemic with the United States leading the world. **European Heart Journal** 2005;26(Suppl. 1):683.
226. Oliveira GBF, Anstrom KJ, Honeycutt EF, Becker RC, Moliterno DJ, Moll S, **Ohman EM**, Granger CB, on behalf of the CATCH Registry Investigators. Intravenous unfractionated heparin, patient profile, and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH registry. **European Heart Journal** 2005;26(Suppl. 1):725.
227. Dumaine RL, Salpetriere P, Bhatt DL, **Ohman EM**, Montalescot G, on behalf of the REACH Investigators. Renal insufficiency is frequent and undertreated among outpatients at high risk of atherothrombotic events: lessons from the REACH Registry. **Circulation** 2005(Suppl.);112:II-225.
228. Boden WE, Elkousta RA, Dada M, Roe MT, Peterson ED, Newby LK, Milford-Beland S, Redberg R, Hochman JS, Diercks DB, Gibler WB, Smith SC Jr, **Ohman EM**. Sex-related differences in in-hospital clinical outcomes among high-risk non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the CRUSADE Quality Improvement Initiative. **Circulation** 2005(Suppl.);112:II-322.
229. Mehta RH, Roe MT, Mulgund J, **Ohman EM**, Cannon CP, Gibler WB, Pollack CV, Smith SC Jr, Peterson ED. The impact of clopidogrel use before coronary artery bypass grafting in patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE Quality Improvement Initiative. **Circulation** 2005;112(Suppl.);II-399.
230. Bennett K, Hernandez AF, Mulgund J, Newby LK, **Ohman EM**, Gibler WB, Roe MT, Peterson ED. Acute coronary syndromes complicated by heart failure with preserved systolic function is high risk and undertreated: data from CRUSADE. **Circulation** 2005;112(Suppl.);II-409.
231. Tickoo S, Roe MT, Peterson ED, Milford-Beland S, Gibler WB, Ohman EM, Pollack CV, Cannon CP. Patterns and impact of aspirin dosing in non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Initiative. **Circulation** 2005;112(Suppl.);II-431.
232. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Schwartz J, Hochman JS, Redberg RF, **Ohman EM**, Gibler WB, Peterson ED. Sex differences in glycoprotein IIb/IIIa inhibitor dosing and bleeding in acute coronary syndromes: results from CRUSADE. **Circulation** 2005;112(Suppl.);II-431-2.

233. Melloni C, Roe MT, Milford-Beland S, Alexander KP, Newby LK, Szczech LA, Pollack CV, Kirk JD, Christenson RH, Harrington RA, Gibler, **Ohman EM**, Fesmire FM, Peterson ED. Renal insufficiency, troponin, and risk of death among patients with non-ST-segment elevation acute coronary syndromes. **Circulation** 2005;112(Suppl.);II-525.
234. Lowry CJ, Costello FM, Lambert ND, Gillespie MJ, Peifer JL, Gettes LS, Tew FT, **Ohman EM**, Menon V. Reduced exercise tolerance in patients with diastolic dysfunction. **Circulation** 2005;112(Suppl.);II-611.
235. Tricoci P, Mulgund J, Harrington RA, Newby LK, Saucedo J, Kleiman N, Bhatt DL, Berger P, Cannon CP, Cohen DJ, Hochman JS, Gibler WB, **Ohman EM**, Peterson ED, Smith SC Jr, Roe MT. Trends for utilization of early cardiac catheterization for non-ST-segment elevation acute coronary syndromes by patient risk status in the CRUSADE Quality Improvement Initiative. **Circulation** 2005;112(Suppl.);II-743.
236. Boden WE, Dada M, Lundbye J, Roe MT, Peterson ED, Newby LK, Milford-Beland S, Redberg R, Hochman JS, Diercks DB, Gibler WB, **Ohman EM**. An early invasive strategy in women who present with high-risk non-ST-segment elevation acute coronary syndromes is associated with more aggressive pharmacotherapy and better in-hospital outcomes: results from the CRUSADE Quality Improvement Initiative. **Circulation** 2005;112(Suppl.);II-744.
237. Cohen MG, Filby SJ, Roe MT, Mulgund J, Menon V, Stouffer GA, Peterson ED, Gibler WB, Smith SC Jr, Pollack CV, **Ohman EM**. Underutilization of cardiac catheterization in high-risk patients with acute coronary syndromes is associated with increased mortality: lessons from the CRUSADE Registry. **Circulation** 2005;112(Suppl.);II-744.
239. Boden WE, Baghdasarian S, Dada M, Peterson ED, Mulgund J, Pollack CV, Gibler WB, Smith SC Jr, Fraulo ES, Calvin JE, **Ohman EM**, Roe MT. Impact of comprehensive guidelines-based acute management of high-risk patients with non-ST-segment elevation acute coronary syndromes. **Circulation** 2005;112(Suppl.);II-745.
240. Mehta RH, Roe MT, Chen AY, Pollack CV, Brindis RG, **Ohman EM**, Gibler WB, Fintel D, Fraulo ES, Peterson ED. Changing practice for non-ST-segment elevation acute coronary syndromes: trends from the CRUSADE Quality Improvement Initiative from 2002 to 2004. **Circulation** 2005;112(Suppl.);II-793-4.
241. Steg PG, Bhatt DL, Wilson PWF, **Ohman EM**, Rother J, Liao CS, Hirsch AT, Mas JL, Goto S, on behalf of the REACH Registry Investigators. REduction of Atherothrombosis for Continued Health (REACH) Registry results: 1-year cardiovascular event rates in a global contemporary registry of over 68,000 outpatients with atherothrombosis. **Journal of the American College of Cardiology** 2006;47(Suppl. A):168A.

242. Hirsh AT, Bhatt DL, McBride PE, **Ohman EM**, Eagle KA, Cannon CP, Califf R, Steg G, on behalf of the REACH Registry Investigators. Global risk factors and treatment intensity in elderly patients with atherosclerosis: the experience of the international REACH Registry. **Journal of the American College of Cardiology** 2006;47(Suppl. A):168A.
243. Gehrie ER, Reynolds HR, Neelon BH, Roe MT, Gibler WB, **Ohman EM**, Newby LK, Peterson ED, Hochman JS. Sex-related differences in non-obstructive coronary artery disease among patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. **Journal of the American College of Cardiology** 2006;47(Suppl. A):172A.
244. Gogo PG Jr., Dauerman HL, Mulgund J, Patel MR, **Ohman EM**, Gibler WB, Harrington RA, Peterson ED, Roe MT. Use of percutaneous coronary intervention versus coronary artery bypass surgery for patients with acute coronary syndromes and multivessel coronary disease in the drug-eluting stent era: data from the CRUSADE Quality Improvement Initiative. **Journal of the American College of Cardiology** 2006;47(Suppl. A):205A.
245. Roe MT, Milford-Beland S, Newby LK, Hernandez AF, Peacock WF, Fesmire FM, Christenson RH, Kirk JD, Gibler WB, **Ohman EM**, Peterson ED. Patterns of brain natriuretic peptide utilization for risk stratification of patients with non-ST-segment elevation acute coronary syndromes. **Journal of the American College of Cardiology** 2006;47(Suppl. A):227A.
246. Allen LaPointe NM, Alexander KP, Chen AY, Roe MT, Pollack CV Jr., **Ohman EM**, Gibler WB, Peterson ED. Enoxaparin dosing and bleeding in real world practice: results from CRUSADE. **Journal of the American College of Cardiology** 2006;47(Suppl. A):235A.
247. Oliveira GB, Anstrom KJ, Honeycutt EF, Abrams CS, Becker RC, Berger PB, Moliterno DJ, Moll S, Rice L, Kleiman N, Rodgers JE, Steinhubl SR, Tapson VF, **Ohman EM**, Granger CB. Prolonged heparin exposure, development of thrombocytopenia, use of GP IIb/IIIa inhibitors, and history of renal dysfunction predict moderate or severe bleeding: a report from the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. **Journal of the American College of Cardiology** 2006;47(Suppl. A):251A.
248. Skolnick AH, Peterson ED, Alexander KP, Chen AY, Roe MT, Pollack CV Jr., **Ohman EM**, Rumsfeld JS, Gibler WB, Cohen DJ. Treatment and outcomes of acute coronary syndromes among 5,577 patients aged ≥ 90 years: results from the CRUSADE National Quality Improvement Initiative. **Journal of the American College of Cardiology** 2006;47(Suppl. A):253A.
249. Peterson ED, Chen AY, Alexander KP, Allen LaPoint NM, Fraulo ES, Newby LK, Roe MT, Gibler WB, **Ohman EM**. The association between hospital guideline adherence, dosing safety, and patient outcomes: results from the CRUSADE Quality Improvement Initiative. **Journal of the American College of Cardiology** 2006;47(Suppl. A):255A.

250. Lytle BL, Fraulo ES, Neelon BH, Miller VA, Roe MT, **Ohman EM**, Gibler WB, Peterson ED. What aspects of hospital culture influence quality? **Journal of the American College of Cardiology** 2006;47(Suppl. A):257A.
251. Dunlay SM, Liang L, Melloni C, Kraschnewski JL, Alexander AP, Gibler WB, Roe MT, **Ohman EM**, Peterson ED. Quality of medical record documentation in an acute coronary syndrome population: results from CRUSADE. **Circulation** 2006;113:e802-3.
252. Leder DM, Peterson ED, Roe MT, DeLong ER, Chen AY, **Ohman EM**, Gibler WB, Lytle BL, Cohen DJ. The “July Phenomenon” revisited: is the quality of care for patients presenting with acute coronary syndromes affected by house officer inexperience? Insights from CRUSADE. **Circulation** 2006;113:e818.
253. **Ohman EM**, Bertrand ME, Feit F, White HD, Stone GW, Pollack Jr, CV, Hoekstra J, Gersh BJ. Outcomes in elderly patients treated with bivalirudin monotherapy vs. glycoprotein IIb/IIIa inhibitors with heparin or LMWH: results from the randomized ACUTY trial. **Circulation** 2006;114 (Suppl.).
254. Feit F, Manoukian SV, Ebrahimi R, Pollack Jr CV, **Ohman EM**, Attubato MJ, Mehran R, Stone GW. Bivalirudin monotherapy improves 30 day clinical outcomes in diabetics with acute coronary syndrome (ACS). report from the ACUTY trial. **Circulation** 2006;114 (Suppl.)
255. White HD, Hoekstra J, Pollack Jr CV, **Ohman EM**, Stone GW. Safety and efficacy of crossover from enoxaparin or unfractionated heparin to bivalirudin: results from ACUTY. **Circulation** 2006;114 (Suppl.)
256. Glickman SW, Mulgund J, Lytle BJ, Rumsfeld JS, Roe MT, Gibler WB, **Ohman EM**, Fintel D, Schulman KA, Peterson ED. The impact of pay for performance (P4P) on quality of care in acute coronary syndromes: initial external evaluation of the Center for Medicare and Medicaid Services P4P Pilot. **Circulation** 2006;114 (Suppl.):II-835.
257. Alexander KP, Chen AY, Newby LK, LaPointe NM, **Ohman EM**, Roe MT, Boden WE, Peterson ED. Blood transfusion and mortality among patients with non-ST-segment elevation acute coronary syndromes: results from CRUSADE. **Circulation** 2006;114 (Suppl.)II-701.
258. Melloni C, Peterson ED, Chen AY, Szczech LA, Newby LK, Harrington RA, Gibler WB, **Ohman EM**, Spinler SA, Roe MT, Alexander KP. Importance of glomerular filtration rate formula for determining chronic kidney disease and clinical care in patients with acute coronary syndromes. **Circulation** 2006;114(Suppl.):II-402.
259. Peterson JL, Roe MT, Mulgund J, Blazing MA, Foody JM, Smith SC Jr, Califf RM, Pollack CV Jr, Harrington RA, **Ohman EM**, Gibler WB, Brindis RG Jr, Peterson ED. Impact of the National Cholesterol Education Program Third Adult Treatment Panel Lipid-lowering Recommendations on the management of patients with non-ST-segment elevation acute coronary syndromes. **Circulation** 2006;114(Suppl.):II-899.

260. Shah B, Glickman SW, Liang L, **Ohman EM**, Pollack CV Jr, Roe MT, Peterson ED. The impact of for-profit hospital status on the care of patients with NSTEMI: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines) National Quality Improvement Initiative. **Circulation** 2006;114(Suppl.):II-740.
261. Spinler SA, Ou F, Roe MT, Gibler WB, **Ohman EM**, Peterson ED. Enoxaparin dosing in obese patients with non-ST-segment elevation acute coronary syndrome: results from CRUSADE. **Pharmacotherapy** 2006;26:e56-e57.
262. Diercks DB, Roe MT, Peacock WF, Kirk JD, Pollack CV Jr, Chen AY, Gibler WB, Smith SC Jr, **Ohman EM**, Peterson ED. Prolonged emergency department length-of-stay is associated with worse guideline compliance and increased adverse events. **Annals of Emergency Medicine** 2006;48(Suppl. 1):S29.
263. Mehta RH, Peterson ED, Liang L, Alexander KP, Gibler WB, Ohman EM, Pollack CV Jr, Roe MT. Contraindications to cardiac catheterization in non-ST-elevation acute coronary syndromes: insights from the CRUSADE Quality Improvement Initiative. **European Heart Journal** 2006;27(Suppl 1):183.
264. Mehta RH, Milford-Beland S, Bhatt DL, Farkouh ME, Brogan GX Jr, Gibler WB, Pollack CV Jr, **Ohman EM**. Characterizing young patients with diabetes mellitus presenting with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE Quality Improvement Initiative. **European Heart Journal** 2006;27(Suppl 1):517.
265. Amsterdam EZ, Peterson ED, Ou FS, Newby LK, Pollack Jr CV, Gibler WB, **Ohman EM**, Roe MT. Trends in the treatment and outcomes of patients with non-ST-segment elevation acute coronary syndromes managed medically without cardiac catheterization. **Journal of the American College of Cardiology** 2007;49(Suppl. A):196A.
266. Alexander D, Ou FS, Roe MT, Pollack Jr, CV, **Ohman EM**, Cannon CP, Gibler WB, Fintel DJ, Peterson ED, Brown DL. Use and outcomes of acute clopidogrel therapy in non-ST-segment elevation myocardial infarction in community practice: results from CRUSADE. **Journal of the American College of Cardiology** 2007;49(Suppl. A):207A.
267. Wang TY, Chen AY, Roe MT, Alexander KP, Newby LK, Smith Jr, SC, Bangalore S, Gibler WB, **Ohman EM**, Peterson ED. Increased bleeding risk among Asians with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE Quality Improvement Initiative. **Journal of the American College of Cardiology** 2007;49(Suppl. A):208A.
268. Wang TY, Chen AY, Peterson ED, Becker RC, **Ohman EM**, Gibler WB, Roe MT. Non-ST-segment elevation acute coronary syndrome patients on chronic warfarin anticoagulation: care and outcomes. **Journal of the American College of Cardiology** 2007;49(Suppl. A):213A.

269. Wang TY, Robinson LA, Roe MT, Ou FS, Peterson ED, **Ohman EM**, Gibler WB, Smith Jr, SC, Becker RC. Continuation of warfarin at hospital discharge in patients with acute coronary syndromes on chronic warfarin anticoagulation. **Journal of the American College of Cardiology** 2007;49(Suppl. A):251A.
270. Rao SV, Liao L, Mark DB, Eisenstein EL, Armstrong PW, **Ohman M**, Granger CB, Califf RM, Harrington RA. Bleeding complications are a major driver of resource use among patients with acute coronary syndromes. **Journal of the American College of Cardiology** 2007;49(Suppl. A):252A.
271. Patel UD, Ou FS, Roe MT, **Ohman EM**, Gibler WB, Peterson ED. Impact of hospital performance on underuse of therapies among patients with chronic kidney disease and non-ST-segment elevation acute coronary syndromes. **Journal of the American College of Cardiology** 2007;49(Suppl. A):289A.
272. Jolicoeur ME, **Ohman EM**, Honeycutt EF, Mazon FJN, Becker RC, Crespo EM, Oliveira GBF, Moliterno DJ, Anstrom KJ, Granger CB. Bleeding is common among patients treated with heparin experiencing thrombocytopenia and confers a high mortality risk: report from the CATCH Registry. **Journal of the American College of Cardiology** 2007;49(Suppl. A):340A.
273. Roe MT, Alexander KP, Ou FS, Newby LK, Gibler WB, Pollack Jr, CV, **Ohman EM**, Smith Jr, SC, Peterson ED. Patterns of HDL levels in patients with non-ST-segment elevation acute coronary syndromes and association with clinical outcomes. **Journal of the American College of Cardiology** 2007;49(Suppl. A):366A.
274. Mehran R, Moses JW, Dangas G, Manoukian SV, White HD, **Ohman EM**, Pocock SJ, Feit F, Colombo A, Stone GW. Safety of drug eluting stents compared to bare stents in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the ACUTY trial. **European Heart Journal** 2007;28(Suppl. 1):134-135.
275. Lopes RD, Mahaffey KM, Harrington RH, Lan LL, Armstrong PA, Newby KN, **Ohman MO**, Van de Werf FVW, Al-Khatib SAK, Granger CBG. Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes. **European Heart Journal** 2007;28(Suppl. 1):259-260.
276. Dangas G, Manoukian SV, Nikolsky E, Mehran R, **Ohman M**, Kirtane AJ, Voeltz MD, Feit F, Stuckey T, Stone GW. Baseline anemia is independently associated with early mortality in patients with ACS: results from the ACUTY trial. **European Heart Journal** 2007;28(Suppl. 1):516.
277. Lopes RD, Mahaffey K, Harrington RA, Horton J, Armstrong P, Newby K, **Ohman M**, Van de Werf F, Al-Khatib SM, Wallentin L, Granger CB. Atrial fibrillation is independently associated with a high risk of death in patients with acute coronary syndromes. **Circulation** 2007;116:II-315.

278. Melloni C, Alexander KP, Chen AY, Roe MT, Newby LK, **Ohman EM**, Gibler WB, Smith SC Jr., Pollack CV, Peterson ED. Unfractionated Heparin Dosing and Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes. **Circulation** 2007;116:II-383.
279. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman N, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC, Pollack CV, Gibler WB, **Ohman EM**, Roe MT, for the CRUSADE Investigators. Polyvascular disease – a novel risk factor for worse ischemic and bleeding outcomes in acute coronary syndromes. **Circulation** 2007;116:II-482.
280. Manoukian SV, Feit F, Voeltz MD, Ebrahimi R, Hamon M, Chew DP, Dangas GD, Desmet W, Lincoff AM, Moses JW, Pollack CV Jr., Hoekstra JW, King SB III, White HD, **Ohman EM**, Mehran R, Stone GW. Impact of the ACUITY and TIMI Major Bleeding Definitions on One-Year Mortality in Patients with Acute Coronary Syndromes. **Circulation** 2007;116:II-482.
281. Mehran R, Kirtane AJ, Dangas GD, **Ohman EM**, Pocock S, Gersh BJ, Bertrand ME, Hamon M, Manoukian SV, Hoekstra J, Pollack CV, Desmet W, Feit F, Stella J, Cequier AR, Stuckey T, Cohen DJ, Lansky AJ, Stone GW. Long-term Outcomes of Acute Coronary Syndrome Patients with Chronic Renal Insufficiency treated with Bivalirudin vs Heparin plus a Glycoprotein IIb/IIIa Inhibitor: One Year Results from the Randomized ACUITY Trial. **Circulation** 2007;116:II-483.
282. Aoki J, Stone GW, Mehran R, Moses J, Bertrand ME, Lincoff AM, **Ohman EM**, White HD, Parise H, Leon MB, Lansky AJ. Predictors of Early Stent Thrombosis in Patients with Acute Coronary Syndromes in the Drug-Eluting Stent Era: Analysis from the ACUITY trial. **Circulation** 2007;116:II-567.
283. Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, **Ohman EM**, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock S, Stone GW. Comparison of Catheterization Lab Initiated Abciximab and Double-Bolus Eptifibatide during Percutaneous Coronary Intervention in Acute Coronary Syndromes: an ACUITY Substudy. **Circulation** 2007;116:II-629.
284. Feit F, Manoukian SV, Dangas GD, Lincoff AM, **Ohman EM**, Attubato MJ, Mehran R, Stone GW. Bivalirudin Monotherapy Provides Similar One-Year Survival Compared to Heparin plus GP IIb/IIIa Inhibitors in Diabetic Patients with Acute Coronary Syndromes: Results from the Randomized ACUITY Trial. **Circulation** 2007;116:II-724.
285. Meadows TA, Bhatt DL, Hirsch AT, Creager M, Califf RM, **Ohman EM**, Cannon CP, Eagle KA, Alberts M, Goto S, Wilson PW, Steg PG, on behalf of the REACH Registry Investigators. Ethnic Differences in the Prevalence and Treatment of Cardiovascular Risk Factors in Outpatients with Peripheral Arterial Disease: Insights from the REACH Registry. **Circulation** 2007;116:II-775.

286. Mehta RH, Bhatt D, Steg G, Liao CS, Eagle KA, Goto S, Wilson PW, **Ohman EM**. Targeting Risk Factors To Goals Is Associated With Better Outcomes Among Patients With Coronary Artery Bypass Surgery: Insights From the REACH Registry. **Circulation** 2007;116:II-798.
287. Alexander KP, Chen AY, Roe MT, Newby LK, Gibler WB, **Ohman EM**, Pollack CV Jr., Peterson ED. Decline in GP 2b3a Inhibitor Overdosing with Site-Specific Feedback in CRUSADE. **Circulation** 2007;116:II-798.
288. Wang TY, Chen AY, Peterson ED, Alexander KP, **Ohman EM**, Gibler WB, Roe MT. Incidence and Bleeding Outcomes of Excess Unfractionated Heparin Dosing Among Patients with ST-Segment Elevation Myocardial Infarction Undergoing Fibrinolysis. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A203.
289. Alexander KP, Bach RG, Chen AY, Subherwal S, Gage BF, Rao SV, Gibler WB, Pollack CV Jr., **Ohman EM**, Roe MT, Peterson ED. Bleeding and Ischemic Events Run Parallel in NSTEMI Patients. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A207.
290. Roe MT, Cannon CP, Chen AY, Rao SV, Rumsfeld JS, Klein LW, **Ohman EM**, Gibler WB, Peterson ED. Decline in the Use of Drug-Eluting Stents for Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Results from the CRUSADE and ACTION Registries. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A211.
291. Subherwal S, Gach RG, Chen AY, Gage BF, Rao SV, Wang TY, Gibler WB, **Ohman EM**, Peterson ED, Roe MT, Alexander KP. The CRUSADE Bleeding Score to Assess Baseline Risk of Major Bleeding in Non-ST-Segment Elevation Myocardial Infarction. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A212.
292. Sorajja P, Gersh BJ, McLaurin BT, Cox DC, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Mehran R, **Ohman EM**, Stone GW. Increased Mortality in Patients with Acute Coronary Syndromes and Delay to Angioplasty of Greater than 24 Hours After Hospital Admission: An ACUTY Substudy. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A215.
293. Wang TY, Ou FS, Roe MT, **Ohman EM**, Gibler WB, Pollack CV Jr., Peterson ED. Incidence and Impact of Acquired Thrombocytopenia Among Patients With Acute Coronary Syndromes. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A217.
294. Pinto DS, Stone GW, York M, Reynolds MR, McLaurin BT, Cox DA, Schneider EA, Shi C, Walczak J, Machon DA, Berezin RH, Mehran R, **Ohman EM**, Lincoff AM, Cohen DJ. Economic Evaluation of Bivalirudin With or Without Glycoprotein IIB/IIIA Inhibition for Early Invasive Management of Acute Coronary Syndromes. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A219.

295. Wang TY, Honeycutt EF, **Ohman EM**, Moll S, Granger CB, Tapson VF. Incidence and Management of Acquired Thrombocytopenia Among Patients Receiving Prolonged Heparin Venous Thromboembolism Prophylaxis: Insights From the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A310.
296. Tamis-Holland JE, Chen AY, Roe MT, Palazzo AM, Chorzempa A, Peterson ED, Gibler WB, **Ohman EM**, Hochman JS. Sex, Age and Outcome of Non-ST Elevation Acute Coronary Syndrome: An Analysis of the CRUSADE Initiative. **Journal of the American College of Cardiology** 2008;51(Suppl. A):A378.
297. Cavender MA, Alexander KP, Broderick S, Shaw LK, Kempf J, **Ohman EM**. Long-term morbidity and mortality among patients with angina and multivessel coronary artery disease in the Duke Cardiovascular Databank. **Circulation** 2008;118 (Suppl. 2):S853.
298. Wang, TY, Chen AY, Roe MR, **Ohman EM**, Gibler WB, Peterson ED. Balancing mortality benefit vs. bleeding risk for intensive antiplatelet therapy among acute coronary syndrome patients: insights from the CRUSADE Registry. **Circulation** 2008;118 (Suppl. 2):S916.
299. Brar SS, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, **Ohman EM**, Mehran R, Lansky A, Parise H, Stone GW. Anti-thrombotic strategies in patients with elevated biomarkers undergoing PCI: results from the ACUITY trial. **Circulation** 2008;118 (Suppl. 2):S917.
300. Lopes RD, Granger CB, Honeycutt EF, Crespo EM, Anstrom KJ, **Ohman EM**, Becker RC. Patients with thrombocytopenia following heparin therapy have early but not late risk of death: results from the CATCH registry. **Circulation** 2008;118 (Suppl. 2):S1052.
301. Goto K, Lansky A, Mutlu H, Cristea E, Mehran R, Cox D, Bertrand M, Feit F, Hamon S, Manoukian SV, Dangas G, **Ohman M**, Gersh B, Moses JW, Stone GW. Myocardial blush predicts outcomes in patients with acute coronary syndromes: an analysis of the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. **Circulation** 2008;118 (Suppl. 2):S1059.
302. Nikolsky E, Mehran R, Parise H, Lansky AJ, Dangas GD, Manoukian SV, Voeltz M, Alexander KP, **Ohman em**, Dudek D, Lincoff AM, Stone GW. Impact of different antithrombotic regimens on ischemic and hemorrhagic outcomes following percutaneous coronary intervention in elderly: pooled analysis from the REPLACE-2, ACUITY and HORIZONS trials. **Journal of the American College of Cardiology** 2009;53 (Suppl. A):A27.

303. Goto K, Lansky AJ, Cristea E, Fahy M, Feit F, **Ohman EM**, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Manoukian SV, Ebrahimi R, Pollack CV, Attubato MJ, Mehran R, Stone GW. Clinical and angiographic predictors of death or myocardial infarction in diabetes with acute coronary syndrome undergoing percutaneous coronary intervention; an ACUTY subanalysis. **Journal of the American College of Cardiology** 2009;53 (Suppl. A):A30.
304. Dangas GD, Guagliumi G, Witzenbichler B, Bhatt D, Feit F, **Ohman M**, Wong SC, Nikolsky E, Caixeta A, Parise H, Lansky AJ, Mehran R, Stone GW. Impact of clopidogrel loading dose on the effectiveness of bivalirudin in primary angioplasty for acute myocardial infarction: the HORIZONS-AMI trial. **Journal of the American College of Cardiology** 2009;53 (Suppl. A):A57.
305. Lansky AJ, Goto K, Fahy M, Jung J, Nikolsky E, **Ohman EM**, White HD, Bertrand ME, Lincoff M, Moses J, Mehran R, Stone GW. Clinical and angiographic risk score to predict ischemic outcomes at 1 year in acute coronary syndromes: the ACUTY risk score. **Journal of the American College of Cardiology** 2009;53 (Suppl. A):A63.
306. Goto K, Lansky AJ, Cristea E, Fahy M, Feit F, **Ohman EM**, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW. Impact of bivalirudin monotherapy on 30-day outcomes in patients with acute coronary syndromes and complex coronary stenosis undergoing percutaneous coronary intervention. **Journal of the American College of Cardiology** 2009;53 (Suppl. A):A66.
307. Alexander KP, Chen AY, Roe MT, Wang TY, **Ohman EM**, Magid DJ, Ho MP, Wiviott SD, Scirica BM, Peterson ED. Antithrombotic strategy during percutaneous coronary intervention in NSTEMI: update from ACTION Registry-GWTG. **Journal of the American College of Cardiology** 2009;53 (Suppl. A):A398.
308. Nikolsky E, Mehran R, Kirtane AJ, Lansky AJ, Lincoff AM, Caixeta A, Fahy M, Moses JW, **Ohman EM**, Stone GW. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors and clinical implications (analysis from the ACUTY Trial). **European Heart Journal** 2009;30 (Suppl. 1):312.
309. Lee E, Stone GW, Mehran R, Cox DA, Bertrand ME, Lincoff AM, **Ohman EM**, White HD, Hooper WC. The predictive value of CRP on 30-Day and 1-year mortality in acute coronary syndromes: An analysis from the ACUTY trial. **European Heart Journal** 2009;30 (Suppl. 1):619.
310. Goyal A, Bhatt DL, Steg PG, Gersh BJ, Alberts MJ, **Ohman EM**, Corbalan R, Eagle KA, Gaxiola E, Gao R, Goto S, D'Agostino RB, Califf RM, Smith SC, Jr, Wilson PW. The impact of attained educational level on incident cardiovascular events differs between high-income countries and low-and-middle-income countries. **Circulation** 2009;120 (Suppl. 18):S415.

311. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, Topol AJ, White HD, Van de Werf F, Ardissino D, Califf RM, Granger CB, **Ohman EM**, Alexander JH. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. **Circulation** 2009;120 (Suppl. 18):S632-S633.
312. Mehran R, Pocock S, Clayton T, Lansky AJ, Kirtane A, Dangas GD, Manoukian SV, Feit F, White HD, **Ohman EM**, Stone GW. Individual patient risks of major bleeding and myocardial infarction and their implications for mortality and for treatment choice in acute coronary syndromes: findings from the ACUITY trial. **Circulation** 2009;120 (Suppl. 18):S961.
313. Shah BR, Roe MT, Chen AY, Alexander KP, Wang TY, **Ohman EM**, Gibler WB, Peterson ED. Association between hospital process performance and 1-year post-discharge mortality in patients with non-ST-elevation myocardial infarction: results from 36,262 patients. **Circulation** 2009;120 (Suppl. 18):S1086.
314. Wang TY, Chen AY, Shah BR, Roe MT, Alexander KP, **Ohman EM**, Gibler WB, Peterson ED. Readmission rates among patients with non-ST-segment elevation myocardial infarction: results in 38,131 patients from the CRUSADE Quality Improvement Initiative. **Circulation** 2009;120 (Suppl. 18):S436-S437.
315. Nikolsky E, Mehran R, **Ohman EM**, Bertrand ME, Lincoff AM, Moses JW, Cristea E, White HD, Fahy M, Lansky AJ, Stone GW. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: analysis from the ACUITY trial. **Journal of the American College of Cardiology** 2010;55 (Suppl.):A190.
316. Lopes R, Alexander KP, Chen AY, Wang TY, Rao SV, **Ohman EM**, Roe MT, Peterson ED. Major bleeding is an independent predictor of one-year post-discharge mortality in patients with non-ST-segment elevation acute coronary syndromes. **Journal of the American College of Cardiology** 2010;55 (Suppl.):A124.
317. Lansky AJ, Ng V, Goto K, Fahy M, Mehran R, Ebrahimi R, Hamond M, **Ohman EM**, Feit F, Manoukian S, Lincoff M, Stone GW. Impact of left ventricular function on mortality in patients with acute coronary syndromes: analysis of the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. **Journal of the American College of Cardiology** 2010;55 (Suppl.):A186.
318. Chan MY, Sun JL, Newby LK, White HD, Moliterno DJ, Theroux P, **Ohman EM**, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, Harrington RA. Temporal trends over 15 years in clinical trials of non-ST elevation acute coronary syndromes: more aggressive treatment yields similar mortality despite higher-risk profiles. **Journal of the American College of Cardiology** 2010;55 (Suppl.):A136.

319. Chin CT, Kelly RV, Cohen MG, Cohen M, Trout JR, Stone GW, Christenson JT, Freedman RJ, Reddy RC, Joseph D, **Ohman EM**. The Impact of Anticoagulation During Intra-Aortic Balloon Counterpulsation Pump Placement on In-Hospital Outcomes in 18,875 Patients Undergoing Cardiac Revascularization. **Circulation** 2010;122:A10175.
320. Leonardi S, Newby LK, **Ohman EM**, Armstrong PW. Lack of Implementation of ESC/ACC Definition of Myocardial Infarction in Contemporary Randomized Clinical Trials. **Circulation** 2010;122:A11021
321. Subherwal S, Li S, Patel MR, Bhatt DL, Wang TY, Alexander KP, Ohman EM, Gibler WB, Peterson ED, Roe MT. Impact of polyvascular disease on long-term mortality in older patients with non-st-segment elevation myocardial infarction. **Journal of the American College of Cardiology** 2011;57:E992
322. Scirica BM, Bhatt DL, **Ohman EM**, Smith Jr SC, Eagle KA, Goto S, Crowley K, Contant C, Steg PG. A history of stable angina significantly increases the risk of cardiovascular death and myocardial infarction in the REACH Registry. **Circulation**. 2011;124:A13420.
323. Claussen BE, Dangas GD, Mehran R, Xu K, Fahy M, Parise H, **Ohman EM**, White HD, Stone GW. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. **Circulation**. 2011;124:A16422.
324. Bahit MC, Lopes RD, Clare R, Pieper KS, Newby LK, Van de Werf F, Armstrong PW, Mahafey KW, Harrington RA, **Ohman EM**, Diaz R, White HD, Hernandez AF, Wallentin L, Califf RM, Granger CB. Heart failure occurring at any time during hospitalization is associated with higher mortality in non-st elevation-acute coronary syndromes. **Circulation**. 2011;124:A14185.
325. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr, SC, Crowley K, Goto S, **Ohman EM**, Bhatt DL, on behalf of the REACH Registry Investigators. Prospective assessment of the relationship between use of evidence-based secondary prevention therapies and long-term (4-year) clinical outcomes in stable outpatients with established atherothrombotic disease: insights from the International REduction of Atherothrombosis for Continued Health (REACH) Registry. **Circulation** 2011;124:A15957.
326. Lopes RD, White JA, Atar D, Keltai M, Kleiman NS, White HD, Widimsky P, Zwymmer U, Jackson K, Giugliano RP, Tricoci P, Braunwald E, Gibson CM, Bode C, **Ohman EM**, Armstrong PW, Van de Werf F, Harrington RA, Newby LK. Antithrombotic use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. **Circulation** 2011;124:A9146.
327. Udel JA, Steg PG, Scirica BM, Smith Jr SC, **Ohman EM**, Eagle KA, Goto S, Cho JI, Bhatt DL, for the REACH Registry Investigators. Living alone and cardiovascular events in stable outpatients at risk of or with atherothrombosis: insight from the REACH Registry. **Circulation** 2011;124:A9328.

328. Ducrocq G, Amarenco P, Labreuche J, Alberts M, Mas JL, **Ohman M**, Goto S, Lavallee P, Ghatt DL, Steg PG, on behalf of the the REACH Registry investigators. History of stroke in patients with coronary artery disease in the REACH Registry: ;impact on cardiovascular and bleeding event rates. **European Heart Journal** 2012;33 (Suppl. 1):673-674.
329. Goodman SG, Roe MT, Armstrong PW, White HD, Fox KA, Prabhakaran D, Brown E, Lokhnygina Y, **Ohman E**. The targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes (TRILOGY ACS) trial. **Canadian Journal of Cardiology** 2012;28:S418.
330. Cohen M, Ghatak A, Kleiman N, Naidu S, **Ohman EM**, Palacios I, Heldman A, O'Neill W. Optimizing rotational atherectomy in high-risk percutaneous coronary interventions. Insights from the PROTECT II study. **Journal of the American College of Cardiology** 2012;60 (Suppl.):B107.
331. Planer D, **Ohman EM**, White H, Moses J, Fahy M, Mehran R, Stone G. Prognosis of patients presenting with non ST-segment elevation myocardial infarction and non-obstructive coronary artery disease: propensity score matched cohort from the ACUTY Trial. **Journal of the American College of Cardiology** 2012;60 (Suppl.):B136.
332. Nicolau JC, Bhatt D, Roe M, Neely B, Corbalan R, Leiva-Pons J, Martinez F, Goodman S, Brown E, Verheugt F, Armstrong P, White H, Fox K, Prabhakaran D, **Ohman EM**. The association between concomitant proton-pump inhibitor use and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the TRILOGY ACS study. **Journal of the American College of Cardiology** 2013;61 (Suppl.):E39.
333. Cornel JH, **Ohman EM**, Neely B, Clemmensen P, Sritara P, Zamoryakhin D, Armstrong P, Prabhakaran D, White H, Fox K, Gurbel P, Roe M. Impact of smoking status on clinical outcomes with prasugrel versus clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial. **Journal of the American College of Cardiology** 2013;61 (Suppl.):E159.
334. White HD, Roe M, Alexander K, Westerhout C, Winters K, Fox K, Prabhakaran D, . Hochman J, Armstrong P, **Ohman EM**. Frailty is associated with worse outcomes in acute coronary syndromes: outcomes in TRILOGY. **European Heart Journal** 2013;34(Suppl. 1):826.
335. Roy A, Roe M, Cyr D, Zamoryakhin D, Fox K, White H, Armstrong P, **Ohman EM**, Prabhakaran D. Differences in the profile and risk of acute coronary syndrome patients stratified by country-level human development index: results from the global TRILOGY ACS trial. **European Heart Journal** 2013;34(Suppl. 1):469.

336. Mennuni MG, Mehran R, Dangas G, Baber U, Kirtane AJ, Genereux P, Brener S, Feit F, Lincoff AM, **Ohman EM**, Hamon M, Stone GW. Which is the ideal revascularization strategy in patients presenting with acute coronary syndrome and proximal AD stenosis? Results from the ACUTY study. **Journal of the American College of Cardiology** 2013;62(Suppl. B):B85.
337. O'Neill WW, Dixon S, Massaro J, Naidu SS, **Ohman EM**, Rihal C, Schreiber T, Wohns DH. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the Uspella Registry. **Journal of the American College of Cardiology** 2013;62(Suppl. B):B137.
338. Clemmensen P, Roe MT, Hochman JS, Cyr DD, Neely ML, McGuire DK, Cornel JH, Huber K, Zamoryakhin D, White HD, Armstrong PW, Fox KA, Prabhakaran D, **Ohman EM**. Outcomes in women compared with men in patients with unstable angina/non-ST-segment elevation myocardial infarction managed without revascularization: insights from the TRILOGY ACS trial. **Circulation**. 2013;128:A12130.
339. Halim S, Yang Q, Schulte P, Hochman J, Melloni C, Mahaffey KW, Moliterno DJ, Harrington RA, White HD, Armstrong PW, **Ohman EM**, Van de Werf F, Giugliano RP, Newby LK. Evolution of differences in women and men with non-ST-segment elevation acute coronary syndromes: insights from clinical trials over 15 years. **Circulation**. 2013;128:A15834.
340. Lopes RD, Neely B, **Ohman EM**, Ardissino D, Hamm C, Goodman SG, Bhatt DL, Brown EB, White HD, Prabhakaran D, Martinez F, Nicolau JC, Fox KA, Armstrong PW, Roe MT. Timing, profile, and predictors of spontaneous myocardial infarction following a non-ST-segment elevation acute coronary syndrome event: insights from the TRILOGY-ACS trial. **Circulation**. 2013;128:A14972.
341. Goyal A, Steg PG, Smith SC Jr., Eagle KA, **Ohman EM**, Koplan JP, Hoffman EB, Im K, Goto S, Wilson PW, Bhatt DL. Cigarette smoking is associated with a greater hazard for adverse outcomes in women compared with men: insights from the global REACH registry. **Circulation**. 2013;128:A13411.
342. Bernacki GM, Alexander KP, Newby LK, Yang Q, Schulte P, White HD, **Ohman EM**, Mahaffey KW, Shah BR, Giugliano RP, Armstrong PW, Harrington RA, Tricoci P, Van de Werf F, Alexander J, Califf RM, Lopes RD. Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials. **Circulation**. 2013;128:A9904.
343. Hagstrom E, Roe M, Hafley G, Neely M, Sidhu M, Brown E, Prabhakaran D, White H, Armstrong P, Fox K, **Ohman EM**, Boden W. Association between very low levels of baseline high-density lipoprotein cholesterol and increased long-term mortality in medically managed acute coronary syndrome patients. **Journal of the American College of Cardiology** 2014;63:A67.

344.

345.

(b) (4)



PUBLICATIONS

1. **Ohman EM**, Teo KK, Johnson AH, Collins PB, Dowsett DG, Ennis JT, Horgan JH. Abnormal cardiac enzyme responses after strenuous exercise - alternative diagnostic aids. **British Medical Journal** 1982;285:1523-1526.
2. Phillips JP, Horner B, **Ohman M**, Horgan J. Increased brain-type creatine phosphokinase in marathon runners. **Lancet** 1982;I:1310.
3. **Ohman EM**, Teo KK, Johnson AH, Collins PB, Dowsett DP, Ennis JT, Horgan JH. Cardiospecific creatine kinase after strenuous exercise in female athletes. **Journal of Sports Medicine and Physical Fitness** 1984;24:270-272.
4. **Ohman EM**, Fitzsimons P, Butler S, Bouchier-Hayes D. The value of ultrasonography in the screening for asymptomatic abdominal aortic aneurysms. **Irish Medical Journal** 1985;78:127-129.
5. Afdhal N, **Ohman EM**, Doyle D, Horgan J. Obstructive sleep apnoea syndrome presenting as cardiac arrhythmia. **Irish Journal of Medical Sciences** 1985;154:120-124.
6. ISIS Steering Committee. Intravenous streptokinase given within 0-4 hours of onset of myocardial infarction reduced mortality in ISIS-2. **Lancet** 1987;I:502.
7. **Ohman EM**, Rogers S, Meenan FO, McKenna TJ. Adrenal suppression following low-dose topical clobetasol propionate. **Journal of the Royal Society of Medicine** 1987;80:422-424.
8. **Ohman EM**, Butler J, Kelly JG, O'Malley K. Adrenoceptor changes with acute exercise. **Journal of Cardiovascular Pharmacology** 1987;10 (Suppl. 4):S110-S112.
9. **Ohman EM**, Butler J, Kelly JG, Horgan J, O'Malley K. Beta-adrenoceptor adaptation to endurance training. **Journal of Cardiovascular Pharmacology** 1987;10:728-731.
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. **Lancet** 1988;II:349-360.
11. Wiseman A, **Ohman EM**, Wharton JM. Transient reversal of bifascicular block during acute myocardial infarction with reperfusion therapy: a word of caution. **American Heart Journal** 1989;117:1381-1383.
12. Brady HR, Kinirons M, Lynch T, **Ohman EM**, Tormey W, O'Malley KM, Horgan JH. Heart rate and metabolic response to competitive squash in veteran players: identification of risk factors for sudden cardiac death. **European Heart Journal** 1989;10:1029-1035.

13. Christenson RH, **Ohman EM**, Clemmensen P, Grande P, Toffaletti J, Silverman LM, Vollmer RT, Wagner GS. Characteristics of creatine kinase-MB and MB isoforms in serum after reperfusion in acute myocardial infarction. **Clinical Chemistry** 1989;35:2179-2185.
14. **Ohman EM**, Casey C, Bengtson JR, Pryor D, Tormey W, Horgan JH. Early detection of acute myocardial infarction: additional diagnostic information by serum myoglobin in patients without ST elevation. **British Heart Journal** 1990;63:335-338.
15. **Ohman EM**, Helmy S, Shaughnessy E, Adams DB, Kisslo J. In-vitro analysis of jets by Doppler color flow imaging: the importance of time to maximum jet area. **European Heart Journal** 1990;11:361-367.
16. Sugarman J, Bashore TM, **Ohman EM**, Jones R, Peters WP. Hypertension and reversible myocardial depression associated with autologous bone marrow transplantation. **American Journal of Medicine** 1990;88:1-51N-1-55N.
17. **Ohman EM**, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack RS, and the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. **Circulation** 1990;82:781-791.
18. Christenson RH, Clemmensen P, **Ohman EM**, Toffaletti J, Silverman LM, Grande P, Vollmer RT, Wagner GS. Relative increase in creatine kinase-MB isoenzyme during reperfusion after acute myocardial infarction is method dependent. **Clinical Chemistry** 1990;36:1444-1449.
19. **Ohman EM**, Califf RM. Thrombolytic Therapy: overview of clinical trials. **Coronary Artery Disease** 1990;1:23-33.
20. Clemmensen P, **Ohman EM**, Sevilla D, Peck S, Wagner NB, Quigley PJ, Grande P, Lee KL, Wagner GS. Changes in standard electrocardiographic ST segment elevation predictive of successful reperfusion in evolving acute myocardial infarction. **American Journal of Cardiology** 1990;66:1407-1411.
21. **Ohman EM**, Sigmon KN, Califf RM. Is diagnostic certainty essential for the use of thrombolytic therapy during myocardial infarction in the 1990's? **Circulation** 1990;82:1073-1075.
22. Gurbel PA, Davidson CJ, **Ohman EM**, Smith JE, Stack RS. Selective infusion of thrombolytic therapy in the acute myocardial infarct-related coronary artery as an alternative to rescue percutaneous transluminal coronary angioplasty. **American Journal of Cardiology** 1990;66:1021-1023.
23. **Ohman EM**, Califf RM, George BS, Quigley PJ, Kereiakes DJ, Harrelson-Woodlief L, Candela RJ, Flanagan C, Stack RS, Topol EJ, and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) study group. The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. **American Heart Journal** 1991; 121:895-901.

24. Christenson RH, **Ohman EM**, Vollmer RT, Clemmensen P, Grande P, Wagner GS. Serum release of the creatine kinase tissue isoforms MM3 and MB2 is simultaneous during myocardial reperfusion in humans. **Clinica Chimica Acta** 1991;200:23-34.
25. Califf RM, Fortin DF, Frid DJ, Harlan WR, **Ohman EM**, Bengtson J, Nelson CC, Tchong JE. Restenosis after coronary angioplasty: an overview. **Journal of the American College of Cardiology** 1991;17:2B-13B.
26. Davidson CJ, Sheikh KH, Kisslo KB, Phillips HR, Peter RH, Behar VS, Kong Y, Krucoff M, **Ohman EM**, Tchong JE, Bauman RP, Stack RS. Intracoronary ultrasound evaluation of interventional technologies. **American Journal of Cardiology** 1991;68:1305-1309.
27. Tenaglia AN, Quigley PJ, Kereiakes DJ, Abbottsmith CW, Phillips HR, Tchong JE, Rendall D, **Ohman EM**. Coronary angioplasty performed with gradual and prolonged inflation using a perfusion balloon catheter: procedural success and restenosis rate. **American Heart Journal** 1992;124:585-589.
28. Califf RM, **Ohman EM**. The diagnosis of acute myocardial infarction. **Chest** 1992;101 (Supl.):106-115.
29. Muhlestein JB, Quigley PJ, **Ohman EM**, Bauman RP, Sketch MH, Tchong JE, Davidson CJ, Peter RH, Behar VS, Krucoff MW, Kong Y, Phillips HR. Prospective analysis of possible myocardial damage or hemolysis occurring as a result of prolonged autoperfusion angioplasty in humans. **Journal of the American College of Cardiology** 1992;20:594-598.
30. Clemmensen P, **Ohman EM**, Sevilla D, Wagner NB, Quigley PS, Grande P, Wagner GS. Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. **American Journal of Cardiology** 1992;70:1391-1396.
31. Jurlander B, Clemmensen P, **Ohman EM**, Wagner GS, Grande P. Serum kreatinkinase isoenzym-MB og myoglobin hos patienter med akut myokardieinfarkt og koronar reperfusion. **Ugeskrift for Laeger (Journal of Danish Medical Association)** 1992;154:2682-2686.
32. Grande P, Clemmensen P, **Ohman EM**, Wagner GS. Biochemical markers of early reperfusion. **Journal of Electrocardiology** 1992;25 Supplement: 6-9.
33. **Ohman EM**, Christenson R, Clemmensen P, Wagner GS. Myocardial salvage after reperfusion. **Journal of Electrocardiology** 1992;25 (Supl.):10-14.
34. Chapman GD, **Ohman EM**, Topol EJ, Candela RJ, Kereiakes DJ, Samaha J, Berrios E, Pieper KS, Young SY, Califf RM. Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] Study Group). **American Journal of Cardiology** 1993;71:783-787.

35. **Ohman EM**, Topol EJ, Califf RM, Bates ER, Ellis SG, Kereiakes DJ, George BS, Samaha JK, Kline E, Sigmon KN, Stack RS, and the Thrombolysis Angioplasty in Myocardial Infarction Study Group. An analysis of the cause of early mortality after administration of thrombolytic therapy. **Coronary Artery Disease** 1993;4:957-964.
36. **Ohman EM**, Christenson RH, Califf RM, George BS, Samaha JK, Kereiakes DJ, Worley SJ, Wall TC, Berrios E, Sigmon KN, Lee K, Topol EJ, and the TAMI 7 Study Group. Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. **American Heart Journal** 1993;126:819-826.
37. Baskin JM, Wilkins ML, **Ohman EM**, Clemmensen P, Grande P, Christenson RH, Sevilla DC, Wagner NB, Wagner GS. Ratio of ST-segment and myoglobin slopes to estimate myocardial salvage during thrombolytic therapy for acute myocardial infarction. **American Journal of Cardiology** 1993;71:1362-1365.
38. Vollmer RT, Christenson RH, Reimer K, **Ohman EM**. Temporal creatine kinase curves in acute myocardial infarction: Implications of a good empirical fit with the log-normal function. **American Journal of Clinical Pathology** 1993;100:293-298.
39. **Ohman EM**, O'Connor CM, Califf RM. Role of thrombolytic therapy in the treatment of acute myocardial infarction in the elderly. **Coronary Artery Disease in the Elderly** 1993;1:54-61.
40. Kleiman NS, **Ohman EM**, Califf RM, George BS, Kereiakes DJ, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. **Journal of the American College of Cardiology** 1993;22:381-389.
41. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. **New England Journal of Medicine** 1993;329:673-682.
42. Clemmensen P, **Ohman EM**, Sevilla DC, Skelton T, Wagner NB, Quigley PS, Grande P, Wagner GS. Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischemia. **European Heart Journal** 1994;15:1356-1361.
43. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. **Lancet** 1994;343:311-322.
44. Granger CB, White H, Bates E, **Ohman EM**, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. **American Journal of Cardiology** 1994;74:1220-8.

45. Hillegass WB, Jollis JG, Granger CB, **Ohman EM**, Califf RM, Mark DB. Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. **American Journal of Cardiology** 1994;73:444-449.
46. Hillegass WB, **Ohman EM**, Leimberger JD, Califf RM. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. **American Journal of Cardiology**. 1994;73:835-839.
47. **Ohman EM**, Marquis J-F, Ricci DR, Brown R, Knudtson ML, Kereiakes DJ, Samaha JK, Margolis JR, Niederman AL, Dean LS, Gurbel PA, Sketch MH, Wildermann NM, Lee KL, Califf RM. A randomized comparison of the effects of gradual prolonged versus standard primary balloon inflation on early and late outcome: results of a multicenter clinical trial. **Circulation** 1994;89:1118-1125.
48. **Ohman EM**, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ, Lundergan C, Hartmann JR, Talley JD, Frey MJ, Taylor G, Leimberger JD, Owens PM, Lee KL, Stack RS, Califf RM for the Randomized IABP Study Group. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: results of a randomized trial. **Circulation** 1994;90:792-799.
49. Horgan J, Crean P, Fennell W, Fitzgerald G, Kenny J, Maurer B, McKiernan P, Quigley P, Sugrue D, Sullivan P, Walsh M, **Ohman EM**, O'Callaghan DM. Guidelines for the use of thrombolysis in acute myocardial infarction: second consensus report 1994. **Irish Journal of Medical Science** 1994;163:121-125.
50. Labinaz M, Ellis SG, Phillips HR, **Ohman EM**. The role of angioplasty after successful thrombolysis for acute myocardial infarction. **Coronary Artery Disease** 1994; 5:399-406.
51. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. **Circulation** 1994;90:1631-1637.
52. Kleiman NS, White HD, **Ohman EM**, Ross A, Woodlief LH, Califf RM, Holmes D, Bates E, Pfisterer M, Vahanian A, Topol EJ. Mortality within 24 hours of thrombolysis for myocardial infarction: the importance of early reperfusion. **Circulation** 1994;90:2658-2665.
53. Ellis SG, Lincoff AM, George BS, Kereiakes DJ, **Ohman EM**, Krucoff MW, Califf RM, Topol EJ, and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. **Coronary Artery Disease** 1994;5:611-615.
54. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, **Ohman EM**, and the ERA Investigators. Low molecular weight heparin in prevention of restenosis after angioplasty: results of enoxaparin restenosis (ERA) trial. **Circulation** 1994;90:908-914.

55. Lincoff AM, Topol EJ, Califf RM, Sigmon KN, Lee KL, **Ohman EM**, Rosenschein U, Ellis SG for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). **American Journal of Cardiology** 1995;75:871-876.
56. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, **Ohman EM**, Califf RM. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. **Circulation** 1995;91:1929-1935.
57. Harrington RA, Lincoff AM, Califf RM, Holmes DR, Berdan LG, Keeler GP, O'Hanesian MA, Garrett K, **Ohman EM**, Topol EJ for the CAVEAT Investigators. Characteristics and consequences of myocardial infarction following percutaneous coronary intervention: insights from CAVEAT. **Journal of the American College of Cardiology** 1995;25:1693-1699.
58. Christenson RH, **Ohman EM**, Topol EJ, O'Hanesian M, Sigmon KN, Duh SH, Kereiakes D, Worley SJ, George BS, Pizzo CK, Wall TC, Califf RM for the TAMI study group. Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography. **Clinical Chemistry** 1995;41:844-852.
59. Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS, **Ohman EM**, Leimberger JD, Mark DB, Califf RM for the TAMI study group. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. **American Journal of Cardiology** 1995;76:1007-1013.
60. Armstrong B, Zidar JP, **Ohman EM**. The Use of Intraaortic Balloon Counterpulsation in acute myocardial infarction and high risk coronary angioplasty. **Journal of Interventional Cardiology** 1995;8:185-191.
61. Popma JJ, Collier BS, **Ohman EM**, Bittl JA, Weitz J, Kuntz RE, Leon MB. Antithrombotic therapy in patients undergoing coronary angioplasty. **Chest** 1995;108 (Suppl. 4):486S-501S.
62. Davenport RJ, Starkey IR, Ruckley CV, Dennis MS, Sandercock PAG, Warlow CP, Porter JM, Jackson G, Hornick P, Taylor KM, **Ohman EM**. How should a patient presenting with unstable angina and a recent stroke be managed? **British Medical Journal** 1995;310:1450-1451.
63. Newby LK, Gibler WB, **Ohman EM**, Christenson RH. Biochemical markers in suspected acute myocardial infarction: the need for early assessment. **Clinical Chemistry** 1995;41:1263-1265.

64. Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, **Ohman EM**, Topol EJ, for the GUSTO Investigators. Regional variation in the United States for the management of acute myocardial infarction: insights from the GUSTO trial. **New England Journal of Medicine** 1995;333:565-72.
65. Phillips HR, **Ohman EM**, Labinaz M, Sketch MH, Stack R. Use of the perfusion balloon as a primary dilation device. **Journal of Invasive Cardiology** 1995;7 (Suppl. B):17B-24B.
66. Kereiakes DJ, Sketch MH, **Ohman EM**. Perfusion balloon angioplasty in patients with complex coronary lesion morphology. **Journal of Invasive Cardiology** 1995;7 (Suppl. B):4B-9B.
67. **Ohman EM**, Harrington RA, Lincoff AM, Kitt MM, Kleiman NS, Tcheng JE. Early clinical experience with integrilin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. **European Heart Journal**. 1995;16 (Suppl. L):50-55.
68. Jurlander B, Clemmensen PM, Ohman EM, Wagner GS, Grande P. Serum myoglobin as a non-invasive marker of coronary reperfusion after intravenous thrombolytic therapy in patients with acute myocardial infarction. *Ugeskr Laeger* 1995;157:440-3. (Danish)
69. Jurlander B, Clemmensen P, **Ohman EM**, Wagner GS, Grande P, Serum myoglobin for the early noninvasive detection of coronary reperfusion in patients with acute myocardial infarction. **European Heart Journal** 1996;17:399-406.
70. Berger PB, Holmes DR, **Ohman EM**, O'Hanesian MA, Murphy JG, Schwartz RS, Serruys PW, Faxon DP for the MARCATOR Investigators. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. **Journal of the American College of Cardiology** 1996; 27:1-7.
71. Gurbel PA, Navetta FI, Bates ER, Muller DW, Tenaglia AN, Miller J, Muhlstein B, Hermiller JB, Davidson CJ, Aguirre FV, Beauman GJ, Berdan LG, Leimberger JD, Bovill EG, Christenson RH, **Ohman EM**. Lesion-directed administration of tissue-plasminogen activator with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. **Catheterization and Cardiovascular Diagnosis** 1996;37:382-391.
72. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, **Ohman EM**, Faxon DP, Jacobs AK, Topol EJ, Califf RM. The relationship between estrogen replacement therapy and restenosis following percutaneous coronary interventions. **Journal of the American College of Cardiology** 1996;28:1111-1118.
73. **Ohman EM**, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE, Califf RM, Topol EJ, for the GUSTO-IIa Investigators. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. **New England Journal of Medicine**. 1996;335:1333-1341.

74. Barsness GW, **Ohman EM**, Califf RM, Kereiakes DJ, George BS, Topol EJ. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials: a decade of reperfusion strategies. **Journal of Interventional Cardiology** 1996;9:89-115.
75. Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, **Ohman EM**, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM, for the GUSTO-I Investigators. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. **Journal of the American Medical Association** 1996;275:777-782.
76. Mahaffey KW, Granger CB, Collins R, O'Connor CM, **Ohman EM**, Bleich SD, Col JJ, Califf RM. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. **American Journal of Cardiology** 1996;77:551-556.
77. Anderson RD, **Ohman EM**. Successful identification and management of high-risk patients with acute myocardial infarction. **Journal of Thrombosis and Thrombolysis** 1996;3:271-278.
78. The GUSTO IIb Investigators. A comparison of recombinant hirudin versus heparin for the treatment of acute coronary syndromes: The Global Use of Strategies to Open Occluded Arteries. **New England Journal of Medicine** 1996;335:775-782.
79. Simoons ML, Van der Werf F, Vahanian A, Gulba DC, Muller J, Arnold AER, Barr F, Vermeer F, Verheugt FWA, Boersma H, van Es GA, Deckers JW, Lenderink T, Steyerberg E, van der Zwaan C, de Boer MJ, Zijlstra F, Wilcox RD, Collins R, Sleight P, Selker HP, Califf RM, Granger C, Lee KL, **Ohman EM**, Weaver DW, Love T, White H. Selection of reperfusion therapy for individual patients with evolving myocardial infarction. **European Heart Journal** 1997;18:1371-1381
80. Talley JD, **Ohman EM**, Mark DB, George BS, Leimberger JD, Berdan LG, Davidson-Ray L, Rawert M, Lam LC, Phillips HR, Califf RM, for the Randomized IABP Study Group. Economic implications of the prophylactic use of intraaortic balloon counterpulsation (IABP) in the setting of acute myocardial infarction. **American Journal of Cardiology** 1997;79:590-594.
81. Califf RM, Lee KL, Granger CB, **Ohman EM**. Predictors of outcome of reperfusion therapy. **European Heart Journal** 1997;18:728-735.
82. Christenson RH, **Ohman EM**, Topol EJ, Peck S, Newby LK, Duh SH, Kereiakes DJ, Worley SJ, Alosozana GL, Wall TC, Califf, RM, for the TAMI-7 Study Group. Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. **Circulation** 1997;96:1776-1782.
83. Anderson RD, **Ohman EM**, Holmes DR, Col J, Stebbins A, Bates ER, Stomel RJ, Granger CB, Topol EJ, Califf RM. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I study. **Journal of the American College of Cardiology** 1997;30:708-715.

84. **Ohman EM**, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen M, Sprigg D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ, for IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. **Circulation** 1997;95:846-854.
85. Kovack PJ, Rasak MA, Bates ER, **Ohman EM**, Stomel RJ. Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. **Journal of the American College of Cardiology** 1997;29:1454-1458.
86. Iparraguirre HP, Grancelli H, Conti C, Grancelli H, **Ohman EM**, Calandrelli M, Volman S, Garber V. Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy. **American Heart Journal** 1997;134:631-8.
87. **Ohman EM**, Tardiff BE. Periprocedural cardiac marker release after percutaneous revascularization: importance and implications. **Journal of the American Medical Association** 1997;277:495-497.
88. Barsness GW, Peterson ED, **Ohman EM**, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf, RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. **Circulation**. 1997;96:2551-2556.
89. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb). Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. **New England Journal of Medicine** 1997;336:1621-1628.
90. **Ohman EM**, Williams PA, Hodgson PK, Weldon PM, Califf RM. Using the internet to enhance clinical trials performance. **Cardio-Vascular Clinical Trials** 1997;1:27-29.
91. The GUSTO-III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. **New England Journal of Medicine**. 1997;337:1118-1123.
92. Califf RM, Abdelmeguid AE, Kuntz R, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky R, Granger CB, Harrington RA, Tardiff BE, Crenshaw B, Bauman RP, Zuckerman B, Chaitman BR, Bittl JA, **Ohman EM**. Myonecrosis after revascularization procedures. **Journal of the American College of Cardiology** 1998;31:241-251.
93. Newby LK, Christenson RH, **Ohman EM**. The role of enzymatic markers in the new millennium: point-of-care testing and beyond. **Journal of Thrombosis and Thrombolysis** 1998;5:S113-S118.

94. Christenson RH, Newby LK, **Ohman EM**, Califf RM, Armstrong PW, Granger CB, Peck S, Pieper KS, Duh SH, Katus HA, Topol EJ for the GUSTO-IIa Investigators. Cardiac troponin T and cardiac troponin I: relative value in short-term risk stratification of patients with acute coronary syndromes. **Clinical Chemistry** 1998; 44:494-501.
95. Anderson DR, **Ohman EM**, Holmes DR, Jr., Harrington RA, Barsness GW, Wildermann NM, Phillips HR, Topol EJ, Califf RM. Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. **Journal of the American College of Cardiology** 1998; 32: 936-941.
96. Gurbel P, Serebruany V, Shustov A, Bahr R, Carpo C, **Ohman EM**, Topol E, for the GUSTO III Investigators. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. **Journal of the American College of Cardiology** 1998;31:1466-1473.
97. Newby LK, Christenson RH, **Ohman EM**, Armstrong PW, Thompson TD, Lee K, Hamm CW, Katus H, Cianciolo C, Granger CB, Topol EJ, Califf RM, for the GUSTO-IIa Investigators. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. **Circulation** 1998; 98:1853-1859.
98. Kleiman NS, Lincoff AM, **Ohman EM**, Harrington RA. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. **American Heart Journal** 1998; 136:S32-S42.
99. The PARAGON Investigators. An international , randomized, dose- ranging, controlled trial of lamifiban, (a platelet glycoprotein IIb/IIIa inhibitor) or heparin or both in unstable angina. **Circulation** 1998; 97:2386-2395.
100. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. **New England Journal of Medicine.** 1998;339:436-43
101. Serebruany VL, Gurbel PA, Shustov AR, **Ohman EM**, Topol EJ. Heterogeneity of platelet aggregation and major surface receptor expression in patients presenting with acute myocardial infarction. **American Heart Journal** 1998;136:398-405.
102. Serebruany VL, Gurbel PA, Shustov AR, Dalesandro MR, Gumbs CI, Grabletz LB, Bahr RD, **Ohman EM**, Topol EJ. Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. **Stroke** 1998;29:235-238.
103. Hirsh, J, Warkentin TE, Raschke R, Granger C, **Ohman EM**, Dalen J. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. **Chest** 1998;114:489S-510S.
104. Harrington RA, Kleiman NS, Granger CB, **Ohman EM**, Berkowitz SD. Relation between inhibition of platelet aggregation and clinical outcomes. **American Heart Journal** 1998; 136:S43-S50.

105. Popma JJ, Weitz J, Bittl JA, **Ohman EM**, Kuntz RE, Lansky AJ, King SB. Antithrombotic therapy in patients undergoing coronary angioplasty. **Chest** 1998; 114:728S-741S.
106. Gurbel PA, Serebruany VL, Shustov AR, Dalesandro M, Gumbs CI, Grablutz LB, Bahr RD, **Ohman EM**, Topol EJ. Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. **Coronary Artery Disease** 1998; 9: 451-456.
107. Bates ER, Stomel RJ, Hochman JS, Ohman EM. The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock. **Interventional Journal of Cardiology**. 1998;65 (Suppl. 1):S37-S42.
108. Kern, MJ, Aquirre, FV, Caracciolo, EA, Bach, RG, Donohue, TH, Lasorda, D, **Ohman, EM**, Schnitzler, RN, King, DL, Ohley, WJ, Grayzel, J. Hemodynamic effects of new intra-aortic balloon counterpulsation timing methods in patients: a multicenter evaluation. **American Heart Journal** 1999; 137:1129-1136.
109. Savonitto S, Ardissino D, Granger CB, Morando G, Prando M, Mafrcici A, Thompson T, Vahanian A, **Ohman EM**, Califf RM, Van de Werf F, Topol EJ. Prognostic value of the admission electrocardiogram in acute coronary syndromes: results from the GUSTO-IIb trial. **Journal of the American Medical Association** . 1999;281:707-13.
110. Tardiff BE, Califf RM, Tchong JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, **Ohman EM**, Teirstein PS, Blankenship J, Kitt MM, Topol EJ, for the IMPACT-II Investigators. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. **Journal of the American College of Cardiology** 1999;33:88-96 .
111. Hasdai D, Holmes D, Topol E, Berger P, Criger D, Hochman J, Bates E, Vahanian A, Armstrong P, Wilcox R, **Ohman EM**, Califf R. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase: results from GUSTO-III. **European Heart Journal**. 1999;20:128-135.
112. Miller JM, Smalling R, **Ohman EM**, Bode C, Betriu A, Kleiman NS, Schildcrout JS, Bastos E, Topol EJ, Califf RM for the GUSTO-III Investigators. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). **American Journal of Cardiology** 1999;84:779-784.

113. Cohen MG, Granger CB, **Ohman EM**, Stebbins AL, Grinfeld LR, Cagide AM, Elizari MV, Betriu A, Kong DF, Topol EJ, Califf RM. Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and -III trials. **Journal of the American College of Cardiology** 1999;34:1729-37.
114. **Ohman EM**, Armstrong PW, White HD, Granger CB, Wilcox RG, Weaver WD, Gibler WB, Stebbins AL, Cianciolo C, Califf RM, Topol EJ. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction: a GUSTO-III substudy. **American Journal of Cardiology** 1999;84:1281-1286.
115. Hudson MP, Christenson RH, Newby LK, Kaplan AL, **Ohman EM**. Cardiac markers: point of care testing. **Clinica Chemica Acta** 1999; 248: 223-237.
116. Hudson MP, Greenbaum AB, Harrington RA, **Ohman EM**. Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. **Journal of Thrombosis and Thrombolysis** 1999; 7:241-245.
117. French PA, **Ohman EM**. The abbreviated life of acronyms. **American Heart Journal** 1999;137:577-8.
118. Kleiman NS, Tracy RP, Talley JD, Sigmon K, Joseph D, Topol EJ, Califf RM, Kitt M, **Ohman EM**. Inhibition of platelet aggregation with a glycoprotein IIb/IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. **Journal of Thrombosis and Thrombolysis** 2000;9:5-12.
119. Christenson RH, Vollmer RT, **Ohman EM**, Peck S, Thompson TD, Duh SH, Ellis SG, Newby LK, Topol EJ, Califf RM for the TAMI Study Group. Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. **American Journal of Cardiology**. 2000;85:543-547.
120. Barsness GW, Buller C, **Ohman EM**, Schechter E, Pucillo A, Taylor M, Miller MJ, Reiner JS, Churchill D, Chandler AB, Gonzalez M, Smith J, Tommaso C, Wildermann NM, Hasdai D, Holmes DR. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts: the EDGE study. **American Heart Journal** 2000;139:824-9.
121. Chang W, Fu Y, **Ohman EM**, Gupta M, Morris A, Roth SN, Granger CB, Califf RM, Topol EJ, Mark DB, Armstrong PW. For the North American GUSTO-I and GUSTO-III Investigators. Temporal evolution in the management of acute ST elevation myocardial infarction: the 7-year GUSTO experience from Canada and the U.S. **Canadian Journal of Cardiology** 2000;16:1231-1239.

122. Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Knight D, Mark DB, Granger CB, Agranatti DA, Mautner B, **Ohman EM**, Topol EJ, Suarez LD, Armstrong PW, Gates K, Wagner GS, for the GUSTO-I Investigators. Use of resources, quality of life, and outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). **American Journal of Cardiology** 2000;86:24-29.
123. Hasdai D, Califf RM, Thompson TD, Hochman JS, **Ohman EM**, Pfisterer M, Bates ER, Vahanian A, Armstrong PS, Topol EJ, Holmes DR. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. **Journal of the American College of Cardiology** 2000;35:136-43.
124. The SPEED Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. **Circulation** 2000;101:2788-2794.
125. Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, **Ohman EM**, Corbalan R, Chierchia SL, Boland JB, Simoons ML, Califf RM, Topol EJ, Harrington RA for the PURSUIT Investigators. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. **Journal of the American Medical Association** 2000; 283:347-353.
126. Newby LK, Kaplan AL, Granger BB, Sedor F, Califf RM, **Ohman EM**. Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit. **American Journal of Cardiology** 2000;85:801-5.
127. Tanguay JF, Cantor WJ, Krucoff MW, Muhlestein B, Barsness GW, Zidar JP, Sketch MH, Tchong JE, Phillips HR, Stack RS, Kaplan AV, **Ohman EM**. Local delivery of heparin after angioplasty: a multicenter, randomized pilot study. **Catheterization and Cardiovascular Interventions** 2000;49:461-467.
128. Menon V, Hochman JS, Stebbins A, Pfisterer M, Col J, Anderson RD, Holmes DR, Bates ER, Topol EJ, Califf RM, **Ohman EM** for the GUSTO Investigators. Lack of progress in cardiogenic shock: lessons from the GUSTO trials. **European Heart Journal** 2000; 21:1928-1936.
129. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, **Ohman EM** for the GUSTO III Investigators. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO III experience. **American Heart Journal** 2000;140:878-85.
130. Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, **Ohman EM**, Pepine CJ, Kopecky SL, Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ for the PURSUIT Trial Investigators. Management of patients with acute coronary syndromes in the United States using platelet glycoprotein IIb/IIIa inhibition: insights from the Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. **Circulation** 2000;102:1093-1100.

131. Roe MT, Harrington RA, Prosper DM, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, **Ohman EM**, Pieper KS, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ, for the PURSUIT Investigators. Clinical and therapeutic profile of patients with acute coronary syndromes who do not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. **Circulation** 2000;102:1101-1106.
132. McGuire DK, Emanuelsson H, Granger CB, **Ohman EM**, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ, for the GUSTO IIb Investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes: findings from the GUSTO IIb study. **European Heart Journal** 2000;21:1750-8.
133. Herrmann HC, Moliterno DJ, **Ohman EM**, Stebbins AL, Bode C, Betriu A, Forycki F, Miklin JS, Bachinsky WB, Lincoff AM, Califf RM, Topol EJ. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO IV Pilot) trial . **Journal of the American College of Cardiology** 2000;36:1489-96.
134. The SYMPHONY Investigators. Comparison of sibrافiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. **The Lancet** 2000;355:337-45.
135. 31st Bethesda Conference: Emergency Cardiac Care (1999). **Journal of the American College of Cardiology** 2000; 35:825-880.
136. **Ohman EM**, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. **Journal of the American Medical Association** 2000;284:876-878.
137. Nair GV, Gurbel PA, Fuzaylov SY, Davis CJ, **Ohman EM**, Bahr RD, Christenson RH, Serebruany VL. Combining necrosis and platelet markers for perfecting myocardial infarction rule out: how close are we? **Cardiology** 2000;93:50-55.
138. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined- a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. **European Heart Journal** 2000;21:1502-1513.
139. Cantor WJ, Peterson ED, Popma JJ, Zidar JP, Sketch MH Jr., Tchong JE, **Ohman EM**. Provisional stenting strategies: Systematic overview and implications for clinical decision-making. **Journal of the American College of Cardiology** 2000;36:1142-51.
140. Campbell KR, Mahaffey KW, Lewis BE, Weitz JI, Berkowitz SC, **Ohman EM**, Califf RM. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. **The Journal of Invasive Cardiology** 2000; 12(Suppl.):14F-19F.

141. Campbell KR, Cantor W, Sketch M, **Ohman EM**. Glycoprotein IIb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction. **American Heart Journal** 2000;140:S115-24.
142. Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, **Ohman EM**, Kubler W, Bode C. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine. **Circulation** 2000;102:1490-1496.
143. Newby LK, **Ohman EM**. Troponins in pericarditis: implications for diagnosis and management of chest pain patients. **European Heart Journal** 2000;21:798-800.
144. Campbell KR, **Ohman EM**, Cantor W, Lincoff AM. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. **The American Journal of Cardiology**. 2000; 85:32C-38C.
145. Campbell KR, **Ohman EM**. Recognizing and evaluating acute coronary syndromes. **Emergency Medicine** 2000;32:38-54.
146. Topol EJ, **Ohman EM**, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode C, White HD, Hochman JS, Emanuelsson H, Vahanian A, Sapp S, Stebbins A, Moliterno DJ, Califf RM. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. **Circulation**. 2000;102:1761-5.
147. Ferguson JJ, Cohen M, Freedman RJ, Graeber GM, **Ohman EM**, Stone GW, Miller MF, Joseph DL. The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. **Journal of the American College of Cardiology** 2001;38:1456-1462.
148. Greenbaum AB, Harrington RA, **Ohman EM**, Hudson MP, MacAulay CM, Wilcox RG, Berdan LG, Guerci A, Cokkinos DM, Lincoff AM, Topol EJ, Califf RM for the PURSUIT Investigators. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. **Journal of the American College of Cardiology** 2001; 37:492-8.
149. Goldmann BU, Christensen RH, Hamm CW, Meinertz T, **Ohman EM**. Implications of troponin testing in clinical medicine. **Current Controlled Trials in Cardiovascular Medicine** 2001;2:75-84.
150. Roe MT, **Ohman EM**, Maas ACP, Christenson RH, Mahaffey KW, Granger CB, Harrington RA, Califf RM, Krucoff MW. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. **Journal of the American College of Cardiology** 2001; 37:9-18.

151. Singh M, Reeder GS, **Ohman EM**, Mathew V, Hillegass WB, Anderson RD, Gallup DS, Garratt KN, Holmes DR Jr. Does the presence of thrombus seen on coronary angiogram affect the outcome after percutaneous coronary angioplasty? An angiographic trials pool data experience. **Journal of the American College of Cardiology** 2001;38:624-630.
152. Cantor WJ, Kaplan AL, Velianou JL, Sketch MH, Barsness GW, Berger PB, **Ohman EM**. Effectiveness and safety of abciximab after failed thrombolytic therapy. **American Journal of Cardiology** 2001;87:439-442.
153. Popma JJ, **Ohman EM**, Weitz J, Lincoff AM, Harrington R, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. **Chest** 2001;119:321S-336S.
154. **Ohman EM**, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. **Chest** 2001;119:253S-277S.
155. Roe MT, Granger CB, Puma JA, Hellkamp AS, Hochman JS, **Ohman EM**, White HD, Van de Werf F, Armstrong P, Ellis SG, Califf RM, Topol EJ. Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. **Journal of the American College of Cardiology** 2001;88:1403-6.
156. Cantor WJ, Hellkamp A, Peterson ED, Zidar JP, Cowper PA, Sketch MI Jr., Tchong JE, Califf RM, **Ohman EM**. Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes? **Journal of the American College of Cardiology** 2001;37:1883-90.
157. Newby LK, **Ohman EM**, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van de Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ for the PARAGON-B Investigators. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B Troponin Substudy. **Circulation** 2001;103:2891-2896.
158. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, **Ohman EM**, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of actions, pharmacokinetics, dosing, monitoring, efficacy, and safety. **Chest** 2001;119:64S-94S.
159. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, **Ohman EM**, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. **Lancet** 2001;357:1063-8.
160. **Ohman EM**, Hochman JS. Aortic counterpulsation in acute myocardial infarction: physiologically important but does the patient benefit? **American Heart Journal** 2001;141:889-92.

161. Wagner GS, Bahit MC, Criger D, Bayes de Luna A, Chaitman B, Clemmensen P, Klootwijk P, Marcus FI, Pahlm O, **Ohman M**. Moving toward a new definition of acute myocardial infarction for the 21st century: status of the ESC/ACC Consensus Conference. **Journal of Electrocardiology** 2001;33 (Suppl.):57-59.
162. Newby LK, Storrow AB, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, Schreiber DH, Tuttle RH, McNulty SE, **Ohman EM**. Bedside multimarker testing for risk stratification in chest pain units. The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) study. **Circulation** 2001;103:1832-1837.
163. Simoons ML for the GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS randomised trial. **The Lancet** 2001;357:1915-24.
164. Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A, Califf RM, **Ohman EM**. Early reinfarction after fibrinolysis: experience from the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) trials. **Circulation** 2001;104:1229-1235.
165. **Ohman EM**, Peterson E. Implications and challenges for health care providers using practice guidelines for chronic angina. **Annals of Internal Medicine** 2001;135:527-529.
166. Herrmann HC, Li RH, **Ohman EM**. Facilitated percutaneous coronary intervention: results from the SPEED trial. **European Heart Journal** 2001;3(Suppl. A):A26-A34.
167. Cantor WJ, **Ohman EM**. "Facilitated" PCI for acute MI: PCI with lysis and platelet inhibition. **Current Interventional Cardiology Reports** 2001;3:321-329.
168. Christenson RH, Duh SH, Roe MT, **Ohman EM**. Determination of the falloff constant (k_f) from modeling biochemical marker release. **Cardiovascular Toxicology** 2001;1:171-176.
169. Bahit MC, Criger D, **Ohman EM**, Granger C, Wagner G. Thresholds for the electrocardiographic change range of biochemical markers of acute myocardial infarction (GUSTO-IIa data). **American Journal of Cardiology** 2002;90:310-312.
170. Cohen M, Ferguson JJ, Freedman RJ, Miller MF, Reddy RC, **Ohman EM**, Stone GW, Joseph DL on behalf of the Benchmark Registry collaborators. Comparison of outcomes after 8 versus 9.5 French size intra-aortic balloon counterpulsation catheters based on 9332 patients in the prospective Benchmark registry. **Catheterization and Cardiovascular Interventions** 2002;56:200-206.

171. Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell M, Dillard P, Davidian M, Zhang M, Cantor WJ, Sketch MH Jr, **Ohman EM**, Zidar JP, Gretler D, DiBattiste PM, Tchong JE, Califf RM, Harrington RA. Randomized COMparison of Platelet inhibition with Abciximab, tiRoFiban and Eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. **Circulation** 2002;106:1470-1476.
172. Christenson JT, Cohen M, Ferguson JJ III, Freedman RJ, Miller MF, **Ohman EM**, Reddy RC, Stone GW, Urban PM. Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery. **Annals of Thoracic Surgery** 2002; 74:1086-90.
173. Gibler, WB, Armstrong PW, **Ohman EM**, Weaver WD, Stebbins A, Gore JM, Newby LK, Califf RM, Topol EJ; The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. Persistence of delays in presentation and treatment for patients with acute myocardial infarction: the GUSTO I and III experience. **Annals of Emergency Medicine** 2002;39:123-30.
174. Anderson RD, White HD, **Ohman EM**, Wagner GS, Krucoff MW, Armstrong PW, Weaver WD, Gibler WB, Califf RM, Topol EJ. Predicting outcome after thrombolysis in acute myocardial infarction according to ST segment resolution at 90 minutes: a substudy of the GUSTO III trial. **American Heart Journal** 2002;144:81-8.
175. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, **Ohman EM** for the GUSTO III Investigators. The management and outcome of patients with atrial fibrillation after acute myocardial infarction. The GUSTO III Experience. **Heart** 2002;88:357-362.
176. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, **Ohman EM**, Holmes DR for the GUSTO IIb, GUSTO III, PURSUIT and PARAGON-A Investigators. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. **Circulation** 2002;106:974-980.
177. Cantor WJ, Miller JM, Hellkamp AS, Kramer JM, Peterson ED, Hasselblad V, Zidar JP, Newby LK, **Ohman EM**. Role of vessel size and body surface area on outcomes after percutaneous coronary interventions in women. **American Heart Journal** 2002;144:297-302.
178. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, **Ohman EM** for the SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy Investigators. Prognostic significance of elevated troponin-I after percutaneous coronary intervention. **Journal of the American College of Cardiology** 2002;39:1738-1744.

179. Wong BYL, Gnarpe J, Teo KK, **Ohman EM**, Prosser C, Gibler WB, Langer A, Chang W, Armstrong PW. Does chronic chlamydia pneumoniae infection increase the risk of myocardial injury: Insights from patients with non-ST elevation acute coronary syndromes. **American Heart Journal** 2002;144:987-94.
180. Savonitto S, Granger CB, Ardissino D, Gardner L, Cavallini C, Galvani M, Ottani F, White HD, Armstrong PW, **Ohman EM**, Pieper KS, Califf RM, Topol EJ, on behalf of the GUSTO-IIb Investigators. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. **Journal of the American College of Cardiology** 2002;39:22-9.
181. Brener SJ, Zeymer U, Adgey AAJ, Vrobel TR, Ellis SG, Neuhaus K, Juran N, Ivanc TB, **Ohman EM**, Strony J, Kitt M, Topol EJ for the INTRO AMI Investigators. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. **Journal of the American College of Cardiology** 2002;39:377-86.
182. Kroll CR, **Ohman EM**. Should reperfusion strategies in myocardial infarction be modified for the very elderly? **American Heart Journal** 2002;143:373-376.
183. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, **Ohman EM**, Mahaffey KW, Newby LK, Califf RM, Topol EJ, Simoons ML, Lauer MS. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. **New England Journal of Medicine** 2002;346:2047-2052.
184. The Prime Investigators. Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. **American Heart Journal** 2002;143:95-105.
185. O'Shea JC, Wilcox RG, Skene AM, Stebbins AL, Granger CB, Armstrong PW, Bode C, Ardissino D, Emanuelsson H, Aylward PE, White HD, Sadowski Z, Topol EJ, Califf RM, **Ohman EM**. Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. **American Journal of Cardiology**. 2002;90:1374-7.
186. Newby LK, Alpert JS, **Ohman EM**, Thygesen K, Califf RM. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. **American Heart Journal**. 2002;144:957-80.
187. Levinsky MJ, **Ohman EM**. Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients. **American Heart Journal** 2002;144:750-752.
188. Bahr RD, Gurbel PA, Malinin AI, Wentz C, Christenson RH, Roe MT, Gibler WB, Kitt MM, **Ohman EM**, Serebruany VL. Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. **American Journal of Cardiology** 2002;90:310-312.

189. Hoekstra JW, Pollack CV Jr., Roe MT, Peterson ED, Brindis R, Harrington RA, Christenson RH, Smith SC, **Ohman EM**, Gibler WB. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. **Academic Emergency Medicine** 2002;9:1146-1155.
190. Gurbel PA, Galbut B, Bliden KP, Bahr RD, Roe MT, Serebruany VL, Gibler WB, Christenson RH, **Ohman EM**; EARLY Platelet Substudy. Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). **Journal of Thrombosis and Thrombolysis** 2002;14:213-9.
191. Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, **Ohman EM**, Granger CB, Van de Werf F, Simoons ML, O'Connor CM, Holmes Jr. DR. Frequency, patient characteristics and outcomes of mild to moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from four international fibrinolytic therapy trials. **American Heart Journal** 2003;145:73-9.
192. Chen EW, Canto JG, Parsons LS, Peterson ED, Littrell KA, Every NR, Gibson CM, Hochman JS, **Ohman EM**, Cheeks M, Barron HV for the Investigators in the National Registry of Myocardial Infarction 2. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. **Circulation** 2003;108:951-7.
193. Newby LK, Goldmann BU, **Ohman EM**. Troponin: an important prognostic marker and risk-stratification tool in non-ST-elevation acute coronary syndromes. **Journal of the American College of Cardiology** 2003;41:31S-36S.
194. Roe MT, Christenson RH, **Ohman EM**, Bahr R, Fesmire FM, Storrow A, Mollod M, Peacock WF, Rosenblatt JA, Yang H, Fraulo ES, Hoekstra JW, and Gibler WB, for the EARLY Investigators and Emergency Medicine Cardiac Research and Education Group (EMCREG) A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. **American Heart Journal** 2003;146:993-8.
195. Ottervanger JP, Armstrong PA, Barnathan ES, Boersma E, Cooper JS, **Ohman EM**, James S, Topol EJ, Wallentin L, Simoons ML. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) Trial. **Circulation**. 2003;107:437-42.
196. Alexander JH, Harrington RA, Bhapkar M, Mahaffey KW, Lincoff AM, **Ohman EM**, Klotzwijk P, Pahlm O, Henden B, Deckers JW, Simoons ML, Califf RM, Wagner GS. Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. **American Journal of Medicine** 2003;115:613-619.

197. Rao SV, **Ohman EM**, Granger CB, Armstrong PW, Gibler WB, Christenson RH, Hasselblad V, Stebbins A, McNulty S, Newby LK. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. **American Journal of Cardiology** 2003;91:936-943.
- 198.. Sanchez CD, Newby LK, Hasselblad V, McNulty SE, Storrow AB, Gibler WB, Garvey JL, Schreiber DH, Tucker JF, **Ohman EM**. Comparison of 30-day outcome, resource use and coronary artery disease severity in patients with suspected coronary artery disease with and without diabetes mellitus assigned to chest pain units. **American Journal of Cardiology** 2003;91:1128-1230.
199. Roe MT, **Ohman EM**, Pollack CV Jr, Peterson ED, Brindis R, Harrington RA, Christenson RH, Smith SC, Califf RM, Gibler WB. Changing the model of care for patients with acute coronary syndromes. **American Heart Journal** 2003;146:605-12.
200. Khot UN, Khot MB, Bajzer CT, Sapp SK, **Ohman EM**, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. **Journal of the American Medical Association** 2003;290:898-904.
201. **Ohman EM**, Miller MF, Joseph DL, Cohen M, Freedman RJ, Stone GW, Urban PM, Reddy RC, Christenson JT, Ferguson JJ III. Validation of a multicenter registry database of intra-aortic balloon pumping in a variety of clinical settings. **Heart Drug** 2003;3:8-13.
202. Kaul P, Newby LK, Fu Y, Hasselblad V, Mahaffey KW, Christenson RH, Harrington RA, **Ohman EM**, Topol EJ, Califf RM, Van de Werf F, Armstrong PW for the PARAGON B Investigators. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. **Journal of the American College of Cardiology** 2003;41:371-380.
203. Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Verheugt FWA, Berger PB, Moliterno DJ, White HD, **Ohman EM**, Van de Werf F, Topol EJ, Califf RM for the SYMPHONY and 2nd SYMPHONY Investigators. Frequency of stent thrombosis after acute coronary syndromes from the SYMPHONY and 2nd SYMPHONY trials. **American Journal of Cardiology** 2003;92:330-3.
204. Stone GW, **Ohman EM**, Miller MF, Joseph DL, Christenson JT, Cohen M, Urban PM, Reddy RC, Freedman RJ, Stamen KL, Ferguson JJ. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction. **Journal of the American College of Cardiology** 2003;41:1940-45.
205. Cohen M, Urban P, Christenson JT, Joseph DL, Freedman RJ Jr., Miller MF, **Ohman EM**, Reddy RC, Stone GW, Ferguson JJ III, on behalf of the Benchmark Registry collaborators. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark[®] Registry. **European Heart Journal** 2003;24:1763-70.
206. Cohen MG, **Ohman EM**. The everlasting effect of primary percutaneous coronary intervention—even after transport? **Canadian Journal of Cardiology** 2003;19:1119-22.

207. Al-Khatib SM, Stebbins AL, Califf RM, Lee KL, Granger CB, White HD, Armstrong PW, Topol EJ, **Ohman EM**; GUSTO-III trial. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. **American Heart Journal**. 2003;145:515-21.
208. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, **Ohman EM**. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 Trial. **Cardiac Electrophysiology Review** 2003;7:201-207.
209. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, **Ohman EM**, Antman EM. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. **Journal of Thrombosis and Thrombolysis** 2003;15:189-96.
210. Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, Shalev Y, Ver Lee P, Traverse JH, Rodriguez AR, **Ohman EM**, Harrington RA, Califf RM, for the ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study; main results. **Journal of Invasive Cardiology** 2003;15:611-6.
211. Roe MT, Peterson ED, Li Y, Pollack CV, Jr., Christenson RH, Peacock WF, Fesmire FM, Newby LK, Jesse RL, Hoekstra JW, Gibler WB, **Ohman EM**, for the CRUSADE Investigators. Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. **Archives of Internal Medicine** 2005;165:1870-6.
212. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, Agrawal M, Ciocca-Denu C, **Ohman EM**, Finn WF. N-Acetylcysteine for the prevention of radiocontrast induced nephropathy: a systematic review of prospective controlled trials. **Journal of the American Society of Nephrology** 2004;15:761-769.
213. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC Jr, Pollack CV Jr, Gibler WB, **Ohman EM**, for the CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. **Journal of the American Medical Association** 2004;292:2096-2104.
214. Stouffer GA, Hirmerova J, Moll S, Rubery B, Napoli M, **Ohman EM**, Simpson R. Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura. **Catheterization and Cardiovascular Interventions** 2004;61:364-7.

215. Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Akkerhuis KM, Simoons ML, Harrington RA, Tardiff BE, Granger CB, **Ohman EM**, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Topol EJ. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. **European Heart Journal** 2004;25:313-21.
216. Gurm HS, Lincoff AM, Lee D, Tang WH, Jia G, Booth JE, Califf RM, **Ohman EM**, Van de Werf F, Armstrong PW, Guetta V, Wilcox R, Topol EJ. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. **Journal of the American College of Cardiology** 2004;43:542-8.
217. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Diercks DB, Brogan GX, Boden WE, Roe MT, **Ohman EM**, Gibler WB, Newby LK. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large scale observations from the CRUSADE National Quality Improvement Initiative. **Journal of the American College of Cardiology** 2005;45:832-7.
218. Hudson MP, O'Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, Gaulden LH, Sedor F, **Ohman EM**. Implications of elevated cardiac troponin T in ambulatory heart failure patients: a prospective analysis. **American Heart Journal** 2004;147:546-52.
219. **Ohman EM**, Nanas J, Stomel RJ, Leesar MA, Nielsen DWT, O'Dea D, Rogers FJ, Harber D, Hudson MP, Fraulo E, Shaw LK, Lee KL. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS trial. **Journal of Thrombosis and Thrombolysis** 2005;19:33-9.
220. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, **Ohman EM**, Peacock WF, Pollack CV, Jr., Gibler WB, Peterson ED. Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE quality improvement initiative. **American Heart Journal** 2005;149:1043-9.
221. Sanchez CD, Newby LK, McGuire DK, Hasselblad V, Feinglos MN, **Ohman EM**. Diabetes-related knowledge, risk factor control and outcomes in acute coronary syndromes. **American Journal of Cardiology** 2005;95:1290-4.
222. **Ohman EM**, Roe MT, Smith SC Jr., Brindis RG, Christenson RL, Harrington RA, Gibler WB, Peterson ED for the CRUSADE Investigators. Care of non-ST-segment elevation patients: Insights from the CRUSADE National Quality Improvement Initiative. **American Heart Journal** 2004;148(5 Suppl):S34-9.
223. Hoekstra J, Roe MT, Peterson ED, Menon V, Mulgund J, Pollack C, Palabrica T, Harrington R, **Ohman EM**, Gibler WB. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndromes: patient selection and associated treatment patterns. **Academic Emergency Medicine** 2005;12:431-8.

224. Agrawal M, Wodlinger AM, Huggins CE, Tudor GE, Pieper GE, Pieper JA, O'Reilly KP, Denu-Ciocca CJ, Stouffer GA, **Ohman EM**. Effect of N-acetylcysteine on serum creatine concentration in patients with chronic renal insufficiency who are undergoing coronary angiography. **HeartDrug** 2004;4:87-91.
225. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, **Ohman M**, White HD. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. **American Heart Journal** 2004;148:764-75.
226. Lader EW, Cannon CP, **Ohman EM**, Cramer LD, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flater M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting. **Circulation** 2004;109: 2672-9.
227. Lader EW, Cannon CP, **Ohman EM**, Cramer LD, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flater M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: Fundamentals of study design. **Circulation** 2004;109:e302-e304.
228. Lader EW, Cannon CP, **Ohman EM**, Cramer LD, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flater M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: Statistical Concepts in Study Design and Analysis. **Circulation** 2004;109:e305-e307.
229. Lenderink T, Boersma E, Ruzyllo W, Widimsky P, **Ohman EM**, Armstrong PW, Wallentin L, Simoons ML, for the GUSTO IV-ACS Investigators. Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS. **American Heart Journal** 2004;147:865-73.
230. Stouffer GA, Pathak A, Whinna HC, **Ohman EM**. Effect of multielement intravascular ultrasound on the anticoagulant potency of enoxaparin. **American Journal of Cardiology** 2004;93:1453-4.
231. Barbagelata A, Califf RM, Sgarbossa EB, Knight D, Mark DB, Granger CB, Armstrong PW, Elizari M, Birnbaum Y, Grinfeld LR, **Ohman EM**, Wagner GS, for the GUSTO-1 Investigators. Prognostic value of predischARGE electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. **American Heart Journal** 2004;148:795-802.
232. Popp RJ, Smith SC Jr, Adams RJ, Antman EM, Kavey RE, DeMaria AN, **Ohman EM**, Pitt B, Willerson JT, Bellande BJ, Fonarow GC, Nishimura RA, Shah PM, Hirshfeld JW Jr, Messer JV, Peterson ED, Prystowsky EN, Anderson JL, Cheitlin MD, Goldstein LB, Grant AO, Beller GA, Hines EF, Jr, Livingston DW, McEntree CW. ACCF/AHA consensus conference report on professionalism and ethics. **Circulation** 2004;110:2506-2549.

233. Califf RM, Nissen SE, DeMaria AN, **Ohman EM**, Pitt B, Willerson JT, Builheimer DW, Cohn JN, Feigal DW, Jr., Hampson L, Lorell BH, Pepine CJ, Popp RL. Task Force 2: Investigator participation in clinical research. **Journal of the American College of Cardiology** 2004;44:1729-1736.
234. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, Schunemann HJ, **Ohman EM**. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. **Chest** 2004;126(Suppl):549S-575S.
235. Popma JJ, Berger P, **Ohman EM**, Harrington RA, Grines C, Weitz JL. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. **Chest** 2004;126(Suppl):576S-599S.
236. Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, **Ohman EM**, James S, Wallentin L, Simoons ML, for the GUSTO IV-ACS Investigators. Association of revascularization with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. **European Heart Journal** 2004;17:1494-1501.
237. Urban PM, Freedman RJ, **Ohman EM**, Stone GW, Christenson JT, Cohen M, Miller MF, Joseph DL, Bynum DZ, Ferguson JJ 3rd, for the Benchmark Registry Investigators. In-hospital mortality associated with the use of intra-aortic balloon counterpulsation. **American Journal of Cardiology** 2004;94:181-185.
238. Santa-Cruz RA, Cohen MG, **Ohman EM**. Aortic counterpulsation: a review of the hemodynamic effects and indications for use. **Catheterization and Cardiovascular Interventions** 2006;67:68-77.
239. Truer AT, Mahaffey KW, Gallup D, Weaver WD, Christenson RH, Every NR, **Ohman EM**. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. **Current Controlled Trials in Cardiovascular Medicine** 2005;6:12.
240. Kaul P, Newby LK, Fu Y, Mark DB, Goodman SG, Wagner GS, Harrington RA, Granger CB, Van de Werf F, **Ohman EM**, Armstrong PW, for the VIGOUR Group. Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns. **Heart** 2005;91:876-81.
241. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, **Ohman EM**, Peacock WF, Pollack CV Jr, Gibler WB, Peterson ED. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. **American Heart Journal** 2005;149:1043-9.
242. Meine TJ, Al-Khatib SM, Alexander JH, Granger CB, White HD, Kilaru R, Williams K, **Ohman EM**, Topol E, Califf RM. Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. **American Heart Journal** 2005;149:670-4.

- 243 Sanchez CD, Newby LK, McGuire DK, Hasselblad V, Feinglos MN, **Ohman EM**. Diabetes-related knowledge, atherosclerotic risk factor control, and outcomes in acute coronary syndromes. **American Journal of Cardiology** 2005;95:1290-4.
- 244 Kandzari DE, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Harrington RA, **Ohman EM**, Gibler WB, Peterson ED. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. **American Heart Journal** 2005;149:474-81.
- 245 **Ohman EM**, Van de Werf F, Antman EM, Califf RM, de Limos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E, for the FASTER (TIMI 24) Investigators. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. **American Heart Journal** 2005;150:79-88.
- 246 **Ohman EM**, Chang PP. Improving quality of life after cardiogenic shock: do more revascularization! **Journal of the American College of Cardiology** 2005;46:274-6.
- 247 **Ohman EM**, Granger CB, Rice L, Abrams CS, Becker RC, Berger PB, Kleiman NS, Moliterno D, Moll S, Rodgers JE, Steinhubl SS, Tapson VF, Sinnaeve P, Anstrom KJ. Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. **Journal of Thrombosis and Thrombolysis** 2005;19:11-9.
- 248 Sonel AF, Good CB, Mulgund J, Roe MT, Gibler WB, Smith SC Jr, Cohen MG, Pollack CV, **Ohman EM**, Peterson ED for the CRUSADE Investigators. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes. Insights from CRUSADE. **Circulation** 2005;111:1225-32.
- 249 Foody JM, Roe MT, Chen AY, Smith SC Jr, Brindis RG, Peterson ED, Gibler WB, **Ohman EM** for the CRUSADE Investigators. Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). **American Journal of Cardiology** 2005;95:483-485.
- 250 Kandzari DE, Roe MT, **Ohman EM**, Milford-Beland S, Chen AY, Lytle BL, Cohen DJ, Smith SC Jr, Harrington RA, Gibler WB, Peterson ED. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. **American Journal of Cardiology** 2005;96:750-5.
- 251 Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, **Ohman EM**, Peterson ED, Pollack CV. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department. **Annals of Emergency Medicine** 2005;46:185-97.

- 252 Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Diercks DB, Brogan GX, Boden WE, Roe MT, **Ohman EM**, Gibler WB, Newby LK. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large scale observations from the CRUSADE National Quality Improvement Initiative. **Journal of the American College of Cardiology** 2005;45:832-7.
- 253 Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, **Ohman EM**, Peterson ED, Pollack CV. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and outcomes Research Interdisciplinary Working Group, in Collaboration with the Society of Chest Pain Centers. **Circulation** 2005;111:2699-710.
- 254 Mehta RH, Califf RM, Garg J, Pieper KS, Alexander JH, Moliterno DJ, Van de Werf F, **Ohman EM**, White HD, Topol EJ, Granger CB. Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. **American Journal of Cardiology** 2005;95:1371-5.
- 255 Cohen MG, **Ohman EM**. Drug-eluting stents in acute myocardial infarction: is science catching up with practice? **Journal of the American Medical Association** 2005;293:2154-6.
- 256 Ly HQ, Kirtane AJ, Buros J, Giugliano RP, Popma JJ, Antman EM, Harrington RA, **Ohman EM**, Gibson CM for the TIMI Study Group. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. **American Journal of Cardiology** 2005;95:383-6.
- 257 Kirtane AJ, Martinez-Clark P, Rahman AM, Ray KK, Karpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Roe MT, Harrington RA, **Ohman EM**, Braunwald E, Gibson CM. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. **Journal of the American College of Cardiology** 2005;45:321-3.
- 258 Kirtane AJ, Weisbord A, Karpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, **Ohman EM**, Roe MT, Braunwald E, Gibson CM for the TIMI Study Group. Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. **American Journal of Cardiology** 2005;95:224-7.
259. Roe MT, Peterson ED, Li Y, Pollack CV Jr, Christenson RH, Peacock WF, Fesmire FM, Newby LK, Jesse RL, Hoekstra JW, Gibler WB, **Ohman EM**. Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. **Archives of Internal Medicine** 2005;165:1870-6.

260. Alexander KP, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Foody JM, Boden WE, Smith SC Jr, Gibler WB, **Ohman EM**, Peterson ED, for the CRUSADE Investigators. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. **Journal of the American College of Cardiology** 2005;46:1479-87.
261. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, Rao SV, Gibler WB, **Ohman EM**, Peterson ED, for the CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvements Initiative. **Journal of the American College of Cardiology** 2005;46:1490-1495.
262. Ryan JW, Peterson ED, Chen AY, Roe MT, **Ohman EM**, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Normand SL, Pollack CV Jr, Cohen DJ, for the CRUSADE Investigators. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE Registry. **Circulation** 2005;112:3049-3057.
263. Cohen MG, Kelly RV, Kong DF, Menon V, Shah M, Ferreira J, Pieper KS, Criger D, Poggio R, Ohman EM, Gore J, Califf RM, Granger CB. Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials. **American Journal of Medicine** 2005;118:482-8.
264. Reddan DN, Szczech L, Bhapkar MV, Moliterno DJ, Califf RM, **Ohman EM**, Berger PB, Hochman JS, Van de Werf F, Harrington RA, Newby LK, for the SYMPHONY and 2nd SYMPHONY Investigators. Renal function, concomitant medication use and outcomes following acute coronary syndromes. **Nephrology, Dialysis, Transplantation** 2005;20:2105-12.
265. Roe MT, Peterson ED, Pollack CV Jr, Newby LK, Li Y, Christenson RH, Peacock WF, Fesmire FM, Diercks D, Kirk JD, Smith SC, Jr, **Ohman EM**, Gibler WB, for the CRUSADE Investigators. Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. **Annals of Emergency Medicine** 2005 Apr;45(4):355-62.
266. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, **Ohman EM**, Peterson ED, for the CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. **Journal of the American Medical Association** 2005;294:3108-3116.
267. Kelly RV, Tan WA, Cho H, Tudor G, **Ohman EM**, Struthers AC. Prevalence of symptomatic diastolic heart failure in patients hospitalized with cerebral or peripheral vascular disease. **Congestive Heart Failure** 2005;11:256-261.

268. Newby LK, Roe MT, Chen AY, **Ohman EM**, Christenson RH, Pollack CV Jr, Hoekstra JW, Peacock WF, Harrington RA, Jesse RL, Gibler WB, Peterson ED, for the CRUSADE Investigators. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. **Journal of the American College of Cardiology** 2006;47:312-8.
269. **Ohman EM**, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liao CS, Mas JL, Richard AJ, Rother J, Wilson PW, for the REACH Registry Investigators. The **RE**duction of **A**therothrombosis for **C**ontinued **H**ealth (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events – study design. **American Heart Journal** 2006;151:786.e1-10.
270. Bhatt DL, Steg PG, **Ohman EM**, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liao CS, Richard AJ, Rother J, Wilson PW, for the REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. **Journal of the American Medical Association** 2006;295:180-9.
271. Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV Jr, Kirk JD, Smith SC Jr, Gibler WB, **Ohman EM**, Blomkalns AL, Newby LK, Hochman JS, Peterson ED, Roe MT. Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). **American Journal of Cardiology**. 2006;97:437-42.
272. Januzzi JL Jr, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, **Ohman EM**, Cannon CP, Braunwald E.. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. **American Heart Journal**. 2006;151:360-6.
273. Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, **Ohman EM**, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. **American Heart Journal** 2006;151:16-24.
274. Mehta RH, Marks D, Califf RM, Sohn S, Pieper KS, Van de Werf F, Peterson ED, **Ohman EM**, White HD, Topol EJ, Granger CB. Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. **American Journal of Medicine**. 2006;119:70.e1-8.
275. Mehta RH, Roe MT, Mulgund J, Ohman EM, Cannon CP, Gibler, Jr WB, Pollack, Jr CV, Smith SC, Ferguson TB, Peterson ED. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. **Journal of the American College of Cardiology**. 2006; 48: 281-286.

276. Henry TD, Atkins JM, Cunningham MS, Francis GS, Groh WJ, Hong RA, Kern KB, Larson DM, **Ohman EM**, Ornato JP, Peberdy MA, Rosenberg MJ, Weaver WD. ST-segment elevation myocardial infarction: recommendations on triage of patients to heart attack centers: is it time for a national policy for the treatment of ST-segment elevation myocardial infarction? **Journal of the American College of Cardiology**. 2006;47:1339-1345.
277. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, **Ohman EM**, for the ACUTY Investigators. Bivalirudin for patients with acute coronary syndromes. **New England Journal of Medicine** 2006;355:2203-16.
278. Calvin JE, Roe MT, Chen AY, Mehta RH, Brogan GX Jr, Delong ER, Fintel DJ, Gibler WB, **Ohman EM**, Smith SC Jr, Peterson ED. Insurance coverage and care of patients with non-ST-segment elevation acute coronary syndromes. **Annals of Internal Medicine** 2006;145:739-48.
279. Touze E, Mas JL, Rother J, Goto S, Hirsch AT, Ikeda Y, Liao CS, **Ohman EM**, Richard AJ, Wilson PW, Steg PG, Bhatt DL, for the REACH Registry Investigators. Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry. **Stroke** 2006;37:2880-5.
280. Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, **Ohman EM**, Gibler WB, Harrington RA, Smith SC Jr, Roe MT, for the CRUSADE Investigators. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). **American Journal of Cardiology** 2006;98:1172-6.
281. Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Brindis RG, Smith SC Jr, Harrington RA, Fintel D, Fraulo ES, Califf RM, Gibler WB, **Ohman EM**, Peterson ED. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE Initiative. **Archives of Internal Medicine** 2006;166:2027-34.
282. Mehta RH, Newby LK, Patel Y, Hoekstra JW, Miller CD, Chen AY, Lytle BL, Diercks DB, Summers RL, Brogan GX, Peacock WF, Pollack CV Jr, Roe MT, Peterson ED, **Ohman EM**, Gibler WB, for the CRUSADE Investigators. The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes. **American Heart Journal** 2006;152:648-60.

283. Patel MR, Chen AY, Peterson ED, Newby LK, Pollack CV Jr, Brindis RG, Gibson CM, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, **Ohman EM**, Harrington RA, Roe MT. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) Initiative. **American Heart Journal** 2006;152:641-7.
284. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, Roe MT, Gibler WB, **Ohman EM**, Peterson ED, for the CRUSADE Investigators. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines) Initiative. **Circulation** 2006;114:1380-7.
285. Mehta RH, Chen AY, Pollack CV Jr, Roe MT, Zalenski RJ, Clements EA, Gibler WB, **Ohman EM**, Harrington RA, Peterson ED. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. **American Journal of Cardiology** 2006;98:624-7.
286. Mehta RH, Roe MT, Mulgund J, **Ohman EM**, Cannon CP, Gibler WB, Pollack CV Jr, Smith SC Jr, Ferguson TB, Peterson ED. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. **Journal of the American College of Cardiology** 2006;48:281-6.
287. Menon V, Rumsfeld JS, Roe MT, Cohen MG, Peterson ED, Brindis RG, Chen AY, Pollack CV Jr, Smith SC Jr, Gibler WB, **Ohman EM**. Regional outcomes after admission for high-risk non-ST-segment elevation acute coronary syndromes. **American Journal of Medicine** 2006;119:584-90.
288. Diercks DB, Roe MT, Mulgund J, Pollack CV Jr, Kirk JD, Gibler WB, **Ohman EM**, Smith SC Jr, Boden WE, Peterson ED. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines Quality Improvement Initiative. **American Heart Journal** 2006;152:140-8.
289. Brogan GX Jr, Peterson ED, Mulgund J, Bhatt DL, **Ohman EM**, Gibler WB, Pollack CV Jr, Farkouh ME, Roe MT. Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. **Diabetes Care** 2006;29:9-14.
290. Cohen MG, Roe MT, Mulgund J, Peterson ED, Sonel AF, Menon V, Smith SC Jr, Saucedo JF, Lytle BL, Pollack CV Jr, Garza L, Gibler WB, **Ohman EM**. Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE). **American Heart Journal** 2006;152:110-7.

291. Roe MT, Peterson ED, Newby LK, Chen AY, Pollack CV Jr, Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Braunwald E, Gibler WB, **Ohman EM**. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. **American Heart Journal** 2006;151:1205-13.
292. Roe MT, Chen AY, Riba AL, Goswami RG, Peacock WF, Pollack CV Jr, Collins SP, Gibler WB, **Ohman EM**, Peterson ED, for the CRUSADE Investigators. Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. **American Journal of Cardiology** 2006;97:1707-12.
293. Singh KP, Roe MT, Peterson Ed, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Smith SC Jr, Gibler WB, **Ohman EM**, Pollack CV Jr, for the CRUSADE Investigators. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE Initiative. **Journal of Thrombosis and Thrombolysis** 2006;21:211-20.
294. Peterson ED, Roe MT, Mulgund J, DeLong ER, Lytle BL, Brindis RG, Smith SC Jr, Pollack CV Jr, Newby LK, Harrington RA, Gibler WB, **Ohman EM**. Association between hospital process performance and outcomes among patients with acute coronary syndromes. **Journal of the American Medical Association** 2006;295:1912-20.
295. Kaul P, Chang WC, Lincoff AM, Aylward P, Betriu A, Bode C, Califf RM, **Ohman EM**, Guetta V, Steg PG, Van de Werf F, Armstrong PW. Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial. **European Heart Journal** 2006;27:1198-206.
296. Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC Jr, Pollack CV Jr, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, **Ohman EM**, Peterson ED, Harrington RA. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. **Archives of Internal Medicine** 2006;166:806-11.
297. Han JH, Chandra A, Mulgund J, Roe MT, Peterson ED, Szczech LA, Patel U, **Ohman EM**, Lindsell CJ, Gibler WB. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. **American Journal of Medicine** 2006;119:248-54.
298. Kupchak P, Wu AH, Ghani F, Newby LK, **Ohman EM**, Christenson RH. Influence of imprecision on ROC curve analysis for cardiac markers. **Clinical Chemistry** 2006;52:752-3.
299. Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV, Jr., **Ohman EM**, Rumsfeld JS, Gibler WB, Peterson ED, Cohen DJ. Characteristics, management, and outcomes of 5,557 patients age ≥ 90 years with acute coronary syndromes: results from the CRUSADE Initiative. **Journal of the American College of Cardiology**. 2007;49:1790-7.
300. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, **Ohman EM**, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUTY Trial. **Journal of the American College of Cardiology**. 2007;49:1362-8.

301. Dzavik V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, **Ohman EM**, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Bueller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS, for the SShould we inhibit nitric Oxide synthase in Cardiogenic shock 2 (SHOCK-2) Investigators. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. **European Heart Journal** 2007;28:1109-16.
302. Roe MT, Halabi AR, Mehta RH, Chen AY, Newby LK, Harrington RA, Smith SC Jr, **Ohman EM**, Gibler WB, Peterson ED. Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. **American Heart Journal**. 2007;153:507-14.
303. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, **Ohman EM**, Rother J, Liao CS, Hirsh AT, Mas JL, Ikeda Y, Pencina MJ, Goto S, for the REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. **Journal of the American Medical Association** 2007;297:1197-206.
304. Stone GW, White HD, **Ohman EM**, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, for the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) Trial Investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) Trial. **Lancet** 2007;369:907-19.
305. Mehta RH, Califf RM, Yang Q, Pieper KS, White HD, **Ohman EM**, Harrington RA, Granger CB. Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. **American Journal of Cardiology** 2007;99:793-796.
306. Mehta RH, Milford-Beland S, Peterson ED, Bhatt DL, Farkouh ME, Brogan GX, Gibler WB, **Ohman EM**, Roe MT. Characterizing young patients with diabetes and non-ST-segment elevation acute coronary syndromes. **Diabetes Care** 2007;30:731-3.
307. Stone GW, Bertrand ME, Moses JW, **Ohman EM**, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD, for the ACUITY Investigators. Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing Trial. **Journal of the American Medical Association** 2007;297:591-602.
308. Patel MR, Chen AY, Roe MT, **Ohman EM**, Newby LK, Harrington RA, Smith SC Jr, Gibler WB, Calvin JE, Peterson ED. A comparison of acute coronary syndrome care at academic and nonacademic hospitals. **American Journal of Medicine** 2007;120:40-6.

309. Diercks DB, Roe MT, Chen AY, Peacock WF, Kirk JD, Pollack CV Jr, Gibler WB, Smith SC Jr, **Ohman M**, Peterson ED. Prolonged emergency department stays of non-ST-segment-elevation myocardial infarction patients are associated with worse adherence to the American College of Cardiology/American Heart Association guidelines for management and increased adverse events. **Annals of Emergency Medicine** 2007;50:489-96.
310. Wang TY, Chen AY, Roe MT, Alexander KP, Newby LK, Smith SC Jr, Bangalore S, Gibler WB, **Ohman EM**, Peterson ED. Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian White Americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE Quality Improvement Initiative. **American Journal of Cardiology** 2007;100:391-6.
311. Gogo PB Jr, Dauerman HL, Mulgund J, **Ohman EM**, Patel MR, Cohen DJ, Saucedo JF, Harrington RA, Gibler WB, Smith SC Jr, Peterson ED. Roe MT, for the CRUSADE Investigators. Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). **American Journal of Cardiology** 2007;99:1222-6.
312. Tickoo S, Roe MT, Peterson ED, Milford-Beland S, **Ohman EM**, Gibler WB, Pollack CV Jr, Cannon CP, for the CRUSADE Investigators. Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. **American Journal of Cardiology** 2007;99:1496-9.
313. Bennett KM, Hernandez AF, Chen AY, Mulgund J, Newby LK, Rumsfeld JS, Hochman JS, Hoekstra JW, **Ohman EM**, Gibler WB, Roe MT, Peterson ED. Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes. **American Journal of Cardiology** 2007;99:1351-6.
314. Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV Jr, **Ohman EM**, Gibler WB, Roe MT. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). **American Journal of Cardiology** 2007;99:1389-93.
315. Lytle BL, Fraulo ES, Mulgund J, Miller VA, Roe MT, Smith SC Jr, Gibler WB, **Ohman EM**, Peterson ED. What aspects of hospital culture influence quality? **Critical Pathways of Cardiology** 2007;6:145-9.
316. Atwater BD, Milford-Beland S, Newby LK, Hernandez AF, Peacock WF, Gibler WB, Christenson RH, **Ohman EM**, Peterson ED, Roe MT. Patterns and implications of B-type natriuretic peptide measurement in patients with non-ST-segment elevation acute coronary syndromes. **American Journal of Cardiology** 2007;100:1727-33.
317. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, **Ohman EM**, White HD, Feit F, Colombo A, McLaurin BAT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ, for the ACUITY Investigators. Antithrombotic strategies in patients with acute coronary syndromes. **Journal of the American Medical Association** 2007;298:2497-506.

318. Glickman SW, Boulding W, Staelin R, Mulgund J, Roe MT, Lytle BL, Rumsfeld JS, Gibler WB, **Ohman EM**, Schulman KA, Peterson ED. A framework for quality improvement: an analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. **American Heart Journal** 2007;154:1206-20.
319. Zia MI, Goodman SG, Peterson ED, Mulgund J, Chen AY, Langer A, Tan M, **Ohman EM**, Gibler WB, Pollack CV Jr., Roe MT. Paradoxical use of invasive cardiac procedures for patients with non-ST-segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. **Canadian Journal of Cardiology** 2007;23:1073-9.
320. Blomkalns AL, Roe MT, Peterson ED, **Ohman EM**, Fraulo ES, Gibler WB. Guideline implementation research: exploring the gap between evidence and practice in the CRUSADE Quality Improvement Initiative. **Academic Emergency Medicine** 2007;14:949-54.
321. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, Galvine M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, **Ohman EM**, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellenmans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhilb S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal definition of myocardial infarction. **Circulation** 2007;116:2634-53.
322. Shah MR, Hasselblad V, Tasissa G, Christenson RH, Binanay C, O'Connor CM, **Ohman EM**, Stevenson LW, Califf RM. Rapid assay brain natriuretic peptide and Troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). **American Journal of Cardiology** 2007;100:1427-33.
323. Shah BR, Glickman SW, Liang L, Gibler WB, **Ohman EM**, Pollack CV Jr., Roe MT, Peterson ED. The impact of for-profit hospital status on the care and outcomes of patients with non-ST-segment elevation myocardial infarction: results from the CRUSADE Initiative. **Journal of the American College of Cardiology** 2007;50:1462-8.

- 324. Greenbaum AB, **Ohman EM**, Gibson CM, Borzak S, Stebbins AL, Lu M, Le May MR, Stankowski JE, Emanuelsson H, Weaver WD. Preliminary experience with intravenous P2Y₁₂ platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. **American Heart Journal** 2007;154:702-9.
- 325. Jolicoeur EM, Wang T, Lopes RD, **Ohman EM**. Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. **Current Cardiology Reports** 2007;9:396-405.
- 326. Roe MT, Chen AY, Mehta RH, Li Y, Brindis RG, Smith SC Jr., Rumsfeld JS, Gibler WB, **Ohman EM**, Peterson ED. Influence of inpatient service specialty on care processes and outcomes for patients with non-ST-segment elevation acute coronary syndromes. **Circulation** 2007;116:1153-61.
- 327. Sen S, Hinderliter A, Sen PK, Simmons J, Beck J, Offenbacher S, **Ohman EM**, Oppenheimer SM. Aortic arch atheroma progression and recurrent vascular events in patients with stroke or transient ischemic attack. **Circulation** 2007;116:928-35.
- 328. Miller CD, Roe MT, Mulgund J, Hoekstra JW, Santos R, Pollack CV Jr., **Ohman EM**, Gibler WB, Peterson Ed. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. **American Journal of Medicine** 2007;120:685-92.
- 329. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, **Ohman EM**, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. **European Heart Journal** 2007;28:1598-660.
- 330. Glickman SW, Ou FS, DeLong ER, Roe MT, Lytle BL, Mulgund J, Rumsfeld JS, Gibler WB, **Ohman EM**, Schulman KA, Peterson ED. Pay for performance, quality of care, and outcomes in acute myocardial infarction. **Journal of the American Medical Association** 2007;297:2373-80.
- 331. Peterson ED, **Ohman EM**, Brindis RG, Choen DJ, Magid DJ. Development of systems of care for ST-elevation myocardial infarction patients: evaluation and outcomes. **Circulation** 2007;116:e64-7.
- 332. Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, **Ohman EM**, Steinhubl SR, Smyth SS. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirudin on myeloperoxidase release from neutrophils. **Arteriosclerosis, Thrombosis, and Vascular Biology** 2007;27:1850-6.

333. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, **Ohman EM**, American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. **Circulation** 2007;115:2549-69.
334. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, **Ohman EM**, American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. **Circulation** 2007;115:2570-89.
335. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, **Ohman EM**, Wallentin L, Wijns W. ESC 2007 Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. **Revista española de cardiología** 2007;60:1070.e1-80.
336. Harrington RA, **Ohman EM**. The enigma of drug-eluting stents: hope, hype, humility, and advancing patient care. **Journal of the American Medical Association** 2007;297:2028-30.
337. LaPointe NM, Chen AY, Alexander KP, Roe MT, Pollack CV Jr, Lytle BL, **Ohman ME**, Gibler BW, Peterson ED. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. **Archives of Internal Medicine** 2007;167:1539-44.
338. Berger JS, Stebbins A, Granger CB, **Ohman EM**, Armstrong PW, Van de Werf F, White HD, Simes RJ, Harrington RA, Califf RM, Peterson ED. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. **Circulation** 2008;117:192-9.
339. Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, **Ohman EM**, Granger CB, for the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin. **Archives of Internal Medicine** 2008;168:94-102.
340. Rao SV, Kaul PR, Liao L, Armstrong PW, **Ohman EM**, Granger CB, Califf RM, Harrington RA, Eisenstein EL, Mark DB. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. **American Heart Journal** 2008;155:369-74.

341. Wang TY, Robinson LA, Ou FS, Roe MT, **Ohman EM**, Gibler WB, Smith SC Jr., Peterson ED, Becker RC. Discharge antithrombotic strategies among patients with acute coronary syndromes previously on warfarin anticoagulation: physician practice in the CRUSADE Registry. **American Heart Journal** 2008;155:361-8.
342. Melloni C, Alexander KP, Milford-Beland S, Newby LK, Szczech LA, Pollack CV, Kirk JD, Christenson RH, Harrington RA, Gibler WB, **Ohman EM**, Peterson ED, Roe MT, for the CRUSADE Investigators. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and kidney disease. **Clinical Cardiology** 2008;31:125-9.
343. Wang TY, Chen AY, Peterson ED, Becker RC, Gibler WB, **Ohman EM**, Roe MT. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-elevation acute coronary syndromes.: observations from CRUSADE Quality Improvement Initiative. **European Heart Journal** 2008;29:1103-9.
344. McCord J, Jneid H, Hollander JE, de Lemos JA, Cercek B, Hsue P, Gibler WB, **Ohman EM**, Drew B, Philippides G, Newby LK. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. **Circulation** 2008;117:1897-907.
345. Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Gogo S, Matsumoto M, **Ohman EM**, Okada Y, Uchiyama S, D'Agostino R, Hirsch AT, Wilson PW, Steg PG, for the REACH Registry Investigators. Risk factor profile and management of cerebral vascular patients in the REACH Registry. **Cerebrovascular Disease** 2008;25:366-74.
346. Jolicoeur EM, Granger CB, Henry TD, Holmes DJ, Pepine CJ, Mark D, Chaitman BR, Gersh BJ, **Ohman EM**, on behalf of the Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease: Part 1: Contemporary emerging therapies. **American Heart Journal** 2008;155:418-34.
347. Jolicoeur EM, **Ohman EM**, Temple R, Stockbridge N, Smith S, Mark D, Califf RM, Henry TD, Chaitman BR, Granger CB, on behalf of the Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease: Part 2: Trial design, outcomes and regulatory issues. **American Heart Journal** 2008;155:435-44.
348. Mehta RH, Rao SV, **Ohman EM**, Bates ER, Marcucci G, Zhang M, Pieper KS, Armstrong PW, White HD, Van de Werf F, Califf RM, Granger CB. Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. **European Heart Journal** 2008;29:880-7.
349. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, **Ohman EM**, White HD, Wallentin L, Granger CB. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. **Heart** 2008;94:867-73.

350. Melloni C, Peterson ED, Chen AY, Szczech LA, Newby LK, Harrington RA, Gibler WB, **Ohman EM**, Spinler SA, Roe MT, Alexander KP. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. **Journal of the American College of Cardiology** 2008;51:991-6.
351. Boden WE, Shah PK, Gupta V, **Ohman EM**, Contemporary approach to the diagnosis and management of non-ST-segment elevation acute coronary syndromes. **Progress in Cardiovascular Diseases** 2008;50:311-51.
352. Chan MY, Becker RC, Harrington RA, Peterson ED, Armstrong PW, White H, Fox KA, **Ohman EM**, Roe MT. Noninvasive, medical management for non-ST-elevation acute coronary syndromes. **American Heart Journal** 2008;155:397-407.
353. Diercks DB, **Ohman EM**. Hypertension with acute coronary syndrome and heart failure. **Annals of Emergency Medicine** 2008;51(Suppl):S34-6.
354. Feit F, Manoukian SV, Ebrahimi R, Pollack CV, **Ohman EM**, Attubato MJ, Mehran R, Stone GW. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. **Journal of the American College of Cardiology** 2008;51:1645-52.
355. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV Jr, Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, **Ohman EM**, Mehran R, Stone GW. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. **Journal of the American College of Cardiology** 2008;51:1734-41.
356. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM, **Ohman EM**, Roe MT, Boden WE, Harrington RA, Peterson ED; for the CRUSADE Investigators. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. **American Heart Journal** 2008;155:1047-53.
357. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, **Ohman EM**, Parise H, Fahy M, Lansky AK, Stone GW. The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. **American Heart Journal** 2008;156:44-56.
358. Goodman SG, Menon V, Cannon CP, Steg G, **Ohman EM**, Harrington RA; American College of Chest Physicians. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). **Chest** 2008;133(Suppl):708S-775S.
359. Melloni C, Alexander KP, Chen AY, Newby LK, Roe MT, Allen LaPointe NM, Pollack CV Jr., Gibler WB, **Ohman EM**, Peterson ED, for the CRUSADE Investigators. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. **American Heart Journal** 2008;156:209-15.

- 360. Roe MT, Chen AY, DeLong ER, Boden WE, Calvin JE Jr., Cairns CB, Smith SC Jr, Pollack CV Jr., Brindis RG, Califf RM, Gibler WB, **Ohman EM**, Peterson ED. Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. **American Heart Journal** 2008;156:185-92.
- 361. Peacock WF, Bhatt DL, Diercks D, Amsterdam E, Chandra A, **Ohman EM**, Brown DF, Januzzi J. Cardiologists' and emergency physicians' perspectives on and knowledge of reperfusion guidelines pertaining to ST-segment-elevation myocardial infarction. **Texas Heart Institute Journal** 2008;35:152-61.
- 362. Cavender MA, Rao SV, **Ohman EM**. Major bleeding: management and risk reduction in acute coronary syndromes. **Expert Opinion on Pharmacotherapy** 2008;9:1869-83.
- 363. Cavender MA, **Ohman EM**. What do you need to know before performing a percutaneous coronary intervention? **Circulation** 2008;118:609-11.
- 364. Dunlay SM, Alexander KP, Melloni C, Kraschnewski JL, Liang L, Gibler WB, Roe MT, **Ohman EM**, Peterson ED. Medical records and quality of care in acute coronary syndromes: results from CRUSADE. **Archives of Internal Medicine** 2008;168:1692-8.
- 365. Roe MT, Ou FS, Alexander KP, Newby LK, Foody JM, Gibler WB, Boden WE, **Ohman EM**, Smith SC Jr., Peterson ED. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. **European Heart Journal** 2008;29:2480-8.
- 366. Wang TY, Chen AY, Alexander KP, **Ohman EM**, Gibler WB, Peterson ED, Roe MT. Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. **American Journal of Medicine** 2008;121:805-10.
- 367. White HD, **Ohman EM**, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. **Journal of the American College of Cardiology** 2008;52:807-14.
- 368. Alexander D, Ou FS, Roe MT, Pollack CV Jr., **Ohman EM**, Cannon CP, Gibler WB, Fintel DJ, Peterson ED, Brown DL; for the American College of Cardiology/American Heart Association. Use of and in-hospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). **American Heart Journal** 2008;156:606-12.

369. Madala MC, Franklin BA, Chen AY, Berman Ad, Roe MT, Peterson ED, **Ohman EM**, Smith SC Jr., Gibler WB, McCullough PA; for the CRUSADE Investigators. Obesity and age of first non-ST-segment elevation myocardial infarction. **Journal of the American College of Cardiology** 2008;52:979-85.
370. Pollack CV, Jr., Hollander JE, Chen AY, Peterson ED, Bangalore S, Peacock FW, Cannon CP, Canto JG, Gibler WB, **Ohman EM**, Roe MT. Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse. **Critical Pathways in Cardiology** 2009;8:29-33.
371. Patel UD, Ou FS, **Ohman EM**, Gibler WB, Pollack Jr CV, Peterson ED, Roe MT. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. **American Journal of Kidney Disease** 2009;53:426-37.
372. Crespo EM, Oliveira GBF, Honeycutt EF, Becker RC, Berger PB, Moliterno DJ, Anstrom KJ, Abrams CS, Kleiman NS, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapon VF, Granger CB, **Ohman EM**, on behalf of the CATCH Registry Investigators. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. **American Heart Journal** 2009;157:651-7.
373. Alexander D, Mann N, Ou RS, Peterson ED, **Ohman EM**, Gibler WB, Roe MT. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). **American Journal of Cardiology** 2008;102:1335-40.
374. Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liao CS, Rother J, Wilson PW, Richard AJ, Eagle KA, **Ohman EM**, for the REACH Investigators. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. **European Heart Journal** 2008;29:3052-60.
375. Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, **Ohman EM**, Lincoff AM, Cohen DJ, for the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. **Journal of the American College of Cardiology** 2008;52:1758-68.
376. Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, Wilson PW, Mas JL, Rother J, for the Reduction of Atherothrombosis for Continued Health Registry Investigators. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the Reduction of Atherothrombosis for Continued Health (REACH) registry. **Stroke** 2009;40:350-4.

377. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, **Ohman EM**, Wallentin L, Wijns W, Grupo de Trabalho para o Diagnostico e Tratamento de Sindromes Coronarias Agudas sem Elevacao do Segmento ST da European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. **Revista Portuguesa de Cardiologia** 2008;27:1063-143. [Portuguese]
378. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D'Agostino R, **Ohman EM**, Liao CS, Hirsch AT, Mas JL, Wilson PW, Corgalan R, Aichner F, Steg PG, for the REACH Registry Investigators. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. **American Heart Journal** 2008;156:855-63.
379. Piccini JP, **Ohman EM**. ECG interpretation in ST-elevation myocardial infarction: pattern recognition or caliper measurements? **Heart** 2009;95:267-8.
380. Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith SC Jr, **Ohman EM**. Management of hyperlipidemia in older adults. **Journal of Cardiovascular Pharmacology** 2009;14:49-58.
381. Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, **Ohman EM**, White HD, Parise H, Leon MD, Stone GW. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. **Circulation** 2009;119:687-98.
382. Chandra A, Glickman SW, Ou FS, Peacock WF, McCord JK, Cairns CB, Peterson ED, **Ohman EM**, Gibler WB, Roe MT. An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. **Annals of Emergency Medicine** 2009;54:17-25.
383. Lopes RD, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD, Pollack CV Jr, Hoekstra J, Gersh BJ, Stone GW, **Ohman EM**. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. **Journal of the American College of Cardiology** 2009;53:1021-30.
384. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, **Ohman EM**, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-ST-segment –elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. **Circulation** 2009;119:1873-82.

385. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, **Ohman EM**, Roe MT, for the CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. **European Heart Journal** 2009;30:1195-202.
386. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, **Ohman EM**. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. **European Heart Journal** 2009;30:1457-66.
387. Wang TY, Ou FS, Roe MT, Harrington RA, **Ohman EM**, Gibler WB, Peterson ED. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. **Circulation** 2009;119:2454-62.
388. Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, **Ohman EM**, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). **American Journal of Cardiology** 2009 103:1196-203.
389. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK, for the EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. **New England Journal of Medicine** 2009;360:2176-90.
390. Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, Gersh BJ, **Ohman EM**, White HD, Moses JW, Ware JH, Lincoff AM, Stone GW. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery; the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. **Journal of the American College of Cardiology** 2009;53:1965-72.
391. Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liao CS, Goto S, Rother J, Steg PG, Hirsch AT, for the REACH Registry Investigators. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. **Atherosclerosis** 2009;204:e86-92.
392. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, Morrison LJ, Langer A, Dzavik V, Mehta SR, Lassam C, Schwartz B, Casanova A, Goodman SG, for the TRANSFER AMI Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. **New England Journal of Medicine** 2009;360:2705-18.

393. Spinler SA, Ou FS, Roe MT, Gibler WB, **Ohman EM**, Pollack CV, Alexander KP, Peterson ED. Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. **Pharmacotherapy** 2009;29:631-8.
394. Dumaine RL, Motalessot G, Steg PG, **Ohman EM**, Eagle K, Bhatt DL, for the REACH Registry Investigators. Renal function, atherothrombosis extent, and outcomes in high-risk patients. **American Heart Journal** 2009;158:141-148.e1.
395. Jolicoeur EM, **Ohman EM**, Honeycutt E, Becker RC, Crespo EM, Oliveira GB, Moliterno DJ, Anstrom KJ, Granger CB. Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. **American Journal of Cardiology** 2009;104:292-7.
396. Prasad A, Gersh BJ, Bertrand ME, Lincoff AM, Moses JW, **Ohman EM**, White HD, Pocock SJ, McLaurin, BT, Cox DA, Lansky AJ, Mehran R, Stone GW. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. **Journal of the American College of Cardiology** 2009;54:477-86.
397. Mehran R, Nikolsky E, Lansky AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, **Ohman EM**, White HD, Pocock SJ, Dangas GD, Stone GW. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) substudy. **JACC Cardiovascular Interventions** 2009;2:748-57.
398. Cohen MG, Filby SJ, Roe MT, Chen AY, Menon V, Stouffer GA, Gibler WB, Smith SC Jr, Pollack CV Jr, Peterson ED, **Ohman EM**. The paradoxical use of cardiac catheterization in patients with non-ST-elevation acute coronary syndromes: lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) Quality Improvement Initiative. **American Heart Journal** 2009;158:263-70.
399. Wang TY, Newby LK, Chen AY, Mulgund J, Roe MT, Sonel AF, Bhatt DL, DeLong ER, **Ohman EM**, Gibler WB, Peterson ED. Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. **Clinical Cardiology** 2009;32:E22-8.
400. Takakuwa KM, Ou FS, Peterson ED, Pollack CV Jr, Peacock WF, Hoekstra JW, **Ohman EM**, Gibler WB, Blomkalns AL, Roe MT. The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. **Clinical Cardiology** 2009;32:498-505.
401. Fermann GJ, Raja AS, Peterson ED, Roe MT, Hoekstra JW, Milford-Beland S, Diercks DB, Pollack CV Jr, Peacock WF, Summers R, **Ohman EM**, Gibler WB. Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care. **Clinical Cardiology** 2009;32:519-25.

402. Roe MT, Chen AY, Cannon CP, Rao S, Rumsfeld J, Magid DJ, Brindis R, Klein LW, Gibler WB, **Ohman EM**, Peterson ED, for the CRUSADE and ACTION-GWTG Registry Participants. Temporal changes in the use of drug-eluting stents for patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients suppress Adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. **Circulation Cardiovascular Quality and Outcomes** 2009;2:414-20.
403. Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky JJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, **Ohman EM**, Bertrand ME, Cox DA, Mehran R. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. **Journal of the American College of Cardiology** 2009;54:1293-302.
404. Alberts MJ, Bhatt DL, Mas JL, **Ohman EM**, Hirsch At, Rother J, Salette G, Goto S, Smith SC Jr, Liao CS, Wilson PW, Steg PG, for the REACH Investigators. Three-year follow-up and event rates in the international Reduction of Atherothrombosis for Continued Health Registry. **European Heart Journal** 2009;30:2318-26.
405. Gehrie ER, Reynolds HR, Chen AY, Neelon BH, Roe MT, Gibler WB, **Ohman EM**, Newby LK, Peterson ED, Hochman JS. Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease; results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. **American Heart Journal** 2009;158:688-94.
406. Ali RC, Melloni C, Ou FS, Schmader K, **Ohman EM**, Roe MT, Peterson ED, Alexander KP. Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time. **Journal of the American Geriatric Society** 2009;57:1990-6.
407. Lopes RD, **Ohman EM**, Granger CB, Honeycutt EF, Anstrom KJ, Berger PB, Crespo EM, Oliveira GB, Moll S, Moliterno DJ, Abrams CS, Becker RC. Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytoemia Caused by Heparin [CATCH] registry). **American Journal of Cardiology** 2009;104:1285-91.
408. Amsterdam EA, Peterson ED, Ou FS, Newby LK, Pollack CV Jr, Gibler WB, **Ohman EM**, Peterson ED. Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: results from the CRUSADE quality improvement initiative. **American Heart Journal** 2009;158:748-754.e1.

409. Allen LaPointe NM, Chen AY, Roe MT, Cohen DJ, Diercks DB, Hoekstra JW, Fesmire FM, Gibler WB, **Ohman EM**, Peterson ED. Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome. **American Journal of Cardiology** 2009;104:1324-9.
410. Metchtouff L, Touze E, Steg PG, **Ohman EM**, Goto S, Hirsch At, Rother J, Aichner FT, Weimar C, Bhatt DL, Alberts MJ, Mas JL, on behalf of the REACH Registry Investigators. Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease. **Journal of Internal Medicine** 2009;267:621-33.
411. Cavendar MA, Alexander KP, Broderick S, Shaw LK, McCants CB, Kempf J, **Ohman EM**. Long-term morbidity and mortality among medically managed patients with angina and multivessel coronary artery disease. **American Heart Journal** 2009;158:933-40.
412. Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, **Ohman EM**, Cannon CP, Eagle KA, Alberts MJ, Goto S, Smith SC Jr, Wilson PW, Watson KE, Steg PG, for the REACH Registry Investigators. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. **American Heart Journal** 2009;158:1038-45.
413. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA, for the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. **New England Journal of Medicine** 2009;361:2330-41.
414. Pollack CV Jr, Hollander JE, Chen AY, Peterson ED, Bangalore S, eacock FW, Cannon CP, Canto JG, Gibler BW, **Ohman ME**, Roe MT. Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated lwws aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative. **Critical Pathways in Cardiology** 2009;8:29-33.
415. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, **Ohman EM**, White HD, Stone GW. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. **Circulation** 2010;121:43-51.
416. Rao SV, **Ohman EM**. Anticoagulant therapy for percutaneous coronary intervention. **Circulation: Cardiovascular Interventions** 2010;3:80-8.
417. **Ohman EM**, Califf RM. When can noninferior be superior? The multidimensional nature of clinical decision-making calls for innovative approaches to clinical trials. **Journal of the American College of Cardiology** 2010;55:555-7.

418. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, **Ohman ME**, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. **Journal of the American College of Cardiology** 2010;55:2556-66.
419. Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, **Ohman EM**, Steg PG, Eagle KA, Bhatt DL, for the REACH Registry Investigators. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the Reduction of Atherothrombosis for Continued Health [REACH] Registry). **American Journal of Cardiology** 2010;105:445-52.
420. Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, **Ohman EM**, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an acute catheterization and urgent intervention triage strategy (ACUITY) substudy. **Circulation** 2010;121:853-62.
421. Glickman SW, Boulding W, Manary M, Staelin R, Roe MT, Wolosin R, **Ohman EM**, Peterson ED, Schulman KA. Patient satisfaction and its relationship with clinical quality and inpatient mortality in acute myocardial infarction. **Circulation: Cardiovascular Quality and Outcomes** 2010;3:188-95.
422. Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PW, **Ohman EM**, Brennan DM, D'Agostino RB, Bhatt DL, Steg PG, on behalf of the REACH Investigators. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. **European Heart Journal** 2010;31:1257-65.
423. Krempf M, Parhofer KG, Steg PG, Bhatt DL, **Ohman EM**, Rother J, Goto S, Pasquet B, Wilson PW, for the REACH Registry Investigators. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the Reduction of Atherothrombosis for Continued Health [REACH] Registry). **American Journal of Cardiology** 2010;105:667-71.
424. Halim SA, Mulgund J, Chen AY, Roe MT, Peterson ED, Gibler WB, **Ohman EM**, Newby LK. Use of guidelines-recommended management and outcomes among women and men with low-level troponin elevation: insights from CRUSADE. **Circulation: Cardiovascular Quality and Outcomes** 2009;2:199-206.
425. Shah BR, Peterson ED, Chen AY, Mahaffey KW, DeLong ER, **Ohman EM**, Pollack CV Jr., Gibler WB, Roe MT. Influence of clinical trial participation on subsequent antithrombin use. **Clinical Cardiology** 2010;33:E49-55.
426. Hudson M, Greenbaum A, Brenton L, Gibson CM, Siegel R, Reeves LR, Sala MF, McKendall G, Blughermann J, Echt D, **Ohman EM**, Weaver WD. Adjunctive transcutaneous ultrasound with thrombolysis: results of the PLUS (Perfusion by ThromboLytic and UltraSound) trial. **JACC: Cardiovascular Interventions** 2010;33:352-9.

- 427. Michaels AD, Spinler SA, Leeper B, **Ohman EM**, Alexander KP, Newby LK, Ay H, Gibler WB. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. **Circulation** 2010;121:1664-82.
- 428. Parikh SV, de Lemos JA, Jessen ME, Brilakis ES, **Ohman EM**, Chen AY, Wang TY, Peterson ED, Roe MT, Holper EM, for the CRUSADE and ACTION Registry-GWTG Participants. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients: results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). **JACC: Cardiovascular Interventions** 2010;3:419-27.
- 429. Gharacholou SM, Alexander KP, Chen AY, Wang TY, Melloni C, Gibler WB, Pollack CV Jr., **Ohman EM**, Peterson ED, Roe MT. Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: Findings from the CRUSADE Initiative. **American Heart Journal** 2010;159:757-63.
- 430. **Ohman EM**, Roe MT, Armstrong PW, Fox KA, Prabhakaran D, White HD. Public sensationalism and clinical trials: How to address the challenges of science? **American Journal of Medicine** 2010;123:481-3.
- 431. Eisenstein EL, Honeycutt EF, Anstrom KJ, Becker RC, Granger CB, Rao SV, Jolicoeur ME, **Ohman EM**, for the CATCH Investigators. Economic assessment of thrombocytopenia: from the CATCH Registry. **Journal of Medical Systems** 2010;34:379-86.
- 432. Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, **Ohman EM**, for the TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. **American Heart Journal** 2010;160:16-22.e1.
- 433. Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, **Ohman EM**, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, Lansky AJ, Stone GW. Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUTY substudy). **American Journal of Cardiology** 2010;106:180-6.
- 434. Lopes RD, Peterson ED, Chen AY, Roe MT, Wang TY, **Ohman EM**, Magid DJ, Ho PM, Wiviott SD, Scirica BM, Alexander KP. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. **JACC Cardiovascular Interventions** 2010;3:669-77.

435. Lansky AJ, Goto K, Cristea E, Fahy M, Parise H, Feit F, **Ohman EM**, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Moses J, Leon M, Stone GW. Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. **Circulation: Cardiovascular Interventions** 2010;3:308-16.
436. Bhatt DL, Eagle KA, **Ohman EM**, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liao CS, Mas JL, Rother J, Smith SC Jr., Salette G, Contant CF, Massaro JM, Steg PG, for the REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. **JAMA** 2010;304:1350-7.
437. Goyal A, Bhatt DL, Steg PG, Gersh BJ, Alberts MJ, **Ohman EM**, Corbalan R, Eagle KA, Gaxiola E, Gao R, Goto S, D'Agostino RB, Califf RM, Smith SC, Jr, Wilson PW, for the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countries. **Circulation** 2010;122:1167-75.
438. Mehta RH, Chen AY, **Ohman EM**, Gibler WB, Peterson ED, Roe MT, for the CRUSADE National Quality Improvement Initiative Investigators. Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non-ST-segment elevation myocardial infarction. **American Heart Journal** 2010;160:405-11.
439. Ambrosio G, Steinhubl S, Gresele P, Tritto I, Zuchi C, Bertrand ME, Lincoff AM, Moses JW, **Ohman EM**, White HD, Mehran R, Stone GW. Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY Trial. **European Journal of Cardiovascular Prevention and Rehabilitation**. 2011;18:121-8.
440. Hess CN, **Ohman EM**, Patel MR. Amplatzer vascular plug closure of a subclavian arteriovenous fistula associated with implantable cardioverter-defibrillator implantation. **Catheterization and Cardiovascular Interventions** 2011;77:761-3.
441. Tackett AH, Bailey AL, Foody JM, Miller JM, Apperson-Hansen C, **Ohman EM**, Hochman JS, Karnash SL, Califf RM, Topol EJ, Moliterno DJ. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. **American Heart Journal** 2010;160:678-84.
442. Van De Car DA, Rao SV, **Ohman EM**. Bivalirudin: a review of the pharmacology and clinical application. **Expert Review of Cardiovascular Therapy** 2010;8:1673-81.

443. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, **Ohman EM**, Page RL, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology** 2010;56:2182-99.
444. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, **Ohman EM**, Page RL, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology** 2010;56:e50-103.
445. Mudrick DW, Chen AY, Roe MT, Newby LK, Gibler WB, **Ohman EM**, Peterson ED, Alexander KP. Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative. **American Heart Journal** 2010;160:1072-8.
446. Melloni C, Shah BR, Ou FS, Roe MT, Smith SC Jr, Pollack CV Jr, **Ohman M**, Gibler WB, Peterson ED, Alexander KP. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications Applied aNd SusTAINED Over Time (MAITAIN) registry. **American Heart Journal** 2010;160:1121-9, 1129e1.
447. Caixeta A, Stone GW, Mehran R, Lee EA, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, **Ohman EM**, Palmerini T, Syros G, Kittas C, Fahy M, Hooper WC, Lansky AJ, Dangas GD. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. **Journal of Thrombosis and Thrombolysis** 2011;31:154-64. (E-pub Oct 2010)
448. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, Ardissino D, Califf RM, Granger CB, **Ohman EM**, Alexander JH. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. **Critical Care Medicine** 2011;39:78-83.

449. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM; 2011 Writing Group Members, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson SB, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann LS; 2006 Writing Committee Members, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, **Ohman EM**, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Circulation** 2011;123:104-23.
450. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson SB, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann LS, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, **Ohman EM**, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW; ACCF/AHA/HRS. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology** 2011;57(2):223-42.
451. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM; 2006 WRITING COMMITTEE MEMBERS, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson SB, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann LS; ACCF/AHA TASK FORCE MEMBERS, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, **Ohman EM**, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Heart Rhythm** 2011;8:157-76.
452. Mehta RH, O'Shea JC, Stebbins AL, Granger CB, Armstrong PW, White HD, Topol EJ, Califf RM, **Ohman EM**. Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. **Journal of the American College of Cardiology** 2011;57:138-46.
453. Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, **Ohman EM**, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. **American Heart Journal** 2011;161:298-306.e1.

454. Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Claessen B, Sanidas E, White HD, **Ohman EM**, Manoukian SV, Fahy M, Mehran R, Stone GW. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. **American Heart Journal** 2011;161:391-6.
455. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, **Ohman EM**, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. **Circulation** 2011;123:1144-50.
456. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, **Ohman EM**, Stevenson WG, Yancy CW. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Heart Rhythm** 2011;8:e1-8.
457. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, **Ohman EM**, Stevenson WG, Tarkington LG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. **Circulation** 2011;123:e269-367.
458. **Ohman EM**, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified". **Thrombosis and Haemostasis** 2011;105:763-5.

459. Lansky A, Goto K, Fahy M, Cristea E, Mehran R, Stone GW, Feit F, **Ohman EM**, Alexander KP, White HD, Bertrand ME, Desmet W, Hamon M. Response to letters regarding article, "Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy". **Circulation** 2011;123:e410-1.
460. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, **Ohman EM**, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. **Circulation** 2011;123:2736-47.
461. Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, **Ohman EM**, Parise H, Lansky AJ, Lincoff AM, Stone GW. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiogram to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. **JACC Cardiovascular Interventions** 2011;4:654-64.
462. Unverzagt S, Machemer MT, Solms A, Thiele H, Burkhoff D, Seyfarth M, de Waha A, **Ohman EM**, Buerke M, Haerting J, Werdan K, Prondzinsky R. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. **Cochrane Database Systems Review**. 2011 Jul 6;(7):CD007398.
463. Patel MR, Thiele H, Smalling RW, Chandra P, Zhou Y, Cohen M, Perera D, **Ohman EM**. A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial. **American Heart Journal** 2011;162:47-55.e1.
464. Goto K, Lansky AJ, Nikolsky E, Fahy M, Feit F, **Ohman EM**, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. **JACC Cardiovascular Interventions** 2011;4:769-77.
465. Stone GW, **Ohman EM**. Antithrombin alternatives in STEMI. **Lancet** 2011;378:643-5.
466. Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, Chew D, Cohen M, French J, Perera D, **Ohman EM**. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. **Journal of the American Medical Association** 2011 ;306:1329-37.
467. Chenier M, Johnson D, **Ohman M**, Pavlisco E. Cardiac angiosarcoma presenting as progressive dyspnea on exertion. **Journal of Cardiovascular Medicine** 2011;12:904-7.

468. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, **Ohman M**, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). **European Heart Journal** 2011;32:2999-3054.
469. Roe MT, Chen AY, Thomas L, Wang TY, Alexander KP, Hammill BG, Gibler WB, **Ohman EM**, Peterson ED. Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score. **American Heart Journal** 2011;162:875-883.e1
470. Gersh BJ, Varon BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Maidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (Writing Group Members); Jacobs AK, Smith SC Jr, Anderson JL, Albert NM, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Krumholz HM, Kushner FG, Nishimura RA, **Ohman EM**, Page RL, Stevenson WG, Tarkington LG, Yancy CW (Task Force Members). 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of Thoracic Cardiovascular Surgery** 2011;142:e153-203.
471. Gersh BJ, Varon BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Maidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (Writing Group Members); Jacobs AK, Smith SC Jr, Anderson JL, Albert NM, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Krumholz HM, Kushner FG, Nishimura RA, **Ohman EM**, Page RL, Stevenson WG, Tarkington LG, Yancy CW (Task Force Members). 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of Thoracic Cardiovascular Surgery** 2011;142:1303-38.
472. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, **Ohman EM**, Stevenson W, Yancy CW. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. **Catheterization and Cardiovascular Interventions** 2011 Nov 7 doi:10.1002/ccd.233390 [Online]

473. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE (2011 Writing Group Members); Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Tylor LM Jr., White CJ, White JV, White RA (2005 Writing Committee Members); Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, **Ohman EM**, Stevenson W, Yancy CW (ACCF/AHA Task Force Members). 2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. **Catherization and Cardiovascular Interventions** 2011 Sep 29 doi: 10.1002/ccd.23373[Online]
474. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr. 2011 ACCF/AHA Focused update incorporated in the ACC/AHA 2007 guidelines for the management of patients with unstable angina/Non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Circulation** 2011;123:e426-579.
475. Roe MT, **Ohman EM**. A new era in secondary prevention after acute coronary syndrome. **New England Journal of Medicine** 2012;366:85-7.
476. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, DiSesa VJ, Hiratzka LF, Hutter AM Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, **Ohman EM**, Stevenson W, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of Thoracic and Cardiovascular Surgery** 2012;143:4-34.
477. Halim SA, Newby LK, **Ohman EM**. Biomarkers in cardiovascular clinical trials: past, present, future. **Clinical Chemistry** 2012;58:45-53.

478. Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD, Conti JB, Foster E, Jaarsma T, Kloner RA, Lange RA, Lindau ST, Maron BJ, Moser DK, **Ohman EM**, Seftel AD, Stewart WJ; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. **Circulation** 2012;125:1058-72.
479. Gurbel PA, **Ohman EM**, Jeong YH, Tantry US. Toward a therapeutic window for antiplatelet therapy in the elderly. **European Heart Journal** 2012;33:1187-9.
480. Stegman BM, Newby LK, Hochman JS, **Ohman EM**. Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment: is therapeutic hypothermia one possibility? **Journal of the American College of Cardiology** 2012 Feb 14;59(7):644-7.
481. Udell JA, Steg PG, Scirica BM, Smith SC, **Ohman EM**, Eagle KA, Goto S, Cho JJ, Bhatt DL, Reduction Of Atherothrombosis For Continued Health Reach Registry Investigators FT. Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosisliving alone and cardiovascular risk. **Archives of Internal Medicine** 2012;172:1086-95
482. Roe MT, White JA, Kaul P, Tricoci P, Lokhnygina Y, Miller CD, van't Hof AW, Montalescot G, James SK, Saucedo J, **Ohman EM**, Pollack CV Jr, Hochman JS, Armstrong PW, Giugliano RP, Harrington RA, Van de Werf F, Califf RM, Newby LK. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. **Circ Cardiovascular Quality and Outcomes** 2012;5:205-13.
483. Venkitachalam L, Wang K, Porath A, Corbalan R, Hirsch AT, Cohen DJ, Smith SC Jr, **Ohman EM**, Steg PG, Bhatt DL, Magnuson EA; REACH Registry Investigators. Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance. **Circulation** 2012;125:1858-69.
484. Gurbel PA, Roe MT, Jakubowski JA, Shah S, Erlinge D, Goodman SG, Huber K, Chan MY, Cornel JH, Tantry US, **Ohman EM**. Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? **Thrombosis and Haemostasis** 2012;108:12-20.
485. Chan MY, Sun JL, Newby LK, Lokhnygina Y, White HD, Moliterno DJ, Thérroux P, **Ohman EM**, Simoons ML, Mahaffey KW, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, Harrington RA. Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. **Interventional Journal of Cardiology** 2013;167:548-54.

486. Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, Patel MR, **Ohman EM**, Gibler WB, Peterson ED, Roe MT. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-st-segment-elevation myocardial infarction. **Circulation: Cardiovascular and Quality Outcomes** 2012;;5:541-9.
487. Wilson PW, D'Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, Liao CS, **Ohman EM**, Röther J, Reid C, Mas JL, Steg PG; REACH Registry. An international model to predict recurrent cardiovascular disease. **American Journal of Medicine** 2012;125:695-703.e1.
488. Gurbel PA, Erlinge D, **Ohman EM**, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, Zhou C, Jakubowski JA, White HD, Fox KAA, Prabhakaran, Armstrong PW, Tantry US, Roe MT, for the TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therap for patients with ACS treated without revascularization: the TRILOGY ACS Platelet Function substudy. **Journal of the American Medical Association** 2012;308:1785-1794.
489. Dangas GD, Claessen BE, Mehran R, Xu K, Fahy M, Parise H, Henriques JP, **Ohman EM**, White HD, Stone GW. Development and validation of a stent thrombosis risk score in patients with acute coronary syndomes. **JACC Cardiovascular Interventions** 2012;5:1097-105.
490. Alhejily WA, **Ohman EM**. Repeat revascularization after PCI: are we reinventing the wheel or redefining Achilles' heel? **Circulation: Cardiovascular Interventions** 2012;5:746-7.
491. O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, Palacios I, Maini B, Mulukutla S, Dzavík V, Popma J, Douglas PS, **Ohman M**. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. **Circulation**. 2012;126:1717-27.
492. Wang TY, Honeycutt EF, Tapon VF, Moll S, Granger CB, **Ohman EM**. Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis. **American Journal of Medicine** 2012;125:1214-21.
493. Roe MD, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng DC, Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, **Ohman EM**; for the TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. **New England Journal of Medicine** 2012;367:1297-309.

494. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, **Ohman EM**, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL, for the REACH Registry Investigators. **Journal of the American Medical Association** 2012;308:1340-9.
495. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, Goto S. **Ohman EM**, Bakris GL, Peristein TS, Kinlay S, Bhatt DL; on behalf of the REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with anterothrombosis. **European Heart Journal** 2013;34:1204-14.
496. Vavalle JP, **Ohman EM**. Left ventricular support systems for high-risk percutaneous coronary interventions: how can we improve outcomes for rare procedures? **Circulation** 2013;127:162-4.
497. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, **Ohman EM**, Albert NM, Antman EM, Arnett DK, Bertolet M, Bhatt DL, Brindis RG, Creager MA, DeMets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, Normand SL, Ortiz E, Peterson ED, Roach WH Jr, Sacco RL, Smith SC Jr, Stevenson WG, Tomaselli GF, Yancy CW, Zoghbi WA. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Circulation** 2013;127:268-310.
498. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, **Ohman EM**, Albert NM, Antman EM, Arnett DK, Bertolet M, Bhatt DL, Brindis RG, Creager MA, DeMets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, Normand SL, Ortiz E, Peterson ED, Roach WH Jr, Sacco RL, Smith SC Jr, Stevenson WG, Tomaselli GF, Yancy CW, Zoghbi WA, Harold JG, He Y, Mangu PB, Qaseem A, Sayre MR, Somerfield MR. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology** 2013;61:213-65.
499. Ducrocq G, Amarenco P, Labreuche J, Alberts MJ, Mas JL, **Ohman EM**, Goto S, Lavalley P, Bhatt DL, Steg PG. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. **Circulation** 2013;127:730-8.
500. Roe MT, **Ohman EM**, for the TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes. **New England Journal of Medicine**. 2013;368:188-9.
501. Leonardi S, Armstrong PW, Schulte PJ, **Ohman EM**, Newby LK. Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. **European Heart Journal**. 2013;34:894-902d.

502. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, **Ohman EM**, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology** 2013;61:e78-140.
503. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, **Ohman EM**, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology** 2013 ;61:485-510.
504. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, **Ohman EM**, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Circulation** 2013;127:e362-425.
505. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, **Ohman EM**, Pressler SJ, Sellke FW, Shen WK . Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Circulation**. 2013;127:1425-43.

506. Rose JJ, Newby LK, Broderick S, Chiswell K, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, **Ohman EM**, Giugliano RP, Goodman SG, White HD, Califf RM, Granger CB, Lopes RD. Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. **Journal of the American College of Cardiology** 2013;61:1461-3.
507. Doenst T, Cleland JG, Rouleau JL, She L, Vos S, **Ohman EM**, Krzeminska-Pakula M, Airan B, Jones RH, Siepe M, Sopko G, Velazquez EJ, Racine N, Gullestad L, Filgueira JL, Lee KL; for the STICH Investigators. Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease. **Circulation: Heart Failure** 2013;6:443-50.
508. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, **Ohman EM**, Pressler SJ, Sellke FW, Shen WK, Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwimer DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Le Heuzey JY, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology** 2013;61:1935-44.
509. Lopes RD, White JA, Atar D, Keltai M, Kleiman NS, White HD, Widimsky P, Zeymer U, Giugliano RP, Tricoci P, Braunwald E, Bode C, **Ohman EM**, Armstrong PW, Newby LK. Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. **International Journal of Cardiology** 2013;168:2510-2517.
510. Rodés-Cabau J, Dauerman HL, Cohen MG, Mehran R, Small EM, Smyth SS, Costa MA, Mega JL, O'Donoghue ML, **Ohman EM**, Becker RC. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. **Journal of the American College of Cardiology** 2013;62:2349-59.
511. Subherwal S, **Ohman EM**, Mahaffey KW, Rao SV, Alexander JH, Wang TY, Alexander KP, Hasselblad V, Roe MT. Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. **American Heart Journal** 2013;165:644-54. 654.e1.
512. Roe MT, Li S, Thomas L, Wang TY, Alexander KP, **Ohman EM**, Peterson ED. Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction. **Circulation: Cardiovascular Quality and Outcomes** 2013;6:323-32.

513. Vemulapalli S, Zhou Y, Gutberlet M, Kumar AS, Mills JS, Blaxill J, Smalling R, **Ohman EM**, Patel MR. Importance of total ischemic time and preprocedural infarct-related artery blood flow in predicting infarct size in patients with anterior wall myocardial infarction (from the CRISP-AMI Trial). **American Journal of Cardiology** 2013;112:911-7.
514. **Ohman EM**, Roe MT. Excess of solid cancers after prasugrel: the food and drug administration outlook. **American Journal of Therapeutics** 2013. [Epub ahead of print]
515. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr SC, Hoffman E, Goto S, **Ohman EM**, Bhatt DL. REduction of Atherothrombosis for Continued Health Registry Investigators. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. **American Journal of Medicine** 2013;126:693-700.e1
516. Anderson ML, Peterson ED, Peng SA, Wang TY, **Ohman EM**, Bhatt DL, Saucedo JF, Roe MT. Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: a report from NCDR. **Circulation: Cardiovascular Quality and Outcomes** 2013;6:708-15.
517. Kern M, Applegate R, Bach RG, Bailey SR, Bashore TM, Bass TA, Bell M, De Bruyne B, Garratt KN, Jeremias A, Kereiakes DJ, Klein LW, Krucoff MW, Mintz GS, Morrison D, **Ohman EM**, Pichard A, Rosenfield K, Samady H, Stone GW, Tommasco C, Turi ZG, Uretsky B, Vetrovec G, Weiner BH, Welt F, Yeung AC. Conversation in cardiology: should FFR and IVUS be counted as PCI? **Catheterization and Cardiovascular Interventions** 2013;82:110-5.
518. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Jneid H, Guyton RA, Kushner FG, **Ohman EM**, Stevenson W, Yancy CW. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. **Journal of the American College of Cardiology** 2013;61:e179-347.
519. Roe MT, Goodman SG, **Ohman EM**, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, Whiter HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose colpidogrel. **Circulation** 2013;128:823-33.


520. Bagai A, Chen AY, Want TY, Alexander KP, Thomas L, **Ohman EM**, Hochman JS, Peterson ED, Roe MT. Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock. **American Heart Journal** 2013;166:298-305.
521. Williams ES, Thompson VP, Chiswell KE, Alexander JH, White HD, **Ohman EM**, Al-Khatib SM. Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III trial. **Cardiology Journal** 2013;20:439-46.
522. Udell JA, Steg PG, Scirica BM, Eagle KA, **Ohman EM**, Goto S, Alsheikh-Ali AA, Porath A, Corbalan R, Umez-Eronini AA, Hoffman EB, Wilson PW, Bhatt DL, on behalf of the REACH Investigators. Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. **European Journal of Preventive Cardiology** 2013 Aug 5 [Epub ahead of print].
523. Wiviott SD, White HD, **Ohman EM**, Fox KA, Armstrong PW, Prabhakaran D, Hafley G, Likhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. **Lancet** 2013;382:605-13.
524. Rodriguez F, Cannon CP, Steg PG, Kumbhani DJ, Goto S, Smith SC, Eagle KA, **Ohman EM**, Umez-Eronin AA, Hoffman E, Bhatt DL, on behalf of the REACH Registry Investigators. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. **Clinical Cardiology** 2013;36:721-7.
525. Van Diepen S, Reynolds HR, Stebbins A, Lopes RD, Dzavik V, Ruzyllo W, Geppert A, Widimsky P, **Ohman EM**, Parrillo JE, Dauerman HL, Baran DA, Hochman JS, Alexander JH. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. **Critical Care Medicine** 2014;42:281-8.
526. Weisz G, Farzaneh-Far R, Ben-Yehuda O, Debruyne B, Montalescot G, Lerman A, Mahmud E, Alexander KP, **Ohman EM**, White HD, Olmsted A, Walker GA, Stone GW. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. **American Heart Journal** 2013;166:953-959

527. Bahit MC, Lopes RD, Clare RM, Newby LK, Pieper KS, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, Diaz R, **Ohman EM**, White HD, James S, Granger CB. Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. **JACC: Heart Failure** 2013;1:223-9.

(b) (4)



532. (b) (4)



533.

534.

535. (b) (4)

536.

537.

BOOKS

1. **Ohman M**, Cox G, Fort S, Foulger VK. So You're Having Heart Cath and Angioplasty. Hoboken, NJ: John Wiley & Sons, Inc. 2003.
2. Netter's Cardiology. Runge MS, **Ohman EM** (eds). Teterboro, NJ: Icon Learning Systems. 2004.
3. Hochman JM, **Ohman EM**. Cardiogenic Shock. Hoboken, NJ: John Wiley & Sons, Inc. 2009.

BOOK CHAPTERS

1. **Ohman EM**, Teo KK, Johnson AH, Collins PB, Horgan JH. Myocardial scintigraphy and cardiospecific creatine kinase responses in female and male athletes after strenuous exercise. In: Sports Cardiology; Exercise in Health and Cardiovascular Disease. Fagard R, Bekaert I (eds). Dordrecht: Martinus Nijhoff 1986:136-142.
2. **Ohman EM**, Kelly J. Beta-adrenoceptors changes in exercise and physical training. In: Sports Cardiology; Exercise in Health and Cardiovascular Disease. Fagard R, Bekaert I (eds). Dordrecht: Martinus Nijhoff 1986:119-125.
3. Califf RM, **Ohman EM**, Frid DJ, Fortin DP, Mark DB, Hlatky MA, Herndon JE, Bengtson JR. Restenosis: the clinical issues. In: Textbook of Interventional Cardiology. Topol EJ (ed). Philadelphia: W.B. Saunders 1990:363-395.
4. **Ohman EM**, Califf RM. Thrombolytic therapy: overview of clinical trials. In: Management of Acute Myocardial Infarction. Gersh BJ, Rahimtoola SH (eds). New York: Elsevier Science Publishing 1990:308-331.
5. Tenaglia AN, **Ohman EM**, Stack RS. Myocardial protection during angioplasty using autoperfusion catheters. In: Supported Complex and High Risk Coronary Angioplasty. Shawl FA (ed). Norwell: Kluwer Academic Publishing 1991:199-213.
6. Wall TC, **Ohman EM**, Califf RM. Reperfusion therapy: significance of recent trials to the practicing cardiologist. In: Modern Management of Acute Myocardial Infarction in the Community Hospital. Green BG, (ed). Illinois: Scientists Publishing Co. 1991:103-118.
7. Leslie JB, Hawks SJ, Ginsberg B, **Ohman EM**, Croughwell NH, DeBree AS, Leone BJ, Reves JG. Patient-controlled sedation during cardiac angioplasty. In: Anesthesia and sedation by continuous infusion. Reves JG, Sladen RN (eds.) Excerpta Medica, Inc. 1992:1-7.
8. Hillegass WB, **Ohman EM**, Califf RM. Restenosis: The clinical issues. In: Textbook of Interventional Cardiology Second Edition. Topol EJ (ed). Philadelphia: W.B. Saunders Company. 1993:415-435.
9. **Ohman EM**, Christenson RH. Noninvasive assessment of myocardial reperfusion and reocclusion. In: Current Review of Interventional Cardiology. Topol EJ, Serruys PW (eds). Philadelphia: Current Medicine. 1994;Ch 6:1-15.
10. **Ohman EM**, Phillips HR, Califf RM. An approach to percutaneous revascularization in patients with stable coronary ischemia. In: Interventional Cardiovascular Medicine: Principles and Practice. Roubin GS, Califf RM, O'Neill WW, Phillips HR, Stack RS (eds). New York: Churchill Livingstone. 1994:217-237.
11. **Ohman, EM**. Circulatory assistance in the patient with critical hemodynamic disturbances. in: intensive cardiac care 1995. Caturelli G (ed). Casa Editrice Scientifica Internazionale. 1995:38-45.

12. Wilson JS, **Ohman EM**. Supported coronary angioplasty. In: *Advances in Interventional Cardiology: New Technologies and Strategies for Diagnosis and Treatment*. White CJ, Ramee S (eds). New York: Marcel Dekker. 1995:243-271.
13. Hearne SE, **Ohman EM**. Adjunctive agents to reduce ischemia, preserve myocardial function, and reduce mortality. In: *Acute Coronary Care 2nd ed*. Califf RM, Mark DB, Wagner GS (eds). St. Louis: Mosby-Year Book, Inc. 1995:355-369.
14. Krucoff MW, **Ohman EM**, Trollinger KM, Christensen R, Sawchak ST, Shah A, Pope JE, Califf RM. Noninvasive definition of failed reperfusion at the bedside: looking beyond the tip of the catheter. In: *Acute Coronary Care 2nd ed*. Califf RM, Mark DB, Wagner GS (eds). St. Louis: Mosby-Year Book, Inc. 1995:443-468.
15. **Ohman EM**, Harrington RA, Granger CB. Recurrent ischemia and reinfarction after reperfusion. In: *Acute Coronary Care 2nd ed*. Califf RM, Mark DB, Wagner GS (eds). St. Louis: Mosby-Year Book, Inc. 1995:584-598.
16. **Ohman EM**, Wilson J, Phillips HR Jr., Stack RS. Supported percutaneous intervention: The Duke Experience. In: *Strategic Approaches in Coronary Intervention*. Ellis SG, Holmes DR Jr., (eds). Cleveland: Williams & Wilkins. 1996:484-501.
17. Federici R, Tenaglia A, Hillegass W, Harrington R, Gurbel PA, **Ohman EM**. Prevention and management of abrupt closure. In: *Strategic Approaches in Coronary Intervention*. Ellis SG, Holmes DR Jr., (eds). Cleveland: Williams & Wilkins. 1996:626-645.
18. Tanguay JF, Shearer I, **Ohman EM**. Aortic counterpulsation during percutaneous intervention. In: *Handbook of Cardiovascular Interventions*. Sigwart U, Bertrand M, Serruys PW (eds). New York: Churchill Livingstone. 1996:175-183.
19. Mahaffey KW, Kruse KR, **Ohman EM**. Perspectives on the use of intra-aortic balloon counterpulsation in the 1990s. In: *Textbook of Interventional Cardiology*. Topol EJ (ed). Mallinckrodt Medical, Inc., Cardiology Division. 1996:303-321.
20. Kruse KR, Califf RM, **Ohman EM**. Thrombolytic Therapy: A critical review of clinical trials. In: *Acute Myocardial Infarction*. Gersh BJ, Rahimtoola SH (eds). New York: Chapman & Hall. 1996:434-471.
21. Mahaffey KW, Kruse KR, **Ohman EM**. Intraaortic balloon pump counterpulsation: physiology, patient management, and clinical efficacy. In: *Intensive Care Medicine*. Brown S (ed). Philadelphia: W.B. Saunders. 1997;647-656.
22. Anderson, RD, Myerson M, **Ohman EM**. New thrombolytic agents. In: *Current Review of Interventional Cardiology*. Holmes DR, Serruys PW (eds). Philadelphia: Current Medicine. 1997;151-167.
23. Greenbaum A, **Ohman EM**. Acute myocardial infarction: an update from recent clinical trials. In: *Current Opinion in Cardiology*. 1997;12:418-426.

24. Christenson RH, Newby LK, **Ohman EM**. The role of troponins and other markers for myocardial necrosis. In: Acute Coronary Syndromes. Topol EJ (ed). New York: Marcel Dekker. 1998:405-435.
25. Tardiff B, Mahaffey K, **Ohman EM**, Califf RM. Microinfarction associated with percutaneous intervention. In: Diagnostic and Therapeutic Cardiac Catheterization (3rd Edition) . Pepine CJ (ed). 1998;38:872-891.
26. Miller JM, **Ohman EM**, Moliterno DJ, Califf RM. Restenosis: the clinical issues In: Textbook of Interventional Cardiology (3rd Edition) Topol EJ. 1998; 21:379-415.
27. Newby LK, Gibler WB, Christenson RH, **Ohman EM**. Serum markers for diagnosis and risk stratification in acute coronary syndromes. In: Contemporary Cardiology: Management of Acute Coronary Syndromes. Cannon CP (ed) . New York: Humana Press, Inc. 1998;7:147-171.
28. Greenbaum AB, Harrington RA, **Ohman EM**. The use of glycoprotein IIb/IIIa inhibition in acute myocardial infarction. In: Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa in Cardiovascular Disease. Lincoff/Topol (eds.) 1999; 229-249.
29. Hudson MP, Goldmann BU, **Ohman EM**. The use of cardiac markers for therapeutic decisions in acute coronary syndromes. In: Markers in Cardiology: Current and Future Clinical Applications. Adams JE III, Jaffe AS, Wu AHB (eds.) Armonk, NY: Futura Publishing Company Inc. 2001:95-104.
30. Peterson GE, Phillips HR III, Jollis JG, Califf RM, **Ohman EM**. Surgical therapy versus interventional therapy in patients with stable coronary ischemia. In: Interventional Cardiovascular Medicine: Principles and Practice (2nd Edition). Stack RS, Roubin GS, O'Neill WW (eds). New York: Churchill Livingstone International. 2002;200-226.
31. Darrah S, **Ohman EM**. Myocardial infarction. In: Netter's Internal Medicine. Runge MS, Greganti MA (eds). Teterboro, NJ: Icon Learning Systems. 2003:156-166.
32. Runge MS, **Ohman EM**. The history and physical examination. In: Netter's Cardiology. Runge MS, Ohman EM (eds). Teterboro, NJ: Icon Learning Systems. 2004:2-17.
33. Steinhubl SR, **Ohman EM**. Glycoprotein IIb/IIIa receptor inhibitors. In: Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease. Manson JE, Buring JE, Ridker PM, Gaziano JM (eds). Philadelphia, PA : Elsevier Sanders. 2004:97-108.
34. Crouch ED, Menon V, **Ohman EM**, Stone GW. Intravenous direct thrombin inhibition: acute coronary syndromes and heparin-induced thrombocytopenia. In: Therapeutic Strategies in Thrombosis. Kristensen SD, De Caterina R, Moliterno DJ (eds.). Oxford, England. Clinical Publishing. 2006:77-106.

35. **Ohman EM**, Cohen MG. Facilitated percutaneous coronary intervention in acute myocardial infarction. In: Reperfusion Therapy for Acute Myocardial Infarction. Bates ER (ed.) New York, NY: Informa Healthcare USA, Inc. 2008:137-154.
36. Wang TY, **Ohman EM**. Myocardial infarction. In: Netter's Internal Medicine. Runge MS, Greganti MA (eds.). Philadelphia, PA: Saunders Elsevier, Inc. 2009:194-200.
37. Diamantouros P, **Ohman EM**. Cardiogenic shock. In: Pharmacology in the Catheterization Laboratory. Waksman R and Ajani AE (eds.). West Sussex, UK: Wiley-Blackwell. 2010: 179-189.
38. Cavender MA, **Ohman EM**. Heart disease in the elderly. In: Cardiology Secrets (third edition). Levine GN (ed.). Philadelphia, PA: Mosby Elsevier. 2010:424-428.
39. Halim SA, Newby LK, Ohman EM. Diagnosis of acute myocardial ischemia and infarction. In: Cardiology (third edition). Crawford MH, DiMarco JP, and Paulus WJ (eds.). Philadelphia, PA: Mosby Elsevier. 2010:345-360.
40. Cavender MA, **Ohman EM**. Bleeding complications and transfusion in acute coronary syndrome. In: Coronary Care Manual. Thompson PL (ed.). Sydney, Australia: Elsevier Australia. 2011:633-640.

INVITED PUBLICATIONS

1. **Ohman EM**, Fitzsimons P, Butler F, Bouchier-Hayes D. High prevalence rate of asymptomatic abdominal aortic aneurysms in an Irish Population. In: What is new in angiology? Trends and Controversies. Maurer P, Becker H, Heidrich H, Goffman G, Kriessman A, Muller-Weifel H, Pratorius C (eds). Munchen: W. Zuckschwerdt 1986:9-10.
2. **Ohman EM**. Beta-adrenoceptor changes during physical training. Perspective on Therapeutics in Northern Europe 1987;51:5-6.
3. Califf RM, **Ohman EM**. Reocclusion after thrombolytic therapy and percutaneous transluminal coronary angioplasty. **Cardiac Assists**. 1990; 5 (March): 1-6.
4. **Ohman EM**, Califf RM, Topol EJ, Stack RS, George BS, for the TAMI Study Group. Intra-aortic balloon pumping: benefits after thrombolytic therapy. **Cardiology Board Review**. 1991; 8:41-44, 53, 56.
5. Tchong JE, **Ohman EM**, Stack RS, Califf RM. Restenosis after PTCA. **Choices in Cardiology** 1992;6:50-52.
6. Hillegass WB, **Ohman EM**. Clinical trials for preventing restenosis: what have we learned? **Choices in Cardiology** 1993;7:164-167.
7. Harrington RA, **Ohman EM**. Early reocclusion after thrombolytic therapy. **Cardio** 1993:26-35 (July).
8. **Ohman, EM**. Prospective study of intraaortic balloon pump (IABP) counterpulsation confirms significantly reduced incidence of reocclusion following acute MI. **Cardiac Assists** 1994;7:1-4.
9. **Ohman EM**. Trials in acute myocardial infarction. **The Journal of Myocardial Ischemia** 1994;6:24-31.
10. **Ohman EM**, Talley JD. Evaluation of the costs of intra-aortic balloon counterpulsation in acute myocardial infarction. **Cardiac Assists**. 1997.
11. Christenson RH, Newby LK, **Ohman EM**. Cardiac markers in the assessment of acute coronary syndromes. **Maryland Medical Journal**. 1997; 46:18-24 (Suppl.).
12. Barsness GW, Harrington RA, Granger CB, Sketch MH, Jr., **Ohman EM**. Impact of adjunctive medical therapies on outcome after thrombolysis for acute myocardial infarction. **American Journal of Cardiology** 1997; Special Issue-CE Series Part 4; 15-23.
13. Alexander JH, **Ohman EM**, Harrington RA. Platelet GP IIb/IIIa inhibitors in acute MI: pathophysiology and clinical effects. **Acute Coronary Syndromes**. 1998;1:46-51.

14. **Ohman EM**, Kaplan AL. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: a new therapeutic horizon. **Current Practice of Medicine**. 1999;2:17-19.
15. **Ohman EM**. Troponin and other cardiac markers: role in management of acute coronary syndromes. **Australian and New Zealand Journal of Medicine**. 1999;29:436-443.
16. Kaplan AL, Goldmann B, **Ohman EM**. Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. **Journal of Emergency Medicine**. 1999; 17:589-595.
17. Cantor WJ, **Ohman EM**. Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: Improving outcomes. **Cardiology in Review**. 1999;7:232-244.
18. **Ohman EM**, Williams PA, Armstrong PW, Katus HA, Hamm CW, Califf RM, Topol EJ. An early troponin T level predicts mortality after acute coronary ischemia. **Medical Updates on Therapy, Diagnosis, and Prevention**. 1999; 2:42-3.
19. Goldmann BU, Newby LK, **Ohman EM**. Cardiac markers for decision-making in acute ischemic syndromes. **ACC Current Journal Review**. 2000;9:43-45.
20. Kelly RV, Cohen MG, **Ohman EM**. Facilitated percutaneous intervention in acute myocardial infarction: attractive concept but difficult to prove! **American Heart Hospital Journal** 2004;2:211-222.

OTHER PUBLICATIONS

1. **Ohman EM**, Califf, RM, Topol, EJ. Cardiac troponins in acute coronary syndromes. **New England Journal of Medicine**. 1997;336:1258-1259.
2. **Ohman EM**, Califf RM, Topol EJ. Trials in myocardial infarction. **Circulation**. 1997;96:3814-5.
3. Barsness GW, Peterson ED, **Ohman EM**, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf, RM. Myocardial revascularization and survival in diabetes. **International Diabetes Monitor**. 1998;10:11-13.

SELECTED LECTURES:

1990

1. "TAMI-7 Results", Myocardial Reperfusion 1990 - Concepts and Controversies, The University of Michigan Satellite Course preceding the American College of Cardiology Annual Scientific Sessions, New Orleans, Louisiana, March 17, 1990.

1991

1. "U.S. Thrombolysis Through European Eyes", University of Oxford Medical School, Oxford, England, May 24, 1991.

1992

1. "Noninvasive Monitoring", Fifth Annual International Symposium on Myocardial Reperfusion: Concepts and Controversies, Cleveland Clinic Foundation, Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions, Dallas, Texas, April 11, 1992.
2. "Early Diagnosis of Myocardial Infarction", Medical Grand Rounds, Victoria General Hospital, Victoria, British Columbia, Canada, June 17, 1992.
3. "The Open Infarct Artery Hypothesis", Cardiology Grand Rounds, Vancouver General Hospital, Vancouver, British Columbia, Canada, June 18, 1992.
4. "Intra-aortic Balloon Pumping To Preserve Infarct Angioplasty Patency", Eighth International Workshop on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, The George Washington University, Satellite Symposium preceding the American Heart Association Annual Scientific Sessions, New Orleans, Louisiana, November 15, 1992.
5. "The Open Artery Hypothesis: Evaluation of Strategies in Acute Myocardial Infarction", Cardiology Grand Rounds, University of Virginia, Charlottesville, Virginia, December 1, 1992.

1993

1. "The Role of Angioplasty in Acute Myocardial Infarction; Primary, Rescue or Adjunctive", Japanese Society for Interventional Cardiology, Tokyo, Japan, July 7, 1993.

2. "The Role of Mechanical Approaches to Acute Myocardial Infarction: Primary or Rescue PTCA and Adjunctive Therapies", Louisiana Chapter of the American College of Cardiology 4th Annual Meeting, New Orleans, Louisiana, October 23, 1993.
3. "Summary of Thrombolytic and Primary Angioplasty Trials." Cardiovascular Society of Arizona, Phoenix, Arizona, December 7, 1993.

1994

1. "Role of Intraaortic Balloon Pumping in the Management of Acute Myocardial Infarction", Cardiology Grand Rounds, University of Toronto, Toronto, Canada, January 11, 1994.
2. "Glycoprotein IIb/IIIa Receptor Blockade in Conjunction with Thrombolytic Therapy in Acute Myocardial Infarction", Myocardial Reperfusion: Concepts and Controversies, The Cleveland Clinic Foundation Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions, Atlanta, Georgia, March 12, 1994.
3. "Future of Enzyme Measurements in Acute Coronary Syndromes", Co-chairman, Cardiac Troponin T for the Diagnosis of Myocardial Injury Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions, Atlanta, Georgia, March 12, 1994.
4. "New Adjunctive Therapies with Thrombolytic Therapy in Acute Myocardial Infarction", Cardiology Grand Rounds, George Washington University, Washington, D.C., May 18, 1994.
5. "Utilização da Contrapulsção em Infarto Agudo do Miocárdio - Experiência da Duke University", "Utilização do Balão Intra-Aórtico em Cardiologia Invasiva", In Cor, Sao Paulo, Brazil, July 18, 1994.
6. "Intraaortic Balloon Pumping in Acute Myocardial Infarction", "Primary Angioplasty in Acute Myocardial Infarction", "Adjunctive Antiplatelet/Antithrombin Agents in Connection with Thrombolysis in Acute Myocardial Infarction", Favaloro Institute, Buenos Aires, Argentina, July 21, 1994.
7. "Adjunctive Technologies to Improve the Outcome in Coronary Angioplasty", South Cleveland Hospital, Teeside, North Yorkshire, England, October 19, 1994.
8. "PTCA During Acute Myocardial Infarction", Sahlgrenska University Hospital, Gothenburg, Sweden, October 20, 1994.
9. "Thrombolytic Therapy for Acute Myocardial Ischemic Syndromes", American College of Chest Physicians 60th Annual International Scientific Assembly, New Orleans, Louisiana, November 3, 1994.

10. "Integrilin: Glycoprotein IIb/IIIa Receptor Blocker as a Conjoint to Thrombolytic Therapy in Acute Myocardial Infarction", Tenth International Workshop on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, The George Washington University, Satellite Symposium preceding the American Heart Association Annual Scientific Sessions, Dallas, Texas, November 13, 1994.
11. "Lytic Failures", Council on Clinical Cardiology, American Heart Association 67th Scientific Sessions, Dallas, Texas, November 14, 1994.

1995

1. "Current Experiences with Specific Platelet IIb-IIIa Receptor Blockers and Antithrombins: Antiplatelet Therapy in PTCA: Peptide GP IIb-IIIa Receptor Blockers", European Heart House, Sophia Antipolis, France, February 16-18, 1995.
2. "Troponin T in GUSTO-2: An Update: Ischemic Heart Disease: Biochemical Markers in Risk and Outcomes Assessment", Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions, New Orleans, Louisiana, Saturday, March 18, 1995.
3. "Intra-aortic Balloon Counterpulsation", New Frontiers in the Treatment of Cardiogenic Shock Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions, New Orleans, Louisiana, Saturday, March 18, 1995.
4. "Mechanical Adjuncts to Reperfusion: Which Patients are Helped?", "New Antithrombotic Agents: Are They Necessary?" Challenges in Cardiovascular Case Management 1995 Update, Hamilton, Bermuda, May 4-6, 1995.
5. "Circulatory Assistance in the Patient with Critical Hemodynamic Disturbances", International Symposium on Cardiological Intensive Care '95, Venice, Italy, May 16, 1995.
6. "Use of Intra-aortic Balloon Pump and Primary Angioplasty" The Society for Cardiac Angiography and Interventions 18th Annual Meeting and Melvin P. Judkins Cardiac Imaging Symposium, Orlando, Florida, May 19, 1995.
7. "The Management of Shock During AMI", Acute Interventional Cardiology Symposia, Cardiology Center University Hospital, Geneva, Switzerland, June 27, 1995.
8. "Early Non-invasive Diagnosis of Failed Reperfusion Therapy" XVIIth Congress of the European Society of Cardiology, Amsterdam, The Netherlands, August 21, 1995.

9. “When and Why Thrombolytics”, “The Best Moment to Approach Unstable Angina: Is It Really Better to Wait?”, “Primary Angioplasty in Acute Myocardial Infarction”, “Acute Myocardial Infarction: Identification and Management of High Risk Patients”, “Rescue Angioplasty and Utilization of Mechanical Assistance Devices as Adjunctive to Angioplasty in AMI” XXII Congress of the Argentinean Society of Cardiology, Buenos Aires, Argentina, September 27-29, 1995.
10. “Troponin T Testing: A Practical Method for Risk and Outcomes Assessment”, Satellite Symposium, American Heart Association Annual Scientific Sessions, Anaheim, California, November 14, 1995.
11. “Role of Primary Angioplasty in the Management of Acute Myocardial Infarction”, “The IMPACT AMI Study and Discussion of Methodological Issues in This and Other Related Trials”, “Acute Ischemic Syndromes: the Continuum from Unstable Angina to Acute Myocardial Infarction-Current Issues in Management”, Hamilton General Hospital, Toronto, Canada, December 12, 1995.

1996

1. “Novel Anti-Thrombotic Therapies in AMI and PTCA”, Brigham and Women’s Hospital Cardiovascular Grand Rounds, Boston, Massachusetts, February 29, 1996.
2. “New Antithrombin Therapies: How to Perform Clinical Trials to Answer the Right Questions”, Cardiology Basic Science Conference, “The Role of IABP in Acute MI”, Cardiology Grand Rounds, St. Luke’s Episcopal Hospital/The Texas Heart Institute, Houston, Texas, March 1, 1996.
3. “Troponin - Prediction of Outcome”, “Myocardial Reperfusion and Acute Coronary Syndromes: GUSTO II and Beyond”, Ninth Annual International Symposium, Cleveland Clinic, Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions, Orlando, Florida, Saturday, March 23, 1996.
4. “Importância do emprego do BIA nos resultados de Angioplastia Coronária no Infarto Agudo do Miocárdio”, “Experiência global com a contrapulsção na Duke University”, “Conduitas nas complicações”, “Critérios e estratégias de desmame”, Rio de Janeiro, Brazil, June 16-18, 1996.

5. "New Cardiac Markers for Risk Stratification", Cardiology Grand Rounds, Cleveland Clinic Foundation, Cleveland, Ohio, October 11, 1996.
6. "The Role of Novel Enzymatic Markers: Point of Care and Beyond", Canadian Cardiovascular Society Satellite Symposium, Montreal, Quebec, Canada, October 29, 1996.
7. "The PRIME Trial: Efgatran in Acute Myocardial Infarction", Twelfth International Workshop on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, The George Washington University, preceding the 69th Annual American Heart Association Scientific Sessions, New Orleans, Louisiana, November 9, 1996.
8. "New Insights on Risk Stratification: Troponin and ST-Segment Monitoring", AMI Symposium, Reperfusion 1996: From Crisis to Lysis to Survival, Cleveland Clinic, preceding the 69th Annual American Heart Association Scientific Sessions, New Orleans, Louisiana, November 9, 1996.

1997

1. "GUSTO-III (Reteplase vs. Alteplase) Rationale and Design", The Cleveland Clinic Foundation, 10th Annual Myocardial Reperfusion: Concepts and Controversies, Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions Anaheim, California, March 15, 1997.
2. "Issues in Risk Stratification of Patients with Acute Ischemic Coronary Syndromes", "Reassessing Current Treatment Algorithms in the Management of Acute Ischemic Coronary Syndromes: The Role of Emerging Therapeutic Options", Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions, Anaheim, California, March 15, 1997.
3. "Comparison of Troponin I and T for Risk Stratification in Patients with Acute Coronary Syndrome", "GUSTO Trials: Value of Near Patient Testing in Optimizing Anticoagulation Management", "Prognostic Markers in Acute Myocardial Infarction: Results from the International GUSTO Trials", "The Management of Acute Myocardial Infarction: Results from the International GUSTO Trials", Sukaman Lecture, The 11th Asian Congress of Cardiology, Jakarta, Indonesia, July 8-10, 1997.
4. "Prognostic Values of Troponin T in Patients Presenting with ACS", College of Physicians, Manila, Philippines, July 11, 1997.

5. "A Cardiologist's Perspective: Utilization of Biochemical Markers in the Context of Acute Coronary Syndromes", the 49th Annual American Association for Clinical Chemistry (AACC) Meeting, Atlanta, Georgia, July 24, 1997.
6. "Platelet Inhibition in Acute Myocardial Infarction: Role of GP IIb/IIIa Inhibitors", "Role of PTCA in Acute Myocardial Infarction", "Is Primary Angioplasty the Strategy of Choice?" Second Meeting of the Latin American Society for Interventional Cardiology (SOLACI), Buenos Aires, Argentina, July 31-August 1, 1997.
7. "Update on Thrombolysis in Acute Coronary Syndromes", Cardiac Society of Australia and New Zealand 45th Annual Scientific Meeting, Melbourne, Australia, August 9, 1997.
8. "Balloon Pumping in Acute MI - Extravagance or Essential?" Cardiac Society of Australia and New Zealand 45th Annual Scientific Meeting, Melbourne, Australia, August 9, 1997.
9. "Recent Trends in Acute Myocardial Infarction", Cardiac Society of Australia and New Zealand 45th Annual Scientific Meeting, Melbourne, Australia, August 9, 1997.
10. "Troponin/Other Enzymes-Role in Management?" Heart and Blood Vessels in Health and Disease, Satellite Symposium, Australian Society of Cardiology, Hobart, Australia, August 13-15, 1997.
11. "Monitoring Anticoagulation Treatment with a Bedside Meter After Acute Myocardial Infarction: The GUSTO Experience", XIXth Congress of the European Society of Cardiology, Stockholm, Sweden, August 24, 1997.
12. "Re-stratification in Acute Coronary Syndromes: Do We Need the Troponin Markers?" Cardiology Core Lecture; "GUSTO III: Results and Key Substudy Analysis", Cardiology Grand Rounds, University of Texas Medical School, Houston, Texas, September 4, 1997.
13. "The Continuum of Care in Rapid AMI Management: Minimizing Time to Treatment/Maximizing Favorable Outcome", Co-Chairman, Satellite Symposium preceding the 70th Annual American Heart Association Scientific Sessions, Orlando, Florida, November 8, 1997.
14. "Prognostic Value of Whole-Blood Qualitative Troponin T Testing in Patients with Acute Myocardial Infarction in the GUSTO-III Trial," 70th American Heart Association Annual Scientific Sessions, Orlando, Florida, November 10, 1997.

1998

1. “New Treatment Strategies in Acute Myocardial Infarction with Special Reference to IIb/IIIa Blockade”, “Antithrombotic Strategies in Acute Coronary Syndromes, Uppsala, Sweden, March 5, 1998.
2. “GUSTO 4 Pilot”, The Cleveland Clinic Foundation, 11th Annual Myocardial Reperfusion: Concepts and Controversies, Satellite Symposium preceding the American College of Cardiology Annual Scientific Sessions, Atlanta, Georgia, March 28, 1998.
3. “Is There a Value with Revascularization in Patients with Coronary Artery Disease?” Cardiology Research Rounds, Sunnybrook Hospital, Toronto, Canada, April 7, 1998.
4. “Risk Stratification in Acute Coronary Syndromes: Evaluation of New Approaches” Medical Grand Rounds, Sunnybrook Hospital, Toronto, Canada, April 7, 1998.
5. “Bypass Surgery and Angioplasty in Diabetes”, The Cardiac Society of Australia and New Zealand, Christchurch, New Zealand, May 17, 1998;
6. “IIb/IIIa Receptor Antagonists: Magic Bullets Coming Over the Horizon” The Cardiac Society of Australia and New Zealand, Queenstown, New Zealand, May 19, 1998.
7. “Troponin T as a Prognosis Indicator/EPISTENT Results”, Green Lane Hospital, Auckland, New Zealand, May 21, 1998.
8. “Use of GP IIb/IIIa Inhibitors in ST Elevation Patients-The Interventional Approach: GUSTO IV Pilot (SPEED) Results”, “Need Of Cardiac Markers For Management Of Chest Pain Patients - the GUSTO Lessons”, XXth Congress of the European Society of Cardiology, Vienna, Austria, August 22, 1998.
9. “Troponins (I and T) in ACS”, International Cardiology Forum, 2nd International Meeting, Cannes, France, September 18, 1998.
10. “Cardiogenic Shock: IABP and Acute Revascularization”, International Summit on Acute Coronary Care, European Society of Cardiology, Treviso, Italy, September 18, 1998.
11. “The Reality of Combination Therapy with Fibrinolytics and Platelet Glycoprotein IIb/IIIa Receptor Inhibitors: Experience from the SPEED and TIMI 14 Trials”, What Emergency Physicians Need to Know, American College of Emergency Physicians Symposium, San Diego, California, October 11, 1998.
12. “Acute Coronary Syndromes: Algorithm for Triage and Risk Stratification”, Antiplatelet Strategies for Empiric Management of Acute Coronary Syndromes, Satellite Symposium preceding the American Heart Association Annual Scientific Sessions, Dallas, Texas, November 7, 1998.

13. "Pharmacodynamic Considerations in Evaluating the GP IIb/IIIa Inhibitors", Glycoprotein (GP) IIb/IIIa Inhibitors in the Management of Acute Coronary Syndromes: A New Standard of Care, Satellite Symposium preceding the American Heart Association Annual Scientific Sessions, Dallas, Texas, November 8, 1998.
14. "Using Cardiac Markers for Admission and Discharge Decisions", 71st Annual Scientific Sessions of the American Heart Association, Dallas, Texas, Plenary Session III, November 9, 1998.

1999

1. "Which New Fibrinolytic Agents or Which Association with Antithrombotic Drugs?" Fourth International Fibrinogen Symposium, Paris, France, February 5, 1999.
2. "Mission Possible: GP IIb/IIIa Inhibition for Acute Myocardial Infarction", Chairman of Satellite Symposium preceding the American College of Cardiology 48th Annual Scientific Sessions, New Orleans, Louisiana, March 6, 1999.
3. "Role of GP IIb/IIIa Blockade in PTCA and in the Management of Acute Coronary Syndrome" Clinical Application of GP IIb/IIIa Blockade in CAD, Taipei, Taiwan, March 19-21, 1999.
4. "Risk Stratification and Treatment of Acute Coronary Syndromes", Emory University, Atlanta, Georgia, May 23, 1999.
5. "Risk Stratification in Ischemic Heart Disease", Medical Grand Rounds, University of Florida, Gainesville, Florida, July 15, 1999.
6. "New Reperfusion Therapies for Acute Myocardial Infarction", Cardiology Grand Rounds, University of Florida, Gainesville, Florida, July 16, 1999.
7. "The Future of Biochemical Markers for Managing the Acute Coronary Syndrome Patient", American Association for Clinical Chemistry 51st Annual Meeting, New Orleans, Louisiana, July 26, 1999.
8. "Advances in Interventional Cardiology – Coronary Brachytherapy: Is it a Cure for Restenosis?", Satellite Symposium preceding the 72nd Annual American Heart Association Scientific Sessions, Atlanta, Georgia, November 6, 1999.
9. "Indirect Thrombin Inhibitors and the LMW Heparins", Satellite Symposium preceding the 72nd Annual American Heart Association Scientific Sessions, Atlanta, Georgia, November 6, 1999.

10. "Coronary Revascularization in Diabetics with Chronic Angina", Satellite Symposium preceding the 72nd Annual American Heart Association Scientific Sessions, Atlanta, Georgia, November 6, 1999.
11. "Uncovering the Benefits of Facilitated PCI: Promoting Lysis-PCI and Lysis Plus GP IIb/IIIa-PCI Compatibility", "International Differences in Treatment Outcome in Acute Coronary Syndromes." 72nd Annual American Heart Association Scientific Sessions, Atlanta, Georgia, November 7-8, 1999.
12. "Role of Glycoprotein IIb/IIIa Receptors Blocking Agents in Patients Receiving Interventional Percutaneous Procedures", "New Cardiac Markers For Risk Stratification in Acute Coronary Syndromes", "Future of Interventional Cardiology", "Ideal Antithrombotic Management In Acute Coronary Syndromes", 15th Congreso Uruguayo de Cardiologia, Montevideo, Uruguay, December 5-6, 1999.

2000

1. "Combination Strategies with Low-Dose Fibrinolytics and GP IIb/IIIa Receptor Inhibitors: Theory and Practice", Satellite Symposium preceding the American College of Cardiology 49th Annual Scientific Sessions, Anaheim, California, March 11, 2000.
2. "Current State of Management of ACS", ACS Town Hall Meeting, Satellite Symposium preceding the American College of Cardiology 49th Annual Scientific Sessions, Anaheim, California, March 11, 2000.
3. "The Pathophysiology and Management of Non Q-Wave Myocardial Infarction and Implications of Clinical Trials", State of the Art Lecture, Clinical Cardiology Symposium, American College of Cardiology 49th Annual Scientific Sessions, Anaheim, California, March 12, 2000.
4. "Can We Extend the Reperfusion Horizon? Exploring Facilitated PCI on a Lysis / GP IIb/IIIa Platform", Evolving Trends in Fibrinolytic and Interventional Therapy in AMI, American College of Cardiology Conference at Lake Louise, Alberta, Canada, March 25, 2000.
5. "The Role of IIb/IIIa Blockers in the Treatment of Acute MI", "Current Status and Clinical Efficacy of Intravenous and Oral IIb/IIIa Receptor Blockers", American College of Cardiology Conference, 16th Cardiovascular Conference at Lake Louise, Alberta, Canada, March 26-27, 2000.
6. "New Directions in the Treatment of Unstable Angina and Non Q-Wave Myocardial Infarction", Medical Grand Rounds, Henry Ford Hospital, Detroit, Michigan, April 20, 2000.
7. "Medical Therapy for Unstable Angina: GUSTO IV ACS Results", Symposium at the European Society of Cardiology, Amsterdam, The Netherlands, August 29, 2000.

8. "The Value of IABP in Patients with Acute Myocardial Infarction and Cardiogenic Shock", 1st World Conference on Intraaortic Balloon Counterpulsation, Athens, Greece, September 1, 2000.
9. "Unstable Angina and Non-ST Segment Elevation MI", Acute Coronary Syndromes: Triage, Diagnosis, and Therapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, September 16, 2000.
10. "Current Perspective of GP IIb/IIIa Inhibitors in the Treatment of Acute Coronary Syndromes", Third Coimbra International Meeting on Cardiovascular Diseases Acute Coronary Syndromes, Coimbra, Portugal, October 14, 2000.
11. "GP IIb/IIIa in Acute Coronary Syndromes", Acute Coronary Syndromes – NICE Review and Clinical Update, Manchester, United Kingdom, October 16, 2000.
12. "Cardiogenic Shock: Update on New Treatments and Clinical Trials, Satellite Symposium preceding the 73rd Annual American Heart Association Scientific Sessions, New Orleans, Louisiana, November 11, 2000.
13. "Platelet Management and Beyond in Acute Coronary Syndromes, Satellite Symposium preceding the 73rd Annual American Heart Association Scientific Sessions, New Orleans, Louisiana, November 11, 2000.

2001

1. "New Reperfusion Strategies in AMI," Grand Rounds, University of Michigan Medical Center, Ann Arbor, Michigan, January 9, 2001.
2. "The FASTER Trial: Rational For A New Paradigm Of Myocardial Reperfusion", "Have Current Treatment Strategies Improved Outcome Of Cardiogenic Shock?", Second International Summit on Acute Coronary Care, Cogne, Italy, January 31-February 2, 2001
3. "Management of AMI: New Strategies" 16th Annual Don Chapman Lectureship, Baylor College of Medicine, Houston, Texas, March 8, 2001.
4. "Lytics + IIb/IIIa: GUSTO-V", 14th Annual Myocardial Reperfusion Symposium: Concepts and Controversies, Orlando, Florida, March 17, 2001.
5. "Overcoming Angioplasty Treatment Delays: Facilitated PTCA With Combination Lytics and IIb/IIIa Inhibitors – What May Be Gained, and At What Price?", ACS and AMI Symposium: Pharmacological and Interventional Synergies, Orlando, Florida, March 17, 2001.

6. "How Early Should We Discharge Infarct Patients?", "Facilitated Percutaneous Transluminal Coronary Angioplasty", American College of Cardiology 50th Annual Scientific Sessions, Orlando, Florida, March 19-20, 2001.
7. "Learning the Hard Way: Clinical Trials with GP IIb/IIIa Inhibitors", "Acute Coronary Syndromes", 4th Annual GTACC Partners in Cardiac Care Symposium, Huntsville, Ontario, Canada, June 8-10, 2001.
8. "GP IIb/IIIa inhibitors in Combination with Low-Molecular Weight Heparin", 8th International Symposium on Thromboembolism, Florence, Italy, June 15-16, 2001.
9. "Cell Injury Markers of Myocardial Injury and Heart Failure: Interpretation And Potential", American Association for Clinical Chemistry Annual Meeting, Chicago, Illinois, July 30, 2001.
10. "What Constitutes Optimal Pharmacologic Therapy?" 3rd Annual Interventional Cardiology: Bench to Bedside and Beyond, Anaheim, California, November 11, 2001.
11. "Revascularization for Shock: An Unfulfilled Promise" Special Session XI: The Oculostenotic Reflex: When and How Should We Intervene?, American Heart Association Annual Scientific Sessions, Anaheim, California, November 14, 2001.

2002

1. "Facilitating PCI: Do Devices And Pharmacotherapy Mix?", 5th Annual JANUS V Meeting, Cancun, Mexico, January 26, 2002.
2. "Assessment of Quality of Care Delivery In Acute Coronary Syndrome", Improving Patient Care Via Point-of-Care Biomarkers From Bench to Bedside, Dallas, Texas, February 24, 2002.
3. "Prevention of Reinfarction Using Half-Dose Reteplase and Abciximab: GUSTO 5 Observations", "Rescue PTCA and Reperfusion Greater Than 12 Hours Post MI: Selection of Patients", American College of Cardiology 51st Annual Scientific Sessions, Atlanta, Georgia, March 18, 2002.
4. "Optimal Management of The Acute Patient: Time To Intervention – Is It Critical?" 9th International Symposium on Thromboembolism, Thrombosis Research Institute of London, Seville, Spain, June 8, 2002.
5. "Targeting Improved Adherence to the ACC/AHA Guidelines for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes", XXIV Congress of the European Society of Cardiology, Berlin, Germany, September 4, 2002.
6. "FASTER Trial", 18th International Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, George Washington University Medical Center, Chicago, Illinois, November 16, 2002.

2003

1. “Cardiac Markers: A Redefinition of AMI: Implications for Practice”, “ACS: Do We/Should We Follow The Guidelines?”, “PCI vs. Lysis in AMI”, “Ischemic Heart Disease [Panel Discussion Participant]”, 8th Annual Cardiology Symposium at Cancun 2003, Cancun, Mexico, March 7, 2003.
2. “Antithrombotic Therapy in Acute Coronary Syndrome: Is It Time To Replace Heparin?”, Cardiology Grand Rounds, Emory University Hospital, Atlanta, Georgia, March 14, 2003.
3. “Evidenced-based Practice: Does It Matter? Observations from the CRUSADE Registry”, Atherothrombotic Disease: The Art and Science of Long-term Management Symposium [Co-Chair and Speaker], Chicago, Illinois, March 29, 2003.
4. “Acute Myocardial Infarction: Current Approaches” [Session Chair], “Facilitated Percutaneous Coronary Intervention” American College of Cardiology Scientific Sessions, Chicago, Illinois, March 31, 2003.
5. “Defining the Risk”, International Workshop on Acute Coronary Syndromes: Redefining Care in the Era of Aggressive Revascularization, University of Parma, Como, Italy, May 22, 2003.
6. “Moving Forward: How Do We Improve Emergency Cardiovascular Care?” (Moderator), Emergency Cardiovascular Care 2003 Conference, Chapel Hill, North Carolina, May 31, 2003.
7. “Management of a New Clinical Entity: NSTEMI – Interventional approach”, Update in Thrombolysis 2003: Arteriosclerosis, Thrombosis and Cardiovascular Biology, Freiburg, Germany, June 6, 2003.
8. “Antithrombotic Therapy in Interventional Cardiology” (Session Chair), 19th International Symposium on Thromboembolism, London, England, June 14, 2003.
9. “Setting the State: The Key Controversies in AMI Therapy”, “Second Controversy: Primary Intervention With Or Without Pharmacologic ‘Facilitation’?” (Panelist), “The Acute, Thrombotic Lesion” (Panelist), “Emergency Cardiopulmonary Support During AMI Reperfusion Therapy” (Panelist), and “Acute MI Cases” (Panelist), 12th Annual Advanced Cardiovascular Interventions Symposium, Hilton Head, South Carolina, June 20, 2003.
10. “Revascularization for Ischemic Cardiomyopathy: What Will STICH Tell Us?:” Heart Failure Management 2003: Established Therapy and New Frontiers, Amelia Island, Florida, July 18, 2003.
11. “Complex Cardiovascular Disease-2003”, Cardiology Grand Rounds, Rex Healthcare, Raleigh, North Carolina, July 31, 2003.

12. “Evolution of Cardiac Markers And Their Use To Guide Therapy”, Plenary Session Speaker, American Association for Clinical Chemistry Annual Meeting 2003, Philadelphia, Pennsylvania, July 22, 2003.
13. “Using and Monitoring Antithrombotic Therapy in PCI”, Thrombosis Management for Better Outcomes in Cardiac Patients, Satellite Symposium at the European Society of Cardiology Meeting, Vienna, Austria, September 1, 2003.
14. “‘New Age’ Considerations for Oral and Systemic Antiplatelet Therapy: The Dominance of Thienopyridines, and Perspectives On Optimal Glycoprotein IIb/IIIa Inhibitor Use”, “Anticoagulation in Specific Circumstances: Elective PCI, Unstable Angina, Primary and Rescue PCI, and Renal Insufficiency”, “The American Response: Is the US Ahead or Behind the Times, and Future Predictions”, “Adjunct Pharmacology (In and Beyond the Cath Lab)”, “Review of the ‘New’ Anticoagulants for ACS (Factor VII, IX , and X Inhibitors: Pentasaccharides, Oral Direct Antithrombins, and More): Profiles and Potential Benefits”, 15th Annual TCT Scientific Symposium, Washington, DC, September 16-18, 2003.
15. “Short-term Cardiac Risk Stratification in ST-Elevation Acute Coronary Syndromes”, Academy Colloquium, Amsterdam, The Netherlands, October 8, 2003.
16. “The 2002 ACC/AHA guidelines/CRUSADE Quality Improvement Initiative: Cardiologists and Emergency Physicians Working Together”, Satellite Symposium to the 2003 American College of Emergency Physicians Annual Meeting, Boston, Massachusetts, October 11, 2003.
17. “Heparin-Induced Thrombocytopenia: Is It an Underdiagnosed Condition?”, Satellite Symposium at CHEST 2003, Orlando, Florida, October 27, 2003.
18. “High-risk NSTEMI ACC”, “Concordance to the ACC/AHA Guidelines and Patients Outcomes: Insight from CRUSADE”, Satellite Symposium to the American Heart Association 2003 Scientific Sessions, Orlando, Florida, November 8, 2003.
19. “Beyond Heart Failure: How NT-proBNP Fits into the Future of Cardiac Care”, Satellite Symposium to the American Heart Association 2003 Scientific Sessions, Orlando, Florida, November 9, 2003.
20. “Rapid Laboratory Testing for ACS: Critical for Risk Stratification” American Heart Association 2003 Scientific Sessions, Orlando, Friday November 10 2003.

21. “Care of Non-ST-segment Elevation Patients: Insights from CRUSADE “, Satellite Symposium to the American Heart Association 2003 Scientific Sessions, Orlando, Florida, November 10, 2003.
22. “Quality Improvement Initiatives: What CRUSADE Has Taught Us”, Cardiology Grand Rounds, University of California-San Diego, San Diego, California, December 3, 2003.
23. “Quality Improvement Initiatives: What CRUSADE Has Taught Us”, Cardiology Grand Rounds, University of Chicago, Chicago, Illinois, December 5, 2003.

2004

- 1 “CRUSADE Registry”, 27th Cardiovascular Meeting in Denmark, Copenhagen, Denmark, January 23, 2004.
2. “Cardiac Markers in 2004”, 13th Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, Colorado, February 11, 2004.
3. “Therapy of Non-ST-segment Elevation MI”, Halifax Regional Hospital 14th Annual Cardiology Symposium, South Boston, Virginia, March 2, 2004.
4. “Atherothrombosis: Bridging Evolving Science with Clinical Study Results” [Co-Chair], “Optimizing Patient Care: What Have We Learned From Quality Improvement Initiatives?” BMS-Sanofi Symposium preceding the American College of Cardiology Scientific Sessions, New Orleans, Louisiana, March 6, 2004.
5. “The Acute Coronary Syndrome: What Is New?”, “Heparin-induced Thrombocytopenia: Assessment and Management [Session Chair]”, “Acute Myocardial Infarction: New Frontiers” [Session Chair], “Facilitated Percutaneous Coronary Intervention”, “Cardiac Markers In Acute Coronary Syndromes” [Session Co-Chair], American College of Cardiology Scientific Sessions, New Orleans, Louisiana, March 7-8, 2004.
6. “Lessons from US Registries” Satellite Symposium for the European Society of Cardiology Meeting, Munich, Germany, August 31, 2004.
7. “Antithrombotic Regimen for Percutaneous Coronary Intervention: Open Issues” [Session Co-Chair]. European Society of Cardiology Meeting, Munich, Germany, September 1, 2004.

8. “Emerging Role of the Platelet in the Progression and Management of Atherothrombotic Disease” [Chair], and “Measuring Performance: Improving Patient Outcomes Through Guideline Adherence”, Satellite Symposium at the America Heart Association Scientific Sessions, New Orleans, Louisiana, November 7, 2004.
9. “How to Use Natriuretic Peptides Effectively” [Session Moderator], America Heart Association Scientific Sessions, New Orleans, Louisiana, November 8, 2004
10. “What’s New in ACS?” Satellite Symposium at the America Heart Association Scientific Sessions, New Orleans, Louisiana, November 8, 2004.

2005

1. “State-Of-The-Art Therapy Of Acute Myocardial Infarction”, Cardiology Grand Rounds, Sinai Hospital, Baltimore, Maryland, January 27, 2005.
2. “The Invasive Management of CAD”, Area Health Education Centers Program, Wilson, North Carolina, February 5, 2005.
3. “Management of the Patient With Non-STEMI or UA: Standards of Care vs. Reality”, New Horizons in Cardiac Care Symposium, Grand Blanc, Michigan, February 12, 2005.
4. “Evolving Clinical Markers Of Risk In Acute Coronary Syndromes: Fasten Your Seatbelt!”, and “Managing Anticoagulation In Setting Of Dropping Platelet Count: The Dark Side Of Heparin”, 14th Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, Colorado, February 15-16, 2005.
5. “Quality Improvement Initiatives In Non-ST-ACS”, Cardiology Grand Rounds, University of Virginia, Charlottesville, Virginia, February 22, 2005.
6. “High Mortality After Discharge Among Patients with High Risk for Developing Heparin-Induced Thrombocytopenia or Thrombosis: 6-Month Follow-up Results of the Complications after Thrombocytopenia Caused by Heparin (CATCH Registry)”, American College of Cardiology Scientific Meetings, Orlando, Florida, March 7, 2005.
7. “Plaque Instability – From Mechanistic Insights To Tailored Treatment”, “Management Of A Patient With Non-ST-Segment Elevation Acute Coronary Syndromes”, European Society of Cardiology Scientific Sessions, Stockholm, Sweden, September 4-5, 2005.

8. “Cardiogenic Shock”, Cardiology Grand Rounds, Newark Beth Israel Medical Center, Newark, New Jersey, October 14, 2005.
9. “Acute Coronary Syndromes: Current Guidelines And Report Card”, Transcatheter Cardiovascular Therapeutics (TCT) Conference, Washington, DC, October 17, 2005.
10. “Acute Ischemic Coronary Syndrome – AICS”, Brigham & Women’s Heart Course, Las Vegas, Nevada, November 4-5, 2005.
11. Optimal Anti-Thrombotic Therapy, “Optimal Reperfusion Strategies For STEMI In Facilities Without PCI”, How to Detect, Diagnose, and Treat HIT, American Heart Association Scientific Sessions, November 13-14, 2005, Dallas, Texas
12. “Crusading for Quality Of Care Improvement In ACS: Role Of Guidelines” AHA Satellite Symposium, November 13, 2005, Dallas, Texas.
13. “Optimizing Outcomes in PCI”, and “Taking the HIT: Issues in PCI: Strategies for Prevention”, AHA Satellite Symposium, November 14, 2005, Dallas, Texas.

2006

1. “Cardiogenic Shock”, Cardiology Grand Rounds, St. Joseph’s Hospital, Tampa, Florida, January 19, 2006.
2. “Multimarker Panels in ACS: Can They Speed Up the Diagnostic Evaluation?”, 15th Annual Cardiology Conference at Beaver Creek, Beaver Creek, Colorado, February 15, 2006
3. “Detection and Risk Stratification of Myocardial Damage: The Troponin Story”, National Academy of Sciences Meeting, Washington, DC, March 2, 2006.
4. “Cardiovascular Emergencies 2006”, ACC Satellite Symposium, Atlanta, Georgia, March 11, 2006.
5. “Facilitated Percutaneous Coronary Intervention,” Meet the Experts Session, “Advanced Coronary Heart Disease: Scope of the Problem in an Aging Population” [Joint Session of the American College of Cardiology and the European Society of Cardiology] American College of Cardiology Scientific Sessions, .Atlanta, Georgia, March 11-14, 2006
6. “Burden of Atherothrombotic Diseases and Its Impact on Heath Care Practices: Lessons Learned from the REACH and CRUSADE Registries,” ACC Satellite Symposium, Atlanta, Georgia, March 13, 2006.
7. “Observations in Antithrombotic Therapy for Patients with ACS: Trials and Registries,” ACC Satellite Symposium, Atlanta, Georgia, March 14, 2006.
8. “Approach to the patient with ACS: Conservative vs. invasive strategies, triage, timing issues and more”, Interventional Fellows Course, San Jose, California, April 1, 2006.

9. “Cardiogenic Shock”, Cardiology Grand Rounds, Mt. Sinai Medical Center, Miami, Florida, April 6, 2006.
10. “Benefits of Antiplatelet Therapy: Evidence in Large Registries”, University of Cincinnati CME Program, Philadelphia, Pennsylvania, April 8, 2006.
11. “Cardiogenic Shock”, Memorial Mission Medical Center Cardiology Conference, Asheville, North Carolina, April 11, 2006.
12. “Cardiogenic Shock”, University of Texas Cardiology Grand Rounds, Houston, Texas, April 13, 2006.
13. “Antiplatelet Therapy in the Real World: Insights from US and Global Registries”, Satellite Symposium of the Society of Hospital Medicine Annual Meeting, Washington, DC, May 3, 2006.
14. “2006: Will Multivessel Stenting Compete with CABG?”, 4th Annual Cardiology Conference, Daytona Beach, Florida, May 4, 2006.
15. “Management of Non-ST Elevation Acute Coronary Syndromes “, “Treatment of plaque instability”, European Society of Cardiology Scientific Sessions, Barcelona, Spain, September 4-5, 2006.
16. “Crusading for Quality of Care Improvements in Acute Coronary Syndrome”, 2006 Eric R. Powers Lecturer, University of Virginia, Charlottesville, VA, October 6, 2006.
17. “Examining the Approval Process for IABP as a new PMA Device”, Dartmouth Device Symposium, Woodstock, Vermont, October 12, 2006.
18. “Quality of Health Care Delivery: What Have We Learned from CRUSADE”, Johns Hopkins Cardiology Update 2006, Captiva Island, Florida, October 13, 2006.
19. “Cardiovascular and Neurovascular Emergencies – a Panel Discussion”, EMCREG International Symposium, New Orleans, Louisiana, October 17, 2006.
20. "Success of Identification and Treatment of HIT", “Outcomes in Elderly Patients Treated with Bivalirudin Monotherapy vs. Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results from the Randomized ACUTY Trial”, American Heart Association Scientific Sessions, Chicago, Illinois, November 13-15, 2006.

2007

1. “Management of Cardiogenic Shock in Patients with Acute Coronary Syndrome”, “Clinical Significance of Biomarkers in Non ACS Patients – Pulmonary Embolism, Heart Failure, Pericarditis, etc.”, “Biomarkers – Diagnostic and Prognostic Indications for Acute Coronary Syndrome”, and “Acute Coronary Syndrome”, Midwinter Cardiovascular Conference 2007, Snowshoe, West Virginia, February 5, 2007.

2. "Best Management of Stable Angina in the Elderly", Annual Cardiology Conference at Beaver Creek, Beaver Creek, Colorado, February 12, 2007
3. "Advanced CAD in the Current Health Care Environment", Medical Affairs Grand Rounds, CV Therapeutics, Palo Alto, California, March 2, 2007.
4. "Multivessel Revascularization in Acute Myocardial Infarction", "Advanced Coronary Artery Disease: Scope of the Problem", "Managing Heparin-induced thrombocytopenia in Patients with Coronary Disease", and "Preprocedure N-Acetylcysteine", American College of Cardiology Scientific Sessions, New Orleans, Louisiana, March 26-27, 2007.
5. "Case-by-Case Analysis of Why, When, and How To Manage Patients with Acute Coronary Syndromes", ACC Satellite Symposium, New Orleans, Louisiana, March 27, 2007.
6. "Changes in Cardiovascular Care: What Have We Learned from Quality Improvement Initiatives?", Cardiac Catheterization Conference, Medical College of Virginia, Richmond, Virginia, April 5, 2007.
7. "The CRUSADE Acute Coronary Syndrome Registry", EPIC Lunch and Learn Program, Emory University, Atlanta, Georgia, April 28, 2007.
8. "Acute Coronary Syndrome: Post –PCI Management Strategies for Improved Patient Outcomes", SCA&I Satellite Symposium, Atlanta, Georgia, May 10, 2007.
9. "Antithrombin Therapy in PCI: Recommendations for Clinical Practice", SCA&I Scientific Sessions, Atlanta, Georgia, May 11, 2007.
10. "CRUSADE: Acute Coronary Syndromes, Risk Assessment and Treatment Strategies", Pitt Memorial Hospital, Greenville, North Carolina, May 24, 2007.
11. "Updates in ACS: Risk Assessment and Treatment Strategies", Wake Medical Center, Raleigh, North Carolina, May 24, 2007.
12. "Acute Coronary Syndrome: Late Coronary Complications", Vulcan Interventional Cardiovascular Society Meeting, Birmingham, Alabama, May 29, 2007.
13. "Cardiogenic Shock 2007: An Update", Cardiology Grand Rounds, and "IABP: A Clinical Update", Medical Grand Rounds, University of Alabama, Birmingham, Alabama, May 30, 2007.
14. "Update on Acute Coronary Syndrome 2007", 1st Annual Duke/Indian River Medical Center Cardiovascular Symposium, Vero Beach, Florida, July 14, 2007.
15. "Current and Emerging Strategies for Reducing Cardiometabolic Risk", Cardiovascular Conference, Good Samaritan Medical Center, West Palm Beach, Florida, September 27, 2007.
16. "Continuing the Search for Optimal Antiplatelet Use & Therapy in Non-ST Elevation ACS", Canadian Cardiovascular Conference Satellite Symposium, Quebec City, Quebec, October 21, 2007.

17. “Bridging the Gap Between Cardiology and Surgery: What Makes Sense for Our Patients?”, TCT 2007 Satellite Symposium, Washington, DC, October 21, 2007.
18. “Evidence-Based Medicine Therapies in Acute Coronary Syndromes: From Principles to Practice”, TCT 2007 Scientific Sessions, Washington, DC, October 23, 2007.
19. “Registries, Meta-analyses, and Clinical Trials: Challenges, Opportunities, and Impact on Clinical Practice”, 4th Annual Global Cardiovascular Summit, Orlando, Florida, November 2, 2007.
20. “Critical Challenges In Cardiovascular Medicine: Acute Coronary Syndromes-Getting In The Stream Of Things” [Chair], AHA Satellite Symposium, Orlando, Florida, November 5, 2007.
21. “Management of Angina – Drugs, Devices or Both”, Georgia Chapter of the ACC Annual Meeting, Atlanta, Georgia, November 17, 2007.
22. “Cardiogenic Shock”, Duke ICC Lecture Series, Durham, North Carolina, December 18, 2007.

2008

1. “LV Support Devices: IABP, CPS”, Duke ICC Lecture Series, Durham, North Carolina, January 22, 2008.
2. “Cardiogenic Shock”, Johns Hopkins Fellows Conference, Baltimore, Maryland, January 24, 2008.
3. “Management of Angina - Drugs, Devices or Both?”, ”Dosing and Timing of Antiplatelet Therapies in ACS”, “NSTEMI Case Presentation[Moderator]”, “Nightmare Cases” [Panelist], Annual Cardiology Conference at Beaver Creek, Beaver Creek, Colorado, February 12-13, 2008.
4. “Acute Coronary Syndromes” Session [Co-Chair], “New Treatment Strategies for Acute ST-Elevation Myocardial Infarction” [Co-Chair], “Late Breaking Clinical Trials II” [Commentator – SCAI/ACCi2 Joint Session], “Standard Therapy Has Failed and Revascularization is Not an Option: What Do I Do Now?”, American College of Cardiology Scientific Sessions, Chicago, Illinois, March 29-31, 2008.
5. “Approach to the Patient with ACS: Conservative vs. Invasive Strategies, Evidence-Based Medicine Guidelines vs. Performance”, Interventional Fellows Course, San Jose, California, April 5, 2008.
6. “Chronic Angina: Drugs, Devices, or Both?” Grand Rounds, Southeast Area Health Education Center, Wilmington, North Carolina, April 10, 2008.
7. “Cardiogenic Shock”, Duke University Annual Spring Cardiovascular Symposium, Durham, North Carolina, April 18, 2008.

8. "Management of Non-STEMI", and "The Impact of HIT in Interventional Cardiology", Emory Practical Intervention Course (EPIC) 2008. Emory University, Atlanta, Georgia, April 26, 2008.
9. "Angina: Drugs, Devices, or Both?" Visiting Professor, Mount Sinai Medical Center, New York, New York, May 12, 2008.
10. "Management of Patients with Refractory Angina", Cardiology Grand Rounds, George Washington University, Washington, DC, June 11, 2008.
11. "Success of identification and treatment of HIT", Outcomes in Elderly Patients Treated with Bivalirudin Monotherapy Vs. Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results from the Randomized ACUTY Trial, American Heart Association Scientific Sessions, New Orleans, Louisiana, November 13 & 15, 2008.

2009

1. "Biomarkers in ACS, CHF, Valvular Disease", and "Management of Shock Post MI". Cardiovascular Conference at Snowshoe, Snowshoe, West Virginia, February 2, 2009.
2. "The Epidemic of Medically Managed NSTEMI". Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, Colorado, February 9, 2009.
3. "Direct Thrombin Inhibitors". Cardiology Update Course, Davos, Switzerland, February 18, 2009.
4. "Balancing Ischemia and Bleeding Complications", American College of Cardiology Scientific Sessions, Orlando, Florida, March 29, 2009.
5. "Optimal Treatment of SVG's: Pharmacological Adjuncts and Mechanical Strategies". Concepts in Contemporary Cardiovascular Medicine 2009, Texas Heart Center, Houston, Texas, April 16, 2009.
6. "Managing the STEMI with Shock". Emory Practical Intervention Course (EPIC) 2009, Emory University, Atlanta, Georgia, April 25, 2009.
7. "Optimal Upstream Anti-Thrombin Therapy", Optimal Upstream Anti-Thrombin Therapy [Session Moderator], "Antiplatelet Therapy: Issues and Concerns" SCAI Scientific Sessions, Las Vegas, Nevada, May 7 & 8, 2009.
8. The 2007 ACC/AHA and 2008 ESC Guidelines for STEMI: Harmony or Discord?", "The Other MI: Timing of catheterization for optimal management of NSTEMI", "Prevalence, predictors and impact of conservative medical management patients with NSTEMI-ACS", 2009 ACS Master Class, Leuven, Belgium, June 12 & 13, 2009.

9. Update on New Antiplatelet Agents [Discussant], Personalized Clinical Decision-Making Case Study: The Ischemia vs. Bleeding Controversy [Moderator], Gladiators in AMI Therapy: Grappling With the Tough Issues [Moderator], “Should All Patients Undergoing Primary PCI Receive Bivalirudin? What About GPIIb/IIIa Inhibitors?”, Clopidogrel or Prasugrel in STEMI? [Discussant], Life Saving Therapies for the Hemodynamically Compromised Acute AMI & High-Risk PCI Patient: A Current Review [Moderator], Unstable Angina and Non-STEMI Guidelines [Discussant], AMI Therapies and Surrogate Endpoints: Infarct Size vs. Clinical Endpoints, Safety Endpoints, and Adjunctive Pharmacology [Discussant], “Major Bleeding, Minor Bleeding, Access-Site and Non-Access-Site Related, Transfusions”, “Thrombocytopenia in ACS and PCI: What Really Matters?” Choice of Anticoagulation During Primary PCI in STEMI [Discussant], Invasive vs. Conservative Strategies [Moderator], “Primary Medical Management of the Patient with ACS: Patient Selection and TRILOGY Rationale” TCT Scientific Sessions, San Francisco, California, September 23 & 24, 2009.
10. “Novel Percutaneous Cardiovascular Support Devices “, “Left Ventricular Support Devices : A Case Review”, Great Wall International Congress of Cardiology, Beijing, China, October 9 & 10, 2009.
11. "Novel Circulatory Support Devices" Cardiology Grand Rounds, Duke University Medical Center, Durham, North Carolina, October 26, 2009.
12. "LV Support Devices: IABP, CPS" ICC Lecture Series, Duke University Medical Center, Durham, North Carolina, November 10, 2009.
13. "PCI for Cardiogenic Shock in the Young and the Elderly: Estimating the Risk and Benefit from Trials and Registries", PCI for STEMI: Technology, Systems and Outcomes [Moderator], American Heart Association Scientific Sessions, Orlando, Florida, November 15 & 17, 2009.
14. "Cardiogenic Shock/Vasoactive Drugs", ICC Lecture Series, Duke University Medical Center, November 24, 2009.
15. “Overcoming Barriers to HIT Identification and Management in the Hospital Setting: Practical Tips and Tools”, Cardiology Grand Rounds, Beth Israel Medical Center, Newark, New Jersey, December 8, 2009.
16. "New Percutaneous LV Support Systems", Cardiology Section Meeting, Moses Cone Hospital, Greensboro, North Carolina, December 16, 2009.

2010

1. “Bleeding and Ischemia in PCI Among Patients with ACS: How Can We Balance These Competing Issues?”, “New Support Devices for Cardiogenic Shock”. Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, Colorado, February 8, 10, 2010.
2. “Primary PCI in STEMI” [Co-Chair], “Novel Biomarkers and New Applications of Existing Tools with Practical Implication” [Co-Chair], “Stable Ischemic Syndrome – Interventional Strategies” [Discussant], American College of Cardiology Scientific Sessions, Atlanta, Georgia, March 14, 15, 2010.
3. “ACS Managed Medically: Does It Exist and Do We Care?” Cardiology Grand Rounds (Visiting Professor), Case Western University, Cleveland, Ohio, April 15, 2010.
4. “Tailoring Adjunctive Pharmacotherapy in STEMI”, Emory Practical Intervention Course (EPIC) 2010, Emory University, Atlanta, Georgia, April 24, 2010.
5. “Anticoagulant Therapy for STEMI - Which Agent?” Duke ACS Forum, Washington, DC, April 29, 2010.
6. “Great Debates in Interventional Cardiology” [Moderator]; “Percutaneous Circulatory Support Devices in Cardiogenic Shock” [Moderator] and “Clinical Applications of Percutaneous LVAD in Decompensated Heart Failure and Shock” [Speaker]. American Heart Association Scientific Sessions, Chicago, Illinois, November 14 & 16, 2010.

2011

1. “Issues in Management of Patients with Advanced Coronary Disease Not Suitable for Revascularization”, “Interventional Trial Update: Recent Trial Results You Should Know About “, Thienopyridine Issues: Drug Interactions: When Can They Be Stopped After PCI? Will They be Replaced by Ticagrelor, etc: Issues in Management of Patients with Advanced Coronary Disease Not Suitable for Revascularization” [Speaker]. Snowshoe Cardiovascular Conference, Snowshoe, West Virginia, January 28-29, 2011.
2. “Innovations and Roadblocks in Cardiovascular Medicine: FDA Device Panel Update “, “Management of Patients Ineligible for Revascularization”, “Point-counterpoint: DES for all STEMI Patients” [Speaker]. Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, Colorado, February 14-17, 2011.
3. “Inducing Hypothermia in Cardiogenic Shock” [Speaker]. Therapeutic Hypothermia and Temperature Management Conference, Miami, Florida, February 25, 2011.

4. “Are the Guidelines for ACS & AMI Informed by High Quality Evidence?” [Speaker]; “How to Choose Antiplatelet Therapy for Patients with ACS & AMI in 2011” [Panel Discussant]; “Old Antiplatelet Agents - New Strategies” [Speaker]. CRT 2011, Washington, DC, February 27, 2011.
5. “Guideline-Based Therapy Strategies for Patients with ACS” [Speaker]; “Secondary Prevention for High-Risk ACS Patients – What Would You Do?” [Panel Discussant]; “STEMI: “Bottom Line” Recommendations for State-of-the-Art Care” [Co-Chair]; “Interventional Pharmacology” [Panel Discussant]; “State-of-the-Art STEMI Care” {Co-Chair}. American College of Cardiology Scientific Sessions, New Orleans, Louisiana, April 2-4, 2011.
6. “Adjunctive Pharmacotherapy in ACS”. Emory Practical Intervention Course (EPIC) 2011, Emory University, Atlanta, Georgia, April 30, 2011.
7. “Late Breaking Clinical Trials and First Report Investigations” [Moderator] ” TCT Scientific Sessions, San Francisco, California, November 9, 2011.
8. “Acute Coronary Syndrome: Optimizing Outcomes Across the Spectrum of Care”, “Elderly patient with chronic kidney disease”. AHA Scientific Sessions Satellite Symposium, Orlando, Florida, November 15, 2011.

2012

1. “Antiplatelet Therapy in Diabetic ACS Patients”[Speaker, Moderator], “DAPT – How Long is Too Long? How to Balance Bleeding and Thrombosis: Lessons from the PRODIGY Study”. International Update in Cardiology and Cardiovascular Surgery, Antalya, Turkey, March 2-3, 2012.
2. “Optimizing Pharmacology Before, During, and After PCI”, Current State of Equipoise Regarding Upstream Management: The Need to Evaluate the Efficacy of Upstream Therapies Further in the Context of Novel Agents”, “State of the Art STEMI: All You Need to Know” [Co-Chair], “Shock and Hemodynamic Support Case Reviews” [Panel Discussant], “Late Breaking Clinical Trials II”[Panel Discussant]. American College of Cardiology Scientific Sessions, Chicago, Illinois, March 23-26, 2012.
3. “Update On Acute Coronary Syndromes/Acute Myocardial Infarction: Have We Made Any Progress? What’s Next?”, “Are the Evidence Gaps Related to Region, Age And Gender?” [Panel Discussant], “Antifactor Xa”, “Management of Patients with Drug-eluting Stents Before Non-cardiac Surgery”. World Congress of Cardiology 2012, Dubai, United Arab Emirates, April 18-19, 2012

4. “Antithrombotic treatment In 2012”, “Special Conditions and Populations In ACS”. Satellite Symposium at World Congress of Cardiology 2012, Dubai, United Arab Emirates, April 19, 2012.
5. “Hemodynamic Compromise: IABP to LV Support”. Emory Practical Intervention Course (EPIC) 2011, Emory University, Atlanta, Georgia, April 28, 2012.
6. “Evolving Antiplatelet Strategies for Acute Management of ACS: An Evidence-Based Expert Panel Debate” [Discussant]; “Circulatory Support for Cardiogenic” [**Speaker**]; “Optimizing Use of Today's Antithrombotic and Antiplatelet Drugs in ACS and PCI” [Moderator], “Prasugrel Update: TRILOGY” [Speaker], “Adjunctive Pharmacology Spotlight” [Moderator] TCT Scientific Sessions, Miami Beach, Florida, October 23-25, 2012.
7. “Controversies and Conundrums Using Anti-platelet Therapies in 2012” [Speaker]; “What is the Optimal Dose of Antiplatelet Therapy?” [Speaker]; AHA Oral Abstract Session Pharmacology for ACS and PCI [Moderator]; American Heart Association Scientific Sessions Satellite Symposium, Los Angeles, California, November 1-7, 2012.

2013

1. “Cardiogenic Shock: What is the Role of Drugs and Circulatory Support?,” Beaver Creek Cardiovascular Conference, Beaver Creek, Colorado, February 11, 2013.
2. “Percutaneous Ventricular Support: Where Are We Now?,” and “Completeness of Revascularization: Does it Matter?”, Visiting Braunwald Scholar, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts, February 28-March 1, 2013.
3. “Can I Switch Oral Antiplatelet Agents after Hospital Discharge?: Consistent Therapy is Essential!” [Panelist], “PCI in Stable Ischemic Heart Disease” [Session Co-Chair], and “Duration of DAPT after PCI In ACS: Lessons from TRILOGY” [Speaker], American College of Cardiology Scientific Sessions, San Francisco, California, March 9-10, 2013.
4. “Novel Percutaneous Left Ventricular Support Systems” Cardiovascular Grand Rounds, Moses Cone Hospital, Greensboro, North Carolina, April 17, 2013.
5. “New Guidelines for ACS Management”, Emory Practical Intervention Course (EPIC), Atlanta, Georgia, May 4, 2013.
6. “Percutaneous Left Ventricular Support: Where Are We Now?” Cleveland Clinic Heart and Vascular Center Grand Rounds, Visiting Professor, Cleveland, Ohio, May 24, 2013.

7. “The Clinical Data on P2Y12 Inhibitors, With a Look at High-Risk Patient Populations.” Cardiometabolic Health Congress, Boston, Massachusetts, October 3, 2013.
8. “Antithrombotic Therapies Post-ACS in 2013: What Have We Learned of Risk and Benefit?”, American College of Cardiology Kentucky Chapter Annual Meeting, Lexington, Kentucky, October 11, 2013.
9. “Which ADP Antagonist Should Be Used?: The Case for Ticagrelor!” [Speaker], “Optimizing Use Of Today’s Antithrombotic and Antiplatelet Drugs In ACS and PCI. Antithrombotic and Antiplatelet Agent Selection: One Size Doesn’t Fit All” [Moderator], “Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art” [Speaker], “TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use” [Speaker], “A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI” [Speaker], “EUROMAX: Perspectives on Bivalirudin in STEMI” [Speaker], “The State of Interventional Pharmacology” [Moderator]. TCT 2013 Scientific Sessions, San Francisco, California, October 30, 2013.
10. “AHA SIHD Symposium: Refining the Management of Stable Ischemic Heart Disease” [Moderator]. AHA Satellite Symposium, American Heart Association Scientific Sessions, Dallas, Texas, November 18, 2013.
11. “The ACC/AHA Prevention Guidelines: Did They Get It Right or Wrong?” Cardiology Grand Rounds, Duke University Medical Center, Durham, North Carolina, November 26, 2013.

2014

1. “How to Manage Cardiogenic Shock.” Beaver Creek Cardiovascular Conference, Beaver Creek, Colorado, February 10, 2014.
2. “State of the Art of Antiplatelet Therapy for Patients with ACS: Evidence-Based Guidelines for Optimizing Patient Outcomes”, Coastal Cardiovascular Conference, Cambridge, Maryland, February 15, 2014.
3. “Past, Present and Future of Interventional Cardiology”, “Insights Into Thrombus Formation in Acute Coronary Syndromes and Implications For Pharmacological Treatment, and “Dual Antiplatelet Therapy for Medically Managed ACS Patients: Where Are We in 2014?”, CADECI - Cardiology Conference, Guadalajara, Mexico, February 20 & 21, 2014.

4. [SPEAKER]: “TRILOGY-ACS: How the Data Impacts Clinical Use of Prasugrel: Lessons from TRILOGY”, “There Is No Role for Platelet Function and Genomic Testing with the New Antiplatelet Agents”; [MODERATOR]: “Antiplatelet Controversy For ACS: How Will This Impact Our Practice?”, “Optimal Antiplatelet Management of Patients with ACS Treated Medically or by Revascularization - How All These Agents Fit”, “The Oral Factor Xa Inhibitor Controversy”; [PANELIST]: “Antiplatelet Responsiveness, Genetics, Genomics and Drug to Drug Interactions”. Cardiovascular Research Technologies (CRT) 2014, Washington, DC, February 23, 2014.
5. “Optimizing PCI Outcomes: A Vision of 2014”, “Novel Agents in Combination: Greater Efficacy and/or Risk?”, “Position: IABP is the Preferred Mechanical Support Option in Cardiogenic Shock”, American College of Cardiology Scientific Sessions, Washington, DC, March 28-31, 2014.
6. “The New Cholesterol Guidelines”, Inaugural Annual Duke Preventive Cardiology Symposium, Durham, North Carolina, April 26, 2014.
7. “Percutaneous Left Ventricular Support: Where Are We in 2014?” Columbia University Cardiology Grand Rounds and Visiting Professor, New York, New York, May 6, 2014.
8. “Percutaneous Left Ventricular Support: Where Are We in 2014?” University of Minnesota Cardiology Grand Rounds and Visiting Professor, Minneapolis, Minnesota, May 7-8, 2014.